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Ιθάκη 
Σα βγεις στον πηγαιμό για την Ιθάκη, 
να εύχεσαι νάναι μακρύς ο δρόμος, 
γεμάτος περιπέτειες, γεμάτος γνώσεις. 
Τους Λαιστρυγόνας και τους Κύκλωπας, 
τον θυμωμένο Ποσειδώνα μη φοβάσαι, 
τέτοια στον δρόμο σου ποτέ σου δεν θα βρεις, 
αν μεν' η σκέψις σου υψηλή, αν εκλεκτή 
συγκίνησις το πνεύμα και το σώμα σου αγγίζει. 
Τους Λαιστρυγόνας και τους Κύκλωπας, 
τον άγριο Ποσειδώνα δεν θα συναντήσεις, 
αν δεν τους κουβανείς μες στην ψυχή σου, 
αν η ψυχή σου δεν τους στήνει εμπρός σου. 
 
Να εύχεσαι νάναι μακρύς ο δρόμος. 
Πολλά τα καλοκαιρινά πρωϊά να είναι 
που με τι ευχαρίστησι, με τι χαρά 
θα μπαίνεις σε λιμένας πρωτοειδωμένους, 
να σταματήσεις σ' εμπορεία Φοινικικά, 
και τες καλές πραγμάτειες ν' αποκτήσεις, 
σεντέφια και κοράλλια, κεχριμπάρια κ' έβενους, 
και ηδονικά μυρωδικά κάθε λογής, 
όσο μπορείς πιο άφθονα ηδονικά μυρωδικά, 
σε πόλεις Αιγυπτιακές πολλές να πας, 
να μάθεις και να μάθεις απ' τους σπουδασμένους. 
 
Πάντα στον νου σου νάχεις την Ιθάκη. 
Το φθάσιμον εκεί ειν' ο προορισμός σου. 
Αλλά μη βιάζεις το ταξείδι διόλου. 
Καλλίτερα χρόνια πολλά να διαρκέσει 
και γέρος πια ν' αράξεις στο νησί, 
πλούσιος με όσα κέρδισες στο δρόμο, 
μη προσδοκώντας πλούτη να σε δώσει η Ιθάκη. 
 
Η Ιθάκη σ'έδωσε τ' ωραίο ταξείδι. 
Χωρίς αυτήν δεν θάβγαινες στον δρόμο. 
Άλλα δεν έχει να σε δώσει πια. 
 
Κι αν πτωχική την βρεις, η Ιθάκη δε σε γέλασε. 
Έτσι σοφός που έγινες, με τόση πείρα, 
ήδη θα το κατάλαβες οι Ιθάκες τι σημαίνουν. 
 
Κωνσταντίνος Πέτρου Καβάφης (1863-1933) 
 
Aan mijn ouders 
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 General introduction   11 
This thesis addresses the results of the prospective Dutch national study on the 
efficacy and safety of intrathecal baclofen in the treatment of intractable spasticity 
in children with cerebral palsy. 
SPASTICITY 
In 1980, Lance defined spasticity as a motor disorder characterised by a velocity-
dependent increase in tonic stretch reflexes with exaggerated tendon jerks, 
resulting from hyperexcitability of the stretch reflex, as one component of the 
upper motor neuron (UMN) syndrome.1 More recent evidence suggests that 
spasticity is not a pure motor disorder and that it does not exclusively result from 
hyperexcitability of the stretch reflex.2 Moreover, the changes in resistance to 
imposed passive movement cannot be uniquely related to muscle activity and the 
phenomenon of velocity dependence is not exclusive to stretch reflex 
hyperexcitability. Therefore, the SPASM consortium redefined spasticity as a 
disordered sensori-motor control, resulting from an upper motor neuron lesion, 
presenting as intermittent or sustained involuntary activation of muscles.2  
Pathophysiology 
The UMN syndrome includes positive and negative phenomena. Positive 
phenomena are characterised by excessive or inappropriate motor activity, such 
as spasticity, hyperreflexia, extensor plantar responses and clonus. The negative 
phenomena are characterised by a reduction in motor activity, such as weakness, 
fatigue, slow effortful voluntary movement, impaired fine-motor function and 
difficulty in isolating individual movements.3 Upper motor neurons are neurons 
of any long descending tract that control movement and muscle tone. The 
descending tracts may be divided into pyramidal and parapyramidal tracts. Most 
features of the UMN syndrome involve lesions of the parapyramidal tracts, which 
mainly arise in the brainstem. The key tracts are the dorsal reticulospinal tract, 
medial reticulospinal tract and vestibulospinal tract. These descending pathways 
synapse upon interneural networks within the spinal cord that control spinal 
stretch reflexes, flexor and extensor reflexes. The medial reticulospinal tract and 
vestibulospinal tract have a predominantly excitatory influence. The dorsal 
reticulospinal tract is the main inhibitory pathway. Contrary to the other tracts, 
the inhibitory dorsal reticulospinal tract receives a strong cortical facilitatory 
influence. In its normal state, the excitatory and inhibitory influences are in 
balance. However, in the UMN syndrome there is an imbalance, caused by 
lesions affecting some or all of the descending tracts. For example, in cerebral 
palsy the facilitatory cortical influence of the inhibitory dorsal reticulospinal tract 
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is decreased. As a result, the balance tips in favour of excitation, which may 
result in spasticity and other positive phenomena of the UMN syndrome. 
Signs and symptoms 
Spasticity can cause pain, sleeping disorders, increased energy requirements and 
interference with positioning, transfers, dressing and body hygiene. Secondary 
phenomena, such as contractures, pressure sores and heterotopic calcifications of 
joints or tendons can add to the treatment problems.3 
Spastic cerebral palsy 
Spasticity can result from cerebral or spinal injury. The most common aetiology 
of spasticity in children is cerebral palsy (CP).4 CP describes a group of disorders 
of the development of movement and posture, causing activity limitation, that are 
attributed to non-progressive disturbances that occurred in the developing foetal 
or infant brain. The motor disorders of CP are often accompanied by disturbances 
of sensation, cognition, communication, perception, and/or behaviour, and/or by 
a seizure disorder.5 There is some evidence that damage of the spinal cord may 
also play a role in CP.6,7 CP is the most common cause of severe physical 
disability in childhood.8 In developed countries, the overall reported prevalence 
in children aged 3 to 10 years is 2.4 per 1000 children.9-11 The CP syndromes are 
traditionally subdivided into a spastic, dyskinetic, ataxic and mixed type.8 
Spasticity accounts for 70 to 91% of the motor disorders associated with CP.8,12 
The spastic CP syndromes are further divided according to the distribution of the 
upper motor neuron signs. Spastic diplegia is defined as greater involvement of 
the lower limbs, tetraplegia as an equal or greater involvement of the upper 
limbs, and hemiplegia as involvement of one side of the body.9 
SPASTICITY TREATMENT 
In the treatment of spasticity, the first aim is to elicit provocative factors, as 
spasticity is often highly state dependent. It may fluctuate with various internal 
and external stimuli, such as pain, fatigue, stress, excitement, cold, illness, sleep 
disturbance, immobility and hormonal changes.4 Despite lack of support for their 
efficacy, physical and occupational therapy remain important in the management 
of spasticity.13 These approaches aim at lengthening contracted muscles, 
improving muscle strength and coordination, increasing the range of motion of 
restricted joints and, developing compensatory strategies to accomplish tasks.14 
They can be either primary treatments or an integral part of treatment 
programmes. 
Thesis_hoving_v5.pdf   12 19-3-2008   12:31:36
 General introduction   13 
Focal treatments 
Focal treatments for spasticity include intramuscular injection of botulinum toxin, 
orthoses, orthopaedic surgery, selective peripheral neurotomy, selective dorsal 
rhizotomy and percutaneous radiofrequency lesioning of the dorsal root 
ganglion. 
Botulinum toxin blocks the neuromuscular transmission by decreasing the 
presynaptic acetylcholine release at the motor nerve ending. The effect of 
botulinum toxin is temporary, lasting from 2 to 6 months.15  
Orthopaedic surgery includes procedures to lengthen contracted myotendinous 
units, balance joint forces, transfer motor power, fuse unstable joints by 
arthrodesis, correct bony deformities and reduce joint subluxation and 
dislocation. The aims of orthopaedic surgery are to improve joint congruency, 
diminish pain and restore or stabilise spinal deformity.9 Selective peripheral 
neurotomy decreases spasticity by selectively sectioning both afferent and 
efferent fibres of the stretch-reflex at the level of the muscle’s nerve.16 
Selective dorsal rhizotomy is a surgical intervention for the treatment of lower 
extremity spasticity. Operative techniques involve a multilevel laminectomy and 
the transection of carefully selected lumbosacral sensory rootlets.17 Dorsal 
rhizotomy reduces the amount of excitation of the alpha motor neurons, 
decreasing spasticity in the muscles associated with the transected nerves.18 The 
best candidates for selective dorsal rhizotomy are children, aged between 3 and 
8 years, with spastic diplegia and reasonably well-preserved leg strength.19 
A less invasive and safe alternative for selective dorsal rhizotomy is percutaneous 
radiofrequency lesioning of the dorsal root ganglion. De Louw et al. conducted a 
pilot study considering the effects of percutaneous radiofrequency lesioning of 
the dorsal root ganglion in six children with spastic CP. The results of this study 
showed that ease of care and lower-extremity muscle tone improved both at 4 
weeks and 6 months after the lesioning.20 
Generalised treatments 
Generalised treatments for spasticity include therapy with oral spasticity reducing 
agents such as baclofen, dantrolene, tizanidine, and benzodiazepines.21 One of 
the most common used anti-spastic drugs is baclofen.22 Baclofen acts as a γ-
aminobutyric acid (GABA-B) agonist, which is a major inhibitory 
neurotransmitter. In the mammalian spinal cord, GABA is highest concentrated in 
the dorsal grey matter, followed by the ventral grey matter, with only minimal 
amounts in the white matter.23 In the dorsal horn, GABA-B is mainly found in 
laminae I-III in interneurons, which are presynaptic to dendrites, cell bodies, and 
other axon terminals.23 Besides decreasing muscle tone, baclofen has 
antinociceptive effects.24 It is postulated that the presynaptic inhibition and other 
gating mechanisms related to pain and flexor spasms take place in the dorsal 
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horn.25 There is evidence that nitric oxide mediated cyclic guanosine 3', 5' 
monophosphate (cGMP) synthesis plays a role in nociception in the spinal cord 
and that an increased level of cGMP in the dorsal horn is associated with 
hyperalgesia.26 In the rat cervical spinal cord, baclofen had an inhibitory effect on 
the atrial natriuretic peptide-mediated cGMP synthesis in laminae I-III of the 
dorsal horn.26 The effects of baclofen in the spinal cord are considered to be at 
least partially mediated by nitric oxide cGMP.26 The muscle relaxant effect of 
baclofen takes place in the ventral horn, where GABA is localised in interneurons 
presynaptic to motoneuron cell bodies and small and large dendrites.23  
Baclofen passes the blood-brain barrier poorly; as a result, taking oral baclofen 
leads to high blood levels and virtually undetectable levels in the cerebrospinal 
fluid. As a consequence, patients easily experience side effects such as 
drowsiness and lethargy, without an adequate reduction in spasticity. 
Treating intractable spasticity 
A substantial group of children with serious spasticity does not respond to regular 
treatments (intractable spasticity). Children with intractable spasticity often have a 
low health related quality of life.27,28 Continuous infusion of intrathecal baclofen 
(CITB) is a promising treatment option for intractable spasticity.29-31 The blood-
brain barrier is being by-passed, because baclofen is directly infused into the 
cerebrospinal fluid, which surrounds the spinal cord. Because the GABA-B 
receptors are located superficially in the spinal cord, baclofen can easily reach 
these receptors. Administration of a hundredth part of the oral baclofen dose 
intrathecally can relieve spasticity without the side effects often encountered with 
high baclofen doses taken orally.32 Intrathecal baclofen (ITB) can be delivered 
continuously by a programmable infusion pump implanted in an abdominal 
subcutaneous or subfascial pocket, and a connecting catheter, which is inserted 
in the intrathecal space.   
INTRATHECAL BACLOFEN IN CHILDREN WITH SPASTIC CP:  
A LITERATURE OVERVIEW  
In 1985, Penn and Kroin established the effectiveness of CITB in patients with 
spasticity of spinal origin.33 In the same year, Dralle et al. reported on the 
beneficial effect of ITB in a child with spasticity of cerebral origin.34 Since then, 
the use of ITB for both spinal and cerebral spasticity has been addressed in 
several studies. In 2000, the American Academy for Cerebral Palsy and 
Developmental Medicine (AACPDM) published a systematic review on the 
degree of evidence about ITB treatment for spasticity in individuals with CP.35 It 
appeared that only a small and uncertain number of individuals had been 
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studied. Except for two case reports, none of the studies solely concerned 
children. Few outcomes beyond muscle tone had been measured more than 
once. Moreover, the research methodology employed in three quarters of the 
available studies was not capable of confirming treatment effect. The AACPDM 
underlined the need for further prospective, randomised trials that use valid and 
reliable outcome measures, in well-described and homogeneous patient groups. 
Therefore, we started a Dutch national study on the efficacy and safety of ITB in 
the treatment of children with intractable spastic CP in 2002. 
Literature published since the start of the Dutch national ITB study 
2002 In a consecutive case-series (1997-2001), Murphy et al. retrospectively 
studied the efficacy and complications of CITB in 23 children with CP.36 Before 
pump implantation, 24 children underwent a screening trial, 21 via bolus 
injections and three via catheter infusions. All but one child went on to pump 
implantation. Further information on the design of the screening trial or the 
effective ITB dose was not provided. The average Ashworth score of both the 
lower and upper extremities had decreased significantly after 6 months of CITB. 
A limitation of this study was the use of the Ashworth scale as single outcome 
measure. Eleven (44%) of the implanted pumps had to be explanted, mainly 
because of wound dehiscence with secondary infection. Side effects were not 
addressed.36 
Campbell et al. reviewed the long-term safety and efficacy of CITB in the 
treatment of 21 children and adolescents.31 Their study was for the greater part 
retrospective (1994-1998) and included patients with spastic CP, mixed type CP, 
and patients with other causes of cerebral spasticity.31 All participants responded 
to an ITB test dose of 50 or 100 μg. Data on the participants’ weights, the design 
of the test treatment and the incidence of adverse events during the test treatment 
were lacking. After pump implantation, no improvement on the Gross Motor 
Function Measure and the Pediatric Evaluation Disability Inventory was 
observed. During 80 patient-years, there were 153 possible treatment related 
adverse effects, of which 27 device related. The most common non-device 
related adverse events included decreased function (n = 19), pressure sores 
(n = 13), increased tone (n = 12), constipation (n = 10) and lethargy (n = 9). Four 
children died. There was no evidence of pump malfunction or catheter 
displacement in these children before or at the time of death. A single, 
prospective telephone survey was used in the 17 participants who still had a 
pump in 1999. The aim of this survey was to obtain information on the treatment 
goals and the caregivers’ overall satisfaction with CITB. The status of the 
treatment goals was reported by the participants or their caregivers without using 
an outcome measure, such as a visual analogue scale or goal attainment scaling. 
Caregiver satisfaction was high. Of 108 initial treatment goals, 78 (72%) were 
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completely or almost completely achieved and 101 (94%) were at least partly 
achieved. Treatment goals included improvements in dressing, positioning, pain, 
sleep and independent mobility. Fourteen of the 17 caregivers stated that they 
would have their child’s pump replaced if it had to be removed for any reason, 
two were indecisive and one would not have the pump replaced, because of the 
child’s fear of needles at times of pump refilling. Fifteen caregivers would 
recommend CITB to others.31 
2003 Awaad et al. reported the efficacy of CITB in 29 patients with spastic CP, 
focussing on impairments, functional limitations and disability.37 Adverse events 
were not structurally addressed. This prospective study did not only include 
children, but adults as well. Patients with severe contractures were excluded. 
Besides CITB, patients received individualised rehabilitation to maximise the 
functional effects of CITB. Forty-nine eligible candidates for CITB therapy 
underwent a test treatment with a lumbar 50 μg ITB bolus injection. A one-point 
reduction of the average Ashworth score in the lower extremities was considered 
a positive response to the test treatment. Thirty-nine patients decided to have a 
pump implanted. Reported reasons for the 10 patients who did not have a pump 
implanted included the following: three patients chose using oral medication; 
two had family issues; one child was too small for implantation; one child died, 
unrelated to the baclofen test treatment; one child underwent spinal fusion; one 
child had medical issues; and one family decided not to undergo an implantation 
at the time of the study. The authors did not provide any specific information 
about the results of the test treatments. After pump implantation, the outcome 
measures were complete for only 29 of the 39 patients. The mean Ashworth 
score had significantly decreased during all follow-up visits (p < 0.0005). The 
mean Pediatric Evaluation Disability Inventory scores showed significant gains in 
the Functional Skills self-care domain score from 6 months of treatment with 
CITB and in the Caregiver Assistance mobility domain score at the 6,12 and 
18-month follow-up visits.37 
2004 Between 1996 and 2001, Albright et al. prospectively evaluated the 
complications associated with CITB via a Synchromed EL 10-ml pump in 100 
children of whom 90 were diagnosed with CP.38 It was a prospective, open-label, 
non-blinded study, conducted in 11 United States medical centres. The study did 
not address efficacy and possible side effects of CITB.38 The Ashworth scores 
decreased significantly in the upper and lower extremities at 6 and 12 months 
after pump implantation (p < 0.001). There were 69 procedure and device related 
complications during a follow-up of 1178 patient-months. Forty-seven 
complications were serious. The one-year complication-free rate was 79%.38 
2005 Vloeberghs et al. summarised the preliminary results of ITB therapy in 
children (about 90% with CP) at Queens Medical Centre in Nottingham.39 During 
the test treatment, an ITB 50 μg bolus, or 30 μg bolus in the smallest children, 
was administered via a lumbar catheter. The caregiver had to assess the results of 
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the ITB bolus and consequently had to decide whether or not the child would 
have a pump implanted. The investigators considered it not useful to quantify the 
effects of the ITB bolus during the test treatment. Eighty-three children underwent 
a test treatment and 63 children had a pump implanted. In absence of adequate 
objective measures for assessing the effect of CITB treatment, no outcome 
measures were used to assess the effects of CITB after pump implantation. 
Complications requiring surgery were reported in 13 children, including three 
infections, five catheter migrations, four catheter fractures and one pressure sore 
of the skin covering the pump.39 
2006 Vender et al. reviewed the complications encountered in a series of 314 
pump and catheter related procedures in a group of 195 paediatric and adult 
patients with intractable spasticity or dystonia.40 This retrospective study included 
128 children (108 with CP) and 67 adults. The complications were not specified 
for children with spastic CP. In comparison with the adults, both the overall 
complication rate and, specifically, the wound complication rate were 
significantly higher in children.40 
2007 Motta et al. retrospectively evaluated the incidence of three common 
CITB complications in 200 children (175 with CP) without addressing other safety 
aspects.41 They recorded 76 complications during a follow-up of 10,142 patient-
months. Twenty children (10%) had an infection, 34 (17%) leakage of 
cerebrospinal fluid (one pump removal) and 21 (10.5%) catheter-associated 
complications (15 pump removals). The incidence of infections decreased from 
10% to 4.8% after adoption of the subfascial implantation technique and 
modification of the preoperative prophylaxis procedures.41 
De Lissovoy et al. retrospectively studied the cost-effectiveness of CITB in 
American children with severe spasticity of cerebral origin.42 They concluded that 
CITB offers good value for money. 
Conclusions based on the literature overview  
Most of the above reported studies were retrospective and none of the 
prospective studies was randomised. Though the test treatment is an important 
phase ahead of definite treatment with CITB, the reports did not pay much 
attention to the design and results of the test treatment. Moreover, in spite of 
controversy about the importance of the placebo effect of intrathecal bolus 
injections during screening of patients with cerebral spasticity, none of the above 
reported test treatments was placebo-controlled.29,43 After pump implantation for 
CITB, muscle tone as measured with the Ashworth scale decreased significantly 
according to several reports. In only two studies, outcome measures beyond 
muscle tone were used. Prospective studies on the cost-effectiveness of CITB in 
children with intractable spastic CP are lacking. In conclusion, there still is a 
need for further high-level research in the form of prospective, randomised trials 
Thesis_hoving_v5.pdf   17 19-3-2008   12:31:37
18   Chapter 1 
 
that use valid and reliable outcome measures. The prospective Dutch ITB study 
addressed these needs and included a cost-effectiveness analysis.  
OUTCOME MEASURES 
We selected a broad choice of outcome measures for the Dutch ITB study and 
used the International Classification of Functioning, Disability and Health (ICF).44 
The ICF comprises a universal classification of human functioning that can be 
used to document functional status associated with health conditions. It provides 
a framework which uses unifying terminology for the classification of diseases 
and their effect on body structures and functioning, execution of tasks and 
actions (activities), and involvement in life situations (participation). Contextual 
factors, including environmental and personal factors, are added to represent the 
background of an individual’s life (Figure 1.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 International Classification of Functioning, Disability and Health (ICF) model of 
Disability 
ICF domain of body functions and structures 
In spite of its limitations, the Ashworth scale is often used for measuring 
spasticity.45,46 The Ashworth scale is a score for grading muscle tone and does not 
exclusively quantify spasticity. It assesses muscle tone by scoring the resistance 
encountered in a specific muscle group by passively moving a limb at a non-
specified velocity through its range of motion. It lacks sensitivity for the detection 
of small changes in muscle tone, there is no consensus on the exact scoring 
procedure, and the test requires some cooperation of the patient, which is often 
limited in children or patients with cognitive deficits.45 However, the Ashworth 
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scale also has its strengths. First, it quickly provides information on muscle tone 
and only one assessor is needed. Therefore, it can be easily measured several 
times a day. Second, the Ashworth scale can be used on the ward, while the 
patient lies in its hospital bed.45 The latter advantages are particularly of use 
during an ITB test treatment, when muscle tone changes within hours. Therefore, 
we included the Ashworth scale as an outcome measure in the Dutch ITB study. 
According to the definition of spasticity, the Tardieu scale would be a suitable 
instrument to measure spasticity.47 According to Tardieu, spasticity is assessed by 
passively moving a joint at three different velocities. The intensity and duration of 
the muscle reaction to stretch is rated on a 5-point scale together with the joint 
angle at which the muscle response is first felt. However, because this method is 
very time-consuming, its feasibility is questioned, especially for use in children. 
Another weakness of the Tardieu scale is that it lacks standardisation of the three 
different velocities. Therefore, we did not use the Tardieu scale as an outcome 
measure in our study. 
There has so far been no objective measure that is used in daily clinical practice 
to evaluate the spinal cord neuronal response to ITB administration in children. 
From a pathophysiological point of view, both the soleus H-reflex and the flexor 
reflex could be useful and sensitive objective outcome measures. The normal 
flexor reflex, elicited at supramaximal electrical stimulation of the tibial nerve 
behind the ankle, is a two component exteroceptive reflex.49-50 Both components 
are changed by supraspinal influences and it is the second component which is 
associated with the withdrawal response.50 In patients with supratentorial lesions, 
the flexor reflex mostly appears as a single component response of prolonged 
latency and duration.48,50 Flexor spasms are the clinical counterpart of 
hyperactive flexor withdrawal reflexes.50 The flexor reflex threshold is often 
decreased in spasticity and tends to normalise with oral baclofen.25,51 
The H-reflex can be used as a tool to measure the excitability of the neural 
components of the stretch reflex arc, bypassing the effects of gamma 
motoneurons and of muscle spindle discharges.52-54 The ratio of the peak-to-peak 
maximal H-amplitude to maximal M-amplitude indicates the part of motoneurons 
within the pool that can be recruited reflexively and is therefore a measure of 
motoneuron pool excitability.55 
ICF domains of activities and participation 
In the ICF domains of activities and participation, we used the Pediatric 
Evaluation of Disability Inventory (PEDI) and the Gross Motor Function Measure 
(GMFM), both valid and reliable measures.56 The PEDI is a judgement-based 
structural interview for parents used by professionals. It has been primarily 
designed to measure functional status in children aged between 6 months to 7.5 
years. However, it can also be used for older children whose functional status is 
Thesis_hoving_v5.pdf   19 19-3-2008   12:31:37
20   Chapter 1 
 
less than children of 7.5 years without disabilities.57 The PEDI measures both 
capability (what the child can do) and performance (what the child actually does) 
of routine daily childhood activities. There are three content domains, including 
self-care, mobility and social functioning. 
The GMFM is a criterion-referenced observational measure for addressing change 
in gross motor function for children with CP. The 88 items of the GMFM are 
scored on a 4-point ordinal scale and grouped into five dimensions: 1) lying and 
rolling, 2) sitting, 3) crawling and kneeling, 4) standing, and 5) walking, running 
and jumping. Five-year-old children without motor delays are usually able to 
accomplish all GMFM items. 
Measuring individual problems or goals 
Children with spastic CP all have their own spasticity associated problems and 
subsequent treatment goals. Because changes in these individual problems and/or 
goals may not be addressed by standardised outcome measures, highly 
individualised, subjective measures such as the visual analogue scale (VAS) or 
goal attainment scaling (GAS) should be used. 
The VAS is a valid and reliable measure in rating pain intensity in adults and 
children over 6 years of age.58-60 It has also been used for measuring satisfaction, 
feelings, quality of sleep, dyspnoea, emotional function, and fatigue, and 
appeared to be responsive and valid.61-64 In a population of children with 
different problems, the VAS can be used for measuring the severity of the 
individually formulated problems. The VAS for pain is a straight 10 centimetre 
horizontal line with anchor points of ‘no pain’ (score 0) and ‘unbearable pain’ 
(score 10).59 The anchor points can be changed in ‘very dissatisfied’ (score 0) and 
‘very satisfied’ (score 10) to permit the uniform use of the VAS for the defined 
individual problems. Depending on both the ability to understand the test and to 
draw a vertical line, the VAS can be rated by the child or by a caregiver. Because 
we considered any improvement in the children’s individually formulated 
problems as most important, we used the VAS for individual problems as a 
primary outcome measure. 
Goal attainment scaling (GAS) is another method to measure individual progress 
towards individual goals.65 These goals should be clear, relevant and realistic. 
GAS is originally based on an ordinal 5-point scale. A score of 0 represents the 
expected level of success, based on pre-established criteria. In case a patient has 
more progress than expected, a score of +1 or +2 is given, depending on the 
degree of progress. In case the expected goal is not reached, a score of -1 or -2 is 
given. GAS with scales of three, six or seven points are also used. GAS has the 
disadvantage of being time-consuming and its use requires training. The 
reliability of GAS in children is largely unknown. The validity of GAS is 
ambiguous; though its concurrent validity is low, it can exactly measure what 
Thesis_hoving_v5.pdf   20 19-3-2008   12:31:37
 General introduction   21 
needs to be measured.65 In our study, we preferred using the VAS for individual 
problems and did not include GAS. 
Health related quality of life measures 
Health related quality of life (HRQL) measurement has a high priority in current 
CP research, because clinical measurements fail to reflect the well-being of the 
child and its family.66 Because CP specific HRQL measures were lacking, we 
used the Child Health Questionnaire-Parent Form 50. This is a generic child 
health instrument designed to measure the physical and psychosocial well-being 
of children aged 5 years and older.67 
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THESIS OUTLINE  
The Dutch ITB study comprised four phases: 1) the selection phase, 2) the test 
treatment phase, 3) the pump implantation phase, and 4) the follow-up phase. 
Furthermore, the Dutch ITB study included two substudies. The first concerned a 
clinical neurophysiological study, which was embedded in the double-blind, 
randomised, placebo-controlled test treatment phase. We prospectively evaluated 
the soleus H-reflex and flexor reflex as promising objective outcome measures of 
CITB in the ICF domain of body structures and functions. The second substudy 
comprised a cost of illness study and a cost-effectiveness analysis.  
 
Chapter 2 addresses the substudy on the utility and feasibility of the soleus 
H-reflex and flexor reflex in identifying spinal cord neuronal response to ITB 
bolus administration in children with intractable spastic CP. Chapter 3 describes 
the double-blind, randomised, placebo-controlled, dose-finding ITB test 
treatment. The aims were to: 1) select children eligible for CITB treatment, 2) 
assess the effective ITB bolus dose, and 3) evaluate the effects, side effects, 
complications, and procedures. Chapter 4 is about the prospective, randomised 
controlled, open-label, implantation phase. In a randomised controlled trial, we 
studied the 6-month efficacy of CITB in comparison with standard treatment only, 
in the treatment of children with problems caused by intractable spastic CP. 
Chapter 5 comprises the follow-up phase, in which we prospectively studied the 
one-year efficacy of CITB, and its safety from pump implantation up to 24 months 
of follow-up. Chapter 6 describes the use of an Indium111 DTPA flow study in the 
evaluation of a lumbar swelling in a girl with a baclofen pump. Chapter 7 
concerns a cost of illness study in which we estimated and categorised the 
expenditures for children with intractable spastic CP. In Chapter 8 we address the 
cost-effectiveness of CITB in the treatment of children with intractable spastic CP. 
Chapter 9 is the general discussion in which we discuss the findings, as 
presented in this thesis. We also put forward some ideas to optimise intrathecal 
baclofen therapy in children with intractable spastic CP. 
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The Dutch national ITB study has been conducted on behalf of the Dutch 
Study Group on Child Spasticity. The members of this study group are: 
J.G. Becher, VU Medisch Centrum, Amsterdam 
O.F. Brouwer, Universitair Medisch Centrum Groningen, Groningen  
C.E. Catsman-Berrevoets, Erasmus Medisch Centrum, Rotterdam 
J. Gerritsen, Isala Klinieken, Zwolle 
M.J.P.M. Geerts, Revalidatiecentrum Leijpark, Tilburg  
P.H. Jongerius, Sint Maartenskliniek, Nijmegen 
C.G.B. Maathuis, Universitair Medisch Centrum Groningen, Groningen  
O. van Nieuwenhuizen, Universitair Medisch Centrum Utrecht, Utrecht  
J.J. Rotteveel, Universitair Medisch Centrum St Radboud, Nijmegen 
L.A.W.M. Speth, Hoensbroeck Revalidatiecentrum, lokatie Franciscusoord, 
Valkenburg  
H. Stroink, Sint Elisabeth Ziekenhuis, Tilburg 
R.J. Vermeulen, VU Medisch Centrum, Amsterdam 
J.S.H. Vles, Academisch Ziekenhuis Maastricht, Maastricht  
E.G. van der Ziel, Revalidatiecentrum Het Roessingh, Enschede 
 
The Dutch national ITB study could not have been conducted without the 
following referring medical specialists: 
M. Feldmann, Revalidatiecentrum Het Roessingh, Enschede 
J.W. Gorter, Universitair Medisch Centrum Utrecht, Utrecht 
D.W. Jaeken, Hoensbroeck Revalidatiecentrum, locatie Franciscusoord, 
Valkenburg 
G.H.F. van der Leeuw, Franciscus Ziekenhuis, Roosendaal 
R.F. Pangalila, Revalidatiecentrum Rijndam, Rotterdam 
M.J. Poelma, Sint Maartenskliniek, Nijmegen 
R.J. Soorani, Universitair Medisch Centrum Groningen, Groningen 
J.W. Weber, Academisch Ziekenhuis Maastricht, Maastricht
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CHAPTER 2 
 
 
 
 
 
 Placebo controlled utility and feasibility study of 
the H-reflex and flexor reflex in spastic children 
treated with intrathecal baclofen 
 
 
 
 
 
 
 
 
 
MA Hoving, VHJM van Kranen-Mastenbroek, EPM van Raak, GHJJ Spincemaille, 
ELM Hardy, JSH Vles, on behalf of the Dutch Study Group on Child Spasticity 
Clin Neurophysiol 2006;117:1508-1517 
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ABSTRACT 
Objective 
To evaluate feasibility and utility of the soleus H-reflex and tibialis anterior flexor reflex in 
identifying spinal cord neuronal response to intrathecal baclofen in children with severe 
spastic cerebral palsy. 
 
Methods 
During a randomised, double-blind, placebo-controlled dose-escalation test treatment, 
maximum H-amplitude/maximum M-amplitude (H/M ratio) and flexor reflex parameters 
were bilaterally recorded at baseline and 2 to 3 hours after intrathecal bolus 
administration of placebo and increasing doses of baclofen until both an improvement in 
the individual treatment goal(s) and a one-point reduction on the Ashworth scale were 
observed.   
 
Results 
Electrophysiological data of 14 children were studied. The H-reflex was feasible in 13 
children, the flexor reflex threshold area in nine and the flexor reflex, elicited with 
supramaximal stimulation, in only one child. After intrathecal baclofen the H/M ratio 
significantly decreased (left: 0.67 ± 0.47 to 0.15 ± 0.18, p = 0.005; right: 0.55 ± 0.32 to 
0.14 ± 0.19, p = 0.002) without placebo effect. Flexor reflex threshold area after 
intrathecal baclofen, only decreased significantly in children not taking oral baclofen (left: 
146 ± 53 mVms to 41 ± 54 mVms, p = 0.000; right: 156 ± 80 mVms to 66 ± 48 mVms, 
p = 0.002). 
 
Conclusions 
This is the first randomised, double-blind, placebo-controlled dose-escalation study in 
spastic children demonstrating the soleus H-reflex to be a feasible and objective measure 
to quantify the decreasing motoneuron excitability in response to intrathecal baclofen 
bolus administration. Only in children not taking oral baclofen, flexor reflex threshold area 
can also be used as an objective outcome measure, yet feasibility is limited. 
 
Significance 
We suggest introducing the H-reflex as the electrophysiological gold standard for the 
evaluation of the effect of intrathecal baclofen in spastic children. 
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INTRODUCTION 
Cerebral palsy (CP) is the most common cause of severe physical disability in 
childhood.1 It is a term for a heterogeneous collection of clinical syndromes that 
are characterised by abnormal motor actions and postural mechanisms, and that 
are due to non-progressive abnormalities of the developing brain.2 Two thirds of 
the individuals with CP suffer from mild to severe spasticity.1 Spasticity is a motor 
disorder characterised by a velocity-dependent increase in tonic stretch reflexes 
with exaggerated tendon jerks, resulting from hyperexcitability of the stretch 
reflex.3 An effective treatment option for otherwise untreatable spasticity is the 
continuous delivery of intrathecal baclofen (ITB).4-6  
In daily clinical practice, there has been no objective outcome measure yet to 
evaluate the effect of ITB in spastic children. In spite of its clear limitations, the 
standard clinical scale for measuring spasticity is the Ashworth scale.7,8 The 
Ashworth scale is a score for grading muscle tone and does not exclusively 
quantify spasticity. It lacks sensitivity for the detection of small changes in muscle 
tone, there is no consensus on the exact scoring procedure and the test requires 
some cooperation of the patient, which is often limited in children or patients 
with cognitive deficits.7 The Ashworth scale should therefore not be used as the 
gold standard for measuring spasticity.9 
From a pathophysiological point of view, both the soleus H-reflex and the flexor 
reflex (FR) could be useful and sensitive objective outcome measures for the 
spinal cord neuronal response to ITB administration. Baclofen is a selective 
agonist for gamma-aminobutyric acid (GABA)-B receptors.10 As baclofen 
influences both monosynaptic and polysynaptic reflexes, both the H-reflex and 
the FR have been previously considered as suitable, objective outcome measures 
in the evaluation of ITB treatment.11-13 
The normal FR, elicited at supramaximal electrical stimulation of the tibial nerve 
behind the ankle, is a two-component exteroceptive reflex.14-16 Both components 
are changed by supraspinal influences and it is the second component, which is 
associated with the withdrawal response.16 In patients with supratentorial lesions, 
the FR mostly appears as a single component response of prolonged latency and 
duration.14,16 Flexor spasms are the clinical counterpart of hyperactive flexor 
withdrawal reflexes.16 The FR threshold is often decreased in spasticity and tends 
to normalise with oral baclofen.17,18 
The H-reflex can be used as a tool to measure the excitability of the neural 
components of the stretch reflex arc, bypassing the effects of gamma 
motoneurons and of muscle spindle discharges.19-21 The ratio of the peak-to-peak 
maximal H-amplitude to maximal M-amplitude (H/M) indicates the part of 
motoneurons within the pool that can be recruited reflexively and is therefore, a 
measure of motoneuron pool excitability.22 Since the 1960s, the H/M ratio has 
been considered as an index for spasticity, as it is increased in the majority of 
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patients with spasticity.23-29 Nevertheless, the H-reflex has never been introduced 
in daily clinical practice. One explanation for this could be the large range of 
variation of the H/M ratio in spastic and healthy people, limiting the diagnostic 
value of the H/M ratio.23,29 A second reason could be the lack of strong 
correlation between the H/M ratio and clinical assessment scales of muscle tone, 
such as the Ashworth scale.13,27-30 However, we would like to refute these 
argumentations. First, we believe the H/M ratio can still be useful for evaluating 
changes in motoneuron excitability in response to ITB administration in single 
patients, as the reproducibility of the H/M ratio is good.27,31,32 Secondly, it is not 
very useful to compare the H-reflex with the Ashworth scale, as the latter is no 
valid test for measuring spasticity.  
This is the first report on a randomised, double-blind, placebo-controlled dose-
escalation study evaluating the utility and feasibility of the H-reflex and FR as 
objective outcome measures of the effect of ITB bolus administration in a 
relatively large group of severely spastic children with CP. 
METHODS 
Patients 
Children aged between 4 and 16 years, with a spastic diplegia or tetraplegia as 
part of CP, who insufficiently responded to oral spasticity reducing medications, 
were included. Magnetic resonance imaging of the brain was mandatory to rule 
out progressive causes of spasticity. Exclusion criteria were hypersensitivity to 
baclofen, contraindications for general anaesthesia, intractable epileptic seizures, 
an infection of the lumbar skin and a systemic infection. Eligible children from all 
parts of the Netherlands were referred to the University Hospital of Maastricht.  
General study design  
The study was designed as a randomised, double-blind, placebo-controlled dose-
escalation test treatment during which the effects of intrathecal bolus injections 
with increasing doses of baclofen versus placebo were studied. All study phases, 
including the selection of referred children and hospitalisation, took place at the 
University Hospital of Maastricht. After admission, the neurosurgeon inserted an 
external lumbar catheter under general anaesthesia. The next morning, the first 
bolus with study medication was administered intrathecally via the catheter. The 
test regimen was as follows: the first two test days the bolus randomly contained 
ITB 25 μg or placebo. The following six test days the bolus contained ITB 50 μg 
or placebo, then ITB 75 μg or placebo and finally ITB 100 μg or placebo. For 
every patient, an individual randomisation list was used. Randomisation lists 
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were generated by an independent statistician, allowing for a balanced 
distribution of sequences within the same child as well as between the children. 
Randomisation lists were given to the pharmacist, who prepared the study 
medication every day according to the child’s individual randomisation list. The 
numbered study medication was then delivered to the investigator, who 
intrathecally administered it to the child. This means that, except for the 
pharmacist, all involved people were blinded to the contents of the study 
medication bolus. 
To evaluate the effects of bolus administration, individual goals of treatment were 
formulated in close consultation with the child and/or its caregivers in case the 
child was not able to give an opinion. These individual goals were closely 
monitored throughout the test days. To quantify muscle tone, the Ashworth scale 
was used (Table 2.1). At baseline, Ashworth scores were bilaterally measured in 
seven lower extremity muscle groups (hip flexors, hip extensors, hip adductors, 
knee flexors, knee extensors, ankle dorsiflexors and ankle plantar flexors). The 
hip, knee and ankle related muscle groups with the highest tone were then 
selected from these 14 baseline Ashworth scores. This selection was done for the 
left as well as for the right legs in total identifying six muscle groups with a 
relatively high tone per child. For every child, the Ashworth score was measured 
by the same physical therapist each test day before bolus administration and 2, 4 
and 6 hours after the bolus was administered. 
 
 
Table 2.1 Original Ashworth Scale8  
Score Description 
0 
1 
2 
3 
4 
No increase in tone 
Slight increase in tone giving a catch when the limb is moved in flexion or extension 
More marked increase in tone but limb easily flexed 
Considerable increase in tone, passive movement difficult 
Limb rigid in flexion or extension 
 
 
A positive clinical effect was achieved if the following two criteria were both 
met: 1) a satisfying improvement in the individual treatment goals as experienced 
by the child and/or observed by its caregivers, and 2) a minimal reduction of one 
point on the Ashworth scale in at least three of the six individually selected 
muscle groups. Furthermore, this one-point reduction had to last during two 
successive measurements after study medication bolus administration. On the 
day that a positive clinical response was observed, the test treatment was ended 
and the code was broken. Only if this positive clinical response was observed at 
the first test day, the child and/or parents were given the opportunity to 
experience the results of the second test day before the test treatment was ended. 
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If the child had responded to ITB, it was considered eligible for further treatment 
with continuous delivery of ITB. If after eight test days still no positive clinical 
effect had occurred, the child was not eligible for pump implantation.  
Electrophysiological studies 
The H-reflex and FR recordings were carried out in each child at different 
moments during the study. Baseline recordings were carried out at the clinical 
neurophysiology department before the start of the test treatment. At that time, 
the children did not have a spinal catheter in situ yet. During the test treatment, 
the electrophysiological procedures were carried out at the children’s ward. For 
every child, single recordings on the different test days took place at the same 
time interval after study medication bolus administration, which was on average 
150 min (range between children was 120-180 min). All children were awake 
during the recordings and were examined in supine position.  
The H-reflex was elicited by percutaneous stimulation of the posterior tibial nerve 
using handheld bipolar stimulation electrodes placed in the popliteal fossa. 
Stimulation was applied with 1 ms square wave pulses at a rate of 0.3 Hz. The 
reflex was recorded with bipolar surface bar recording electrodes with a 3 cm 
interelectrode distance. These electrodes were placed on the soleus muscle in the 
furrow between the heads of the gastrocnemii. The position of the recording 
electrodes was marked with indelible ink to facilitate equal electrode placement 
on the following test days. Maximum soleus H-reflex (Hmax) and maximum soleus 
motor response (Mmax) recruitment curves were obtained in 20 trails. Hmax and 
Mmax were defined as peak-to-peak maximal amplitudes of the H and M 
responses, respectively. Hmax, Mmax and the H/M ratio were determined, the latter 
defined as the ratio between Hmax and Mmax. 
The FR was evoked by electrical stimulation of the tibial nerve behind the medial 
malleolus. Stimulation consisted of trains of five 1 ms square wave pulses at 300 
Hz.33 The interval between stimulus trains was kept at 60 s to allow time for full 
recovery from the central excitability changes produced by the previous 
stimulus.15 Electromyographic (EMG) activity was recorded from the tibialis 
anterior muscle by placing two silver/silver chloride disk electrodes. The active 
electrode was placed on the belly of the tibialis anterior muscle, four fingers 
below the tibial tuberosity. The reference electrode was placed about 5 cm lower 
on the tibia. FR were recorded in a 1000 ms window amplified with a band pass 
of 30-3000 Hz. First, the FR threshold defined as the lowest intensity to elicit a 
reproducible FR, was registered in milliamperes (mA). The stimulus intensity was 
then increased by 2.5 mA steps. With each stimulus intensity, one trial was 
recorded until the first FR was evoked. If an FR occurred, a second trial with the 
same stimulus intensity was performed to confirm reproducibility. Secondly, the 
concordant area of the FR was calculated by integrating the EMG activity of the 
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response over the 1000 ms window, expressed in mVms. If a two-component FR 
would appear, the EMG activity of both components would be integrated to 
measure the FR area. The amplitude of the stimulus was then gradually increased 
to produce supramaximal stimulation (25% more than the amplitude of the 
stimulus required to produce the FR with minimal latency). The area of the 
supramaximal response was measured as described above.  
Outcome measures 
If the children tolerated the tests at both legs at all different test moments, we 
considered the H-reflex and FR measurements feasible. The electrophysiological 
outcome measures included the values of Hmax, H/M ratio, FR threshold, FR 
threshold area and the FR stimulus intensity and FR area of the response elicited 
with supramaximal stimulation.  
Statistical analysis 
SPSS for Windows statistical package, Release 11.0.1., was used for the statistical 
analyses. Baseline comparisons and comparisons between the children with and 
without oral baclofen were done using the non-parametric Mann-Whitney U test. 
Paired-samples t tests and non-parametric tests (Wilcoxon Signed Rank Test and 
Sign Test) were performed to compare the mean H-reflex and FR measurements 
at baseline, after administration of placebo and after administration of baclofen in 
all children. Three groups of separate analyses were performed: for both legs 
together, for the left legs separately and for the right legs separately. Results with 
p-values below or equal to 0.05 were considered statistically significant. 
Correction for multiple comparisons was done using the Hochberg procedure.34 
According to both the t tests and the non-parametric tests, the same comparisons 
were statistically significant. We chose to describe the results of the Paired-
samples t tests, as the non-parametric tests only provided p-values. 
Ethical aspects 
The study was approved by the local medical ethical committee. The nature of 
the procedures was fully explained to the children and their parents. According 
to local legislation, written informed consent was obtained from the parents and 
also from the children themselves, if they were aged 12 years or older and 
capable of understanding the nature of the procedures. In case a child offered 
resistance or showed inconvenience during the recordings, we immediately 
stopped further testing without any consequences for the participation of the 
child in the study or its medical treatment in general. Children who were able to 
communicate were asked to alert the investigator in case of any discomfort or the 
wish to terminate the recordings. We relied on the parents’ opinion in case a 
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child was not able to communicate, as they recognised best the condition of their 
child. 
RESULTS 
Patients 
Sixteen children, eight boys and eight girls, aged between 7 and 16 years (mean 
13.06 ± 2.82), were included. All children suffered from intractable spasticity due 
to CP. According to the Gross Motor Function Classification System (GMFCS, 
Table 2.2), one child was classified in group III, two in group IV and thirteen in 
group V.35,36 The children classified in GMFCS group III and IV had a spastic 
diplegia and the children classified in GMFCS group V had a spastic tetraplegia. 
Consistent with the clinical pictures of a spastic diplegia and tetraplegia, 
spasticity as assessed during neurological examination was about equal in both 
legs in the majority of children. As we often could not determine which side was 
more involved, analyses were performed for both the left legs and the right legs 
separately. The mean baseline Ashworth scores for the individually selected hip, 
knee and ankle related muscle groups with highest tone were at the left legs, 
respectively, 2.50 ± 0.52, 2.44 ± 1.15 and 2.63 ± 0.89. For the right legs these 
values were, respectively, 2.19 ± 0.91, 2.38 ± 1.03 and 2.31 ± 0.95. Seven 
children were taking oral baclofen (mean dose 1.10 ± 0.31 mg/kg) and they 
continued this during the study. Comparison of children with (n = 7) and without 
(n = 9) the taking of oral baclofen showed no difference in baseline Ashworth 
scores, baseline Hmax, H/M ratio or FR threshold. However, baseline FR threshold 
area was significantly lower in the children taking oral baclofen (left legs of 
children with oral baclofen 51 ± 27 mVms and without oral baclofen 136 ± 63 
mVms, p = 0.019; right legs of children with oral baclofen 70 ± 58 mVms and 
without oral baclofen 149 ± 78 mVms, p = 0.052). 
Clinical effects 
All children showed a positive clinical effect in response to intrathecal bolus 
administration of baclofen at some day during the test treatment and 
subsequently received a pump for the continuous delivery of ITB. The effective 
ITB dose was 12.5 μg in one child, 25 μg in 10 and 50 μg in five children. For the 
child who already responded to ITB 12.5 μg, we deviated from the protocol by 
starting with this lower dose, as this child was known to easily experience side 
effects in response to different oral medications. The children who required ITB 
50 μg to experience a positive clinical response were significantly older 
(p = 0.033) and weighed more (p = 0.007) than the children who positively 
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responded to ITB 12.5 μg or ITB 25 μg. No significant difference was found for 
baseline GMFCS, Hmax, H/M ratio or FR values. The test treatment included at 
least one placebo day for 14 children. Two children received ITB at their first test 
day and showed a clear positive clinical response at once. We did not include 
the electrophysiological data of these two children in the analyses, even though 
the recordings of the H-reflex were feasible in both children and the recordings of 
the FR threshold in one child. 
 
 
Table 2.2 Gross Motor Function Classification System (GMFCS) levels at ages 6 to 12 years  
Level Description 
I 
II 
III 
IV 
 
V 
Walks without restrictions; limitations in more advanced gross motor skills 
Walks without assistive devices; limitations walking outdoors and in the community 
Walks with assistive mobility devices; limitations walking outdoors and in the community 
Self mobility with limitations; children are transported or use power mobility outdoors  
and in the community 
Self-mobility is severely limited even with the use of assistive technology 
 
H-reflex 
Feasibility of the H-reflex was 93% as 13 of the 14 children tolerated the 
evocation of the H-reflex in both legs during baseline measurements and during 
all test days. One child (effective ITB dose 50 μg) did not tolerate the 
electrophysiological measurements at all and was therefore excluded from this 
part of the study. Table 2.3 shows the results of the H/M ratio measurements at 
baseline, after intrathecal administration of placebo and after intrathecal 
administration of the effective baclofen dose. Retrospectively, the baseline 
M -response in the left leg of one child proved to be unreliable, probably as the 
result of malpositioning of the electrodes. When we included this very low 
M-value, it would distort the calculations to such an extent that we decided to 
leave the particular leg out of account in the analyses of the H-reflex. 
Comparison of the results in children who did (n = 5) and did not take oral 
baclofen (n = 8) showed no significant differences between Hmax, Mmax or H/M 
ratio at baseline, after placebo or after ITB. Therefore, the results of the H-reflex 
analyses include all children, irrespective of the taking of oral baclofen. 
After the administration of placebo, Hmax did not change significantly from 
baseline for both legs (left legs: 3.4 ± 2.3 mV at baseline and 3.4 ± 2.2 mV after 
placebo; right legs: 3.4 ± 1.6 mV at baseline and 3.4 ± 2.1 mV after placebo). 
The respective M-waves were also similar (left legs: 6.4 ± 4.5 mV at baseline and 
6.9 ± 4.2 mV after placebo; right legs: 7.8 ± 4.1 mV at baseline and 7.7 ± 3.9 mV 
after placebo). Consequently, H/M ratios were also similar (Table 2.3, Figure 
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2.1A). In relative terms, H/M ratios after placebo on the left and right legs 
measured on average 121% and 109% of the respective baseline values. 
 
 
Table 2.3 Mean H/M ratio values with standard deviations at baseline and after administration of 
placebo and the effective baclofen dose  
Legs n Baseline 
mean H/M 
Placebo 
mean H/M 
Baclofen 
mean H/M 
Difference in 
mean H/M 
95% CI p Corrected 
p 
All 25  0.61 ± 0.40  0.71 ± 0.70   -0.10 ± 0.47  -0.29 - 0.09 0.292 0.614 
 25  0.61 ± 0.40   0.14 ± 0.18  0.46 ± 0.44  0.28 - 0.65 0.000 0.000 
Left 12  0.67 ± 0.47  0.85 ± 0.90   -0.17 ± 0.56  -0.53 - 0.18 0.307 0.614 
 12  0.67 ± 0.47   0.15 ± 0.18  0.53 ± 0.52  0.20 - 0.86 0.005 0.020 
Right 13  0.55 ± 0.32  0.58 ± 0.46   -0.03 ± 0.37  -0.26 - 0.19 0.751 0.751 
 13  0.55 ± 0.32   0.14 ± 0.19  0.40 ± 0.37  0.18 - 0.63 0.002 0.010 
Differences between the H/M ratios are shown with the 95% confidence intervals (CI) and 
corresponding p-values 
 
After the administration of ITB, Hmax decreased significantly for both legs in 
comparison with baseline (left legs: 3.4 ± 2.3 mV at baseline and 0.9 ± 1.2 mV 
after ITB, p = 0.007; right legs: 3.4 ± 1.6 mV at baseline and 0.6 ± 0.7 mV after 
ITB, p = 0.000). The respective M-waves were similar to baseline (left legs: 
6.4 ± 4.5 mV at baseline and 6.9 ± 4.1 mV after ITB; right legs: 7.8 ± 4.1 mV at 
baseline and 6.7 ± 3.2 mV after ITB). Consequently, after ITB the H/M ratios 
significantly decreased for both legs (Table 2.3, Figure 2.1B). In relative terms, 
H/M ratios after ITB on the left and right legs measured on average 25% and 33% 
of the respective baseline values. In 75% and 77% respectively, baseline H/M 
ratio was reduced by at least half. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 A H/M ratios at baseline and after administration of placebo (• left legs,   right legs) 
 B H/M ratios at baseline and after bolus administration of the effective ITB dose (• left 
legs,   right legs). Note that most H/M ratios substantially decreased with ITB 
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Flexor reflex 
Feasibility of the FR threshold and concordant FR threshold area was 64%, as 
nine of the 14 children tolerated the evocation of the FR in both legs during 
baseline measurements and during all test days. In one of these children, the 
baseline recordings of the right leg were missing due to a filing error. Another 
child did not tolerate bilateral FR recordings every time, but all recordings in her 
right leg were accomplished. Thus, the results of 18 legs from 10 children are 
presented. Table 2.4 shows the results of the FR threshold and FR threshold area 
at baseline, after intrathecal administration of placebo and after intrathecal 
administration of the effective baclofen dose. Children taking oral baclofen 
(n = 3) had significantly lower FR threshold area values at these three test 
moments compared to children not taking oral baclofen (n = 7). Therefore, FR 
threshold area analyses were performed for both groups separately (Tables 2.4B 
and 2.4C). Unlike the FR threshold area, the FR threshold values did not show 
significant differences between the children who took oral baclofen and those 
who did not. Therefore, the results of the FR threshold analyses include all 
children, irrespective of the taking of oral baclofen (Table 2.4A). 
After the administration of placebo, neither the FR threshold (Table 2.4A) nor the 
FR threshold area (Tables 2.4B and 2.4C) changed significantly from baseline for 
both legs. In relative terms, FR threshold after placebo at the left and right legs 
measured on average 90% and 118% of the respective baseline values, 
irrespective of the taking of oral baclofen. FR threshold area after placebo at the 
left and right legs measured on average 71% and 121% of the respective baseline 
values for the children not taking oral baclofen, whereas it measured 181% and 
204% respectively, for those taking oral baclofen. 
After the administration of ITB, the FR threshold did not change significantly from 
baseline for both legs (Table 2.4A). In relative terms, FR threshold after ITB at the 
left and right legs measured on average 100% and 158% of the respective 
baseline values. Compared to baseline, the FR threshold area after ITB decreased 
significantly in both legs, but only for those children who did not take oral 
baclofen (Table 2.4B). For those children who took oral baclofen, the FR 
threshold area after ITB bilaterally remained the same (Table 2.4C). In relative 
terms, FR threshold area after ITB at the left and right legs measured on average 
24% and 44% of the respective baseline values for the children not taking oral 
baclofen, whereas it measured 163% and 74% respectively, for the children 
taking oral baclofen. 
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Table 2.4 Mean FR threshold (FRth) and FR threshold area (FRa) values with standard deviations at 
baseline and after administration of placebo and the effective baclofen dose 
A Mean FR threshold (FRth) values in milliamperes (mA) for all children, irrespective of the taking of 
oral baclofen 
Legs n Baseline 
mean FRth 
Placebo 
mean FRth 
Baclofen 
mean FRth 
Difference in 
mean FRth 
95% CI p Corrected 
p 
All 18  7.0 ± 2.9  6.8 ± 3.3   0.2 ± 2.8  -1.2 - 1.6 0.757 0.757 
 18  7.0 ± 2.9   8.3 ± 3.6  -1.2 ± 3.2  -2.8 - 0.4 0.124 0.620 
Left   9  7.0 ± 2.7  5.9 ± 1.8   1.2 ± 2.8  -1.0 - 3.4 0.247 0.757 
   9  7.0 ± 2.7   6.7 ± 1.8  0.3 ± 1.5  -0.9 - 1.5 0.565 0.757 
Right   9  7.0 ± 3.3  7.8 ± 4.2   -0.8 ± 2.5  -2.7 - 1.2 0.385 0.757 
   9  7.0 ± 3.3   9.8 ± 4.4  -2.8 ± 3.8  -5.7 - 0.2 0.061 0.366 
 
B Mean FR threshold area (FRa) values in millivolt milliseconds (mVms) for children not taking oral 
baclofen 
Legs n Baseline 
mean FRa 
Placebo 
mean FRa 
Baclofen 
mean FRa 
Difference in 
mean FRa 
95% CI p Corrected 
p 
All 13  152 ± 66  128 ± 56   24 ± 77  -23 -   71 0.289 0.578 
 13  152 ± 66   55 ± 50  97 ± 39  73 - 120 0.000 0.000 
Left   6  146 ± 53  100 ± 66   46 ± 77  -35 - 127 0.202 0.606 
   6  146 ± 53   41 ± 54  105 ± 29  74 - 136 0.000 0.000 
Right   7  156 ± 80  151 ± 36   5 ± 78  -67 -   77 0.879 0.879 
   7  156 ± 80   66 ± 48  90 ± 47  47 - 133 0.002 0.008 
 
C Mean FR threshold area (FRa) values in millivolt milliseconds (mVms) for children taking oral 
baclofen 
Legs n Baseline 
mean FRa 
Placebo 
mean FRa 
Baclofen 
mean FRa 
Difference in 
mean FRa 
95% CI p Corrected 
p 
All 5  26 ± 16  60 ±   79   -34 ±   65  -115 -   47 0.308 0.540 
 5  26 ± 16   51 ±   94  -26 ±   79  -124 -   73 0.511 0.540 
Left 3  34 ± 16  79 ± 104   -46 ±   88  -264 - 172 0.462 0.540 
 3  34 ± 16   78 ± 122  -45 ± 106  -308 - 218 0.540 0.540 
Right 2  14 ±   3  30 ±   26    -16 ±   24  -229 - 196 0.506 0.540 
 2  14 ±   3   11 ±     6  3 ±     3  -23 -   29 0.359 0.540 
Differences between the FR threshold values are shown with the 95% confidence intervals (CI) and 
corresponding p-values 
 
 
The FR elicited with supramaximal stimulation at baseline was tolerated by two 
children in both legs and by two children in one leg. Feasibility of the FR with 
supramaximal stimulation was 7%, as only one of the 14 children tolerated these 
higher stimulus intensities at both ankles during all different test moments. 
Therefore, we did not carry out any statistical analyses on the FR, elicited with 
supramaximal stimulation. 
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DISCUSSION 
This is the first randomised, double-blind, placebo-controlled dose-escalation 
study demonstrating the H-reflex as a feasible, useful and objective test to 
quantify the decreasing motoneuron excitability in response to ITB bolus 
administration in a relatively large group of spastic children. The mean Hmax and 
H/M ratio values decreased significantly after ITB bolus administration and there 
was no placebo effect. In concordance with the knowledge that mental 
retardation is seen in 60% to 65% of children with a tetraplegia due to CP, 
cooperation was limited in our study group with children suffering from 
intractable spasticity due to CP.37 Nevertheless, in our study the H-reflex was 
feasible in 93% of the children. We therefore consider the H-reflex as a widely 
applicable neurophysiological test.  
The primary aim of an ITB test treatment is to find out whether the patient will 
benefit from pump implantation for the continuous delivery of intrathecal 
baclofen. This decision should be primarily based on a positive clinical response 
to ITB bolus administration as experienced by the patient or as observed by the 
caregivers in case of children or adults who are not able to give their opinion. 
Reducing spasticity is not a treatment goal in itself, as spasticity can be 
functional, enabling the patient to stand in spite of any limb weakness.38 
Spasticity is only treated when it leads to clinical symptoms or signs that are 
considered disabling. For each patient, individual goals of treatment are set. 
Improving (self) care and abolishing pain were main treatment goals in our study 
population and any improvement in these goals could be closely observed during 
the ITB bolus test treatment. In adjunct to this clinical evaluation, Hmax as well as 
the H/M ratio proved to be sensitive parameters in assessing the baclofen 
induced decrease in motoneuron excitability. It is considered that the use of the 
H/M ratio is better, as it includes a normalisation procedure controlling for 
differences in skin impedance and location of the electrodes.21,39 Nevertheless, a 
few of the H/M ratios found in our study were larger than 1.0. These aberrant 
results could be explained by suboptimal positioning of the stimulation 
electrodes. The supine position of the children and knee flexion deformities 
could have interfered with the stimulation of the posterior tibial nerve in the 
popliteal fossa. In case nerve stimulation would be suboptimal, Hmax would still 
be recorded well, whereas Mmax would possibly not have been attained.  
Our findings correspond with the results of Dachy and Dan who carried out a 
non-placebo-controlled study in which they studied changes in the H/M ratio 
and the FR after intrathecal bolus injection of baclofen in five children with 
severe spasticity of mixed aetiology.40 Two hours after administration of a 50 μg 
ITB dose, the H-reflex had disappeared in four children and the H/M ratio was 
reduced by 56% in the fifth child. Yablon and Stokic have reviewed several non-
placebo-controlled studies which have addressed changes in H/M ratio after ITB 
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bolus delivery in a total of 101 adults.11 The H/M ratio typically decreased or the 
H-reflex disappeared after ITB bolus injection, in a dose-dependent 
manner.25,26,41,42 Stokic et al. demonstrated the H/M ratio to be more sensitive 
than the Ashworth score in detecting a physiological response to ITB bolus 
delivery.13  
There are several useful applications for the H-reflex during different phases of 
ITB treatment.11 If a patient for example does not respond to increasing ITB doses, 
it may be questioned whether the baclofen has been delivered at all and whether 
spinal cord neurons have responded yet. In that case H-reflex values can be 
useful by confirming or negating successful ITB delivery.11 Recording an 
individual H-reflex profile can also be useful during ITB dose titration and for 
early indicating pump or catheter related complications.43 The definite intrathecal 
drug delivery system is composed of a programmable infusion pump implanted 
in the abdominal wall and a connecting catheter, which is inserted in the 
intrathecal space in the spine. Sudden or gradual increases in the H/M ratio 
should give rise to suspicion on a low pump reservoir baclofen volume or a 
catheter or pump related complication.43 It is very important to detect these 
complications in an early stage, as abrupt interruption of ITB delivery can lead to 
the potentially life threatening ITB withdrawal syndrome.44,45   
We will now discuss our results with regard to the FR parameters. Unlike the 
Hmax, the H/M ratio and the FR threshold, the average FR threshold area was 
significantly lower in children who took oral baclofen in comparison with 
children who did not take oral baclofen. This difference was observed during the 
measurements at baseline and after the administration of, respectively, placebo 
and baclofen. Apparently, due to oral baclofen the excitability of the FR spinal 
interneuron system had already decreased, whereas the excitability of the 
neurons associated with the H-reflex had not yet changed. Baclofen is a GABA-B 
receptor agonist. In the mammalian spinal cord, GABA is highest concentrated in 
the dorsal grey matter, followed by the ventral grey matter with only minimal 
amounts in the white matter.46 In the dorsal horn, GABA-B is predominantly 
found in laminae I-III in interneurons, which are presynaptic to dendrites, cell 
bodies and other axon terminals.46 It is postulated that the presynaptic inhibition 
and other gating mechanisms related to pain and flexor spasms take place in the 
dorsal horn.18 On the other hand, the muscle relaxant effect of baclofen takes 
place in the ventral horn, where GABA is localised in interneurons presynaptic to 
motoneuron cell bodies and small and large dendrites.46 Thus, our finding that 
oral baclofen only had an inhibitory effect on the FR threshold area may be 
explained by the higher concentrations of GABA in the dorsal horn where the 
connections of the FR interneuronal network are localised.  
In our study, the taking of oral baclofen had already resulted in such a decrease 
in mean FR threshold area that a floor effect seemed to have appeared and no 
further decrease could be observed after ITB administration. However, in the 
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children who did not take oral baclofen, FR threshold area in both legs decreased 
significantly with ITB. In conclusion, our findings imply that only in children who 
do not take oral baclofen, the FR threshold area can also be a useful measure to 
evaluate the effect of ITB administration. Nevertheless, even recording the FR 
threshold and concordant FR threshold area by stimulation with lowest intensities 
was tolerated in only 63% of children. This lower tolerance is probably due to 
the painful stimuli required to activate the small-diameter, high-threshold 
nociceptive A-delta fibers.33 Moreover, during the FR the sudden withdrawal of 
the legs would often result in a generalised startle response and sometimes in 
pain. 
Dachy and Dan described an increase in FR threshold and a decrease in FR 
threshold area after ITB bolus administration in six spastic children.40 Parise et al. 
reported an increase of biceps femoris FR threshold and a decrease of FR area in 
17 spastic adults who were treated with continuous ITB delivery.12 FR area values 
were obtained with high stimulus intensities, which were required to obtain a 
maximal response prior to baclofen treatment. In our study population, increasing 
stimulation intensities to determine the maximum FR was rarely tolerated. We 
therefore advise against the use of the FR, elicited with supramaximal stimulation, 
in spastic children. 
CONCLUSIONS 
Irrespective of the taking of oral baclofen, the soleus H-reflex is a feasible and 
useful objective measure to quantify the decreasing motoneuron excitability in 
response to ITB bolus administration. Being tolerated by children with severe 
spastic type CP, we consider the H-reflex as a widely feasible electro-
physiological test. In children who do not take oral baclofen, the FR threshold 
area can also be used as an objective outcome measure in ITB treatment. 
However, the H-reflex had a better feasibility than the FR in our study 
population. We suggest introducing the H-reflex as the electrophysiological gold 
standard for the evaluation of the effect of ITB in spastic children. 
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ABSTRACT 
Intrathecal baclofen therapy can be very effective in the treatment of intractable spasticity, 
but its effectiveness and safety have not yet been thoroughly studied in children with 
cerebral palsy. The aims of this double-blind, randomised, placebo-controlled, dose-
finding study were to select children eligible for continuous intrathecal baclofen infusion, 
to assess the effective intrathecal baclofen bolus dose and evaluate the effects, side effects 
and complications. Outcome measures included the original Ashworth scale and the 
visual analogue scale for individually formulated problems. We included nine girls and 
eight boys, aged between 7 and 16 years (mean 13y2m ± 2y9m). Twelve children had 
spastic cerebral palsy and five spastic-dyskinetic cerebral palsy. One child was classified 
on the Gross Motor Function Classification System at level III, two at level IV and 14 at 
level V. The test treatment was successful in all 17 children with an effective intrathecal 
baclofen bolus dose of 12.5 μg in one, 20 μg in another, 25 μg in ten and 50 μg in five 
children. Intrathecal baclofen significantly reduced muscle tone, diminished pain and 
facilitated ease of care. Placebo did not have these effects. Nine side effects of intrathecal 
baclofen were registered, including slight lethargy in seven children. Fourteen children 
had symptoms of lowered cerebrospinal fluid pressure. This complication did not occur in 
three children in whom the neurosurgeon had tunnelled the catheter subcutaneously. We 
conclude that intrathecal baclofen bolus administration is effective and safe for carefully 
selected children with intractable spastic cerebral palsy. 
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INTRODUCTION 
Spasticity accounts for 70 to 91% of the motor disorders associated with cerebral 
palsy (CP).1 In severely affected children (Gross Motor Function Classification 
System (GMFCS) levels IV and V), it can cause pain, sleeping disorders, increased 
energy requirements, and interference with positioning, transfers, dressing, and 
body hygiene. Secondary phenomena such as contractures and pressure sores 
can add to the treatment problems. A substantial group of children with severe 
spastic type CP does not respond to regular treatments, such as physical therapy, 
orthopaedic surgery, or oral medication. An effective treatment option for 
intractable spasticity is continuous infusion of intrathecal baclofen (CITB).2-4 
Baclofen acts as a gamma-aminobutyric acid (GABA-B) agonist, which is a major 
inhibitory neurotransmitter predominantly found in laminae I to III of the spinal 
cord dorsal horn.5 Baclofen passes the blood-brain barrier poorly; as a result, 
taking oral baclofen leads to high blood levels and virtually undetectable levels 
in the cerebrospinal fluid (CSF). Conversely, administration of a hundredth part of 
the oral baclofen dose intrathecally can relieve spasticity without the side effects 
often encountered with high baclofen doses taken orally.6 Intrathecal baclofen 
(ITB) can be delivered continuously by a programmable infusion pump implanted 
in an abdominal subcutaneous or subfascial pocket, and a connecting catheter, 
which is inserted in the intrathecal space. Before pump implantation, patients 
will usually have an ITB test treatment to evaluate whether ITB gives the desired 
effect without unacceptable side effects.  
In 1985, Penn and Kroin established the effectiveness of CITB in patients with 
spasticity of spinal origin.7 In the same year, Dralle et al. reported on the 
beneficial effect of ITB in a child with spasticity of cerebral origin.8 In 2000, the 
American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) 
published a systematic review on the degree of evidence about ITB treatment for 
spasticity in individuals with CP.9 They concluded that except for two case 
reports, none of the studies solely concerned children. They underlined the need 
for further prospective, randomised trials that use valid and reliable outcome 
measures, in well-described and homogeneous patient groups. 
In 2002, we started the Dutch national study on the efficacy and safety of CITB 
for intractable spasticity in children with CP. The study included the selection, 
test treatment, pump implantation, and follow-up phases. In the present article 
we report on the double-blind, randomised, placebo-controlled, dose-finding ITB 
test treatment. The aims were: 1) to select children eligible for CITB treatment, 2) 
assess the effective ITB bolus dose, and 3) evaluate the effects, side effects, 
complications and procedures. 
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METHODS 
Participants and general study design  
Medical specialists referred children from all parts of the Netherlands to the 
University Hospital Maastricht for possible participation in the Dutch national 
ITB study. In Maastricht, where all phases of this national study took place, a 
multidisciplinary team decided whether the child met the eligibility criteria 
(Table 3.1). We planned a test treatment for eligible children. After admission, the 
neurosurgeon inserted under general anaesthesia an external lumbar catheter 
(Perifix® 300 Mini Set; B Braun, Melsungen, Germany). Postoperatively and 
during the test days, the children stayed on the paediatric medium care unit, 
where vital signs were monitored. The morning after catheter insertion, the first 
study medication bolus was administered intrathecally via the catheter. During 
the first two test days the bolus randomly contained baclofen 25 μg or placebo. 
On each of the subsequent six test days the bolus contained baclofen 50 μg or 
placebo, then baclofen 75 μg or placebo, and, finally, baclofen 100 μg or 
placebo. Thus, in a given two-day treatment period, patients received baclofen 
and placebo in random order. An independent statistician generated the 
randomisation lists, permitting a balanced distribution of study medication 
sequences within the same child as well as between the children. The pharmacist 
prepared and numbered the study medication in accordance with these 
randomisation lists. All other involved people were blinded to the contents of the 
study medication boluses. 
 
 
Table 3.1 Eligibility criteria for participants 
Inclusion criteria 
   1) Age between 4 and 16 years 
   2) Spastic diplegia or tetraplegia as part of cerebral palsy 
   3) Insufficient response to oral spasticity-reducing medication 
   4) In a mixed cerebral palsy syndrome, spasticity is the most prominent sign 
   5) Spasticity results in a decrease in the quality of life of the child and/or its caregivers 
   6) Sufficient motivation for study participation including availability for follow-up 
   7) Magnetic resonance imaging of the brain rules out progressive diseases 
   8) Minimal weight of 20 kg (valid until January 1st 2004) 
   9) Wheelchair bound without ability to creep or sit unsupported (valid until January 1st 2004) 
 10) Child is able to understand and carry out instructions (valid until January 1st 2004) 
Exclusion criteria 
   1) Hypersensitivity to baclofen 
   2) Contraindications for general anaesthesia 
   3) Insufficient general health 
   4) Intractable epileptic seizures 
   5) Infection of the lumbar skin 
   6) Systemic infection 
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In consultation with the child and the caregivers, we formulated three individual 
problems. The treatment goals were to improve these individually formulated 
problems. During test days, caregivers took notes about the treatment goals, other 
effects, and any side effects, including the time of occurrence. An experienced 
paediatric physiotherapist measured Ashworth scores every day before bolus 
administration (baseline) and 2, 4 and 6 hours afterwards.10 Ashworth scores 
were bilaterally assessed in seven lower-extremity muscle groups (hip adductors, 
flexors, and extensors; knee flexors and extensors; and ankle plantarflexors and 
dorsiflexors). Before catheter insertion, we selected the hip, knee, and ankle-
related muscle group with highest tone on both sides, in total identifying six 
muscle groups per child. We defined the clinical effect as positive only if the 
following two criteria were met: 1) a satisfying improvement in the individual 
treatment goals as experienced by the child and/or the caregivers, and 2) at least 
a one-point reduction on the Ashworth scale compared with the baseline score of 
that specific day, in at least three of the six individually selected muscle groups. 
Furthermore, this one-point reduction had to last for two successive 
measurements on the same day.2,10,11 On the day that a positive clinical response 
was observed, the test treatment ended and the study medication code was 
broken. Only if this positive clinical response was observed at the first test day 
did the child and caregivers have the opportunity to experience the results of the 
second test day before the test treatment was ended. We offered this opportunity, 
because the decision on pump implantation should be well based. Having 
noticed a positive clinical response on the first test day, children and parents 
might have a need for confirmation by observing a lack of effect on the second 
test day. If the code break proved that the child had responded to baclofen, he or 
she was considered eligible for further treatment with CITB. If after eight test days 
no positive clinical effect had been observed, the child was not eligible for pump 
implantation.  
Outcome measures 
We used the original Ashworth scale12 and the visual analogue scale (VAS) for 
individually formulated problems as outcome measures. In daily clinical practice, 
there is as yet no objective outcome measure available to evaluate the effect of 
ITB bolus administration in children with spastic CP. Therefore, in spite of its 
limitations, the standard clinical scale for measuring spasticity is the Ashworth 
scale.12,13 It is a score for grading muscle tone and does not exclusively quantify 
spasticity. It lacks sensitivity for the detection of small changes in muscle tone. 
The strengths of the Ashworth scale are that it quickly provides information on 
muscle tone and it can be easily measured several times a day.13 Children were 
examined in supine position with a cushion under their knees. The environment 
was kept as quiet as possible. For each child, the Ashworth scores were always 
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rated by the same paediatric physical therapist.14 Before muscle tone was graded, 
the particular limb was passively stretched an average of three times.14 In most 
previous studies, Ashworth scores of different muscles had been added up to 
produce a summed Ashworth score.2,10,11 This is methodologically incorrect, 
because the Ashworth score is an ordinal level measure.14 
The VAS is a valid and reliable measure in rating pain intensity in adults and 
children over six years of age.15-17 It has also been used for measuring 
satisfaction,18 feelings,19 quality of sleep,19 dyspnoea,20,21 emotional function,20,21 
and fatigue,20,21 and seemed to be responsive19-21 and valid.21 Because the 
children in our study had different problems, we used the VAS for measuring the 
severity of the individually formulated problems. The VAS for pain is a straight 10 
centimetre horizontal line with anchor points of ‘no pain’ (score 0) and 
‘unbearable pain’ (score 10).16 We changed the anchor points in ‘very 
dissatisfied’ (score 0) and ‘very satisfied’ (score 10) to permit the uniform use of 
the VAS for the defined individual problems. Depending on both the ability to 
understand the test and to draw a vertical line, the VAS was rated by the child or 
by a parent. Each VAS was rated once before the test treatment would start 
(baseline) and at the end of each test day, reviewing the observations of that day. 
During VAS rating, the children and parents did not know the Ashworth scores 
for that day. 
Side effects and complications 
We registered side effects and complications on standardised forms. The form for 
side effects was filled out twice every test day: before bolus administration and at 
the end of the test day, reviewing the observations of that day. In this way we 
could identify better any study medication related side effects. 
Statistical analysis 
The statistical package SPSS for Windows, Release 11.0.1., was used for 
statistical analyses. We applied non-parametric methods, because of the small 
sample size. In small samples, it is not possible to be sure that a variable is 
normally distributed. The Wilcoxon Signed Rank Test was used to compare the 
Ashworth scale and VAS-scores at baseline and after intrathecal administration of 
placebo and the effective baclofen dose. The Mann-Whitney U test was used to 
analyse whether children who required an ITB dose ≥50 μg differed in age, 
weight, sex, GMFCS level, CP type, or the use of oral baclofen from children 
requiring an ITB dose <50 μg. Results with p ≤ 0.05 were considered statistically 
significant. 
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Ethical approval and consent 
The study was approved by the medical ethical committee of the University 
Hospital Maastricht. In accordance with local legislation, we obtained written 
informed consent from the parents, and also from the children, if they were aged 
12 years or older and capable of understanding the nature and impact of the 
study.  
RESULTS 
Participants 
Thirty-eight children, 23 boys and 15 girls, were referred as possible candidates 
for the Dutch national ITB study. The main reasons for referral were ‘having pain’ 
and problems with ‘ease of care’. From January 2002 to December 2003 many 
children who wished to participate were not included because they did not meet 
the weight, mobility, and/or the cognition criteria. We therefore decided to widen 
the eligibility criteria by omitting inclusion criteria 8, 9 and 10 from January 2004 
(Table 3.1). Seventeen children, among them nine girls and eight boys, aged 
between 7 and 16 years (mean 13y2m ± 2y9m), were included. The 
characteristics of the included children are summarised in Table 3.2. Seven 
children still used oral baclofen and they continued this use during the test 
treatment.  
 
Table 3.2 Characteristics of the participants 
Case  Age 
 and 
 sex 
Weight 
(kg) 
Cerebral palsy 
type 
 
Diplegia/ 
tetraplegia 
GMFCSa 
level 
Oral baclofen 
dose 
(mg/kg) 
Associated problemsb 
  1  15 F 34 spastic/dyskinetic  tetra V - con, uro 
  2  11 M 26 spastic  tetra V - spe, dro, con, uro, brp  
  3  14 M 30 spastic  tetra V - spe, dro, con, uro, epi, brp 
  4  12 F 40 spastic/dyskinetic  tetra V - spe, dro, vis 
  5  16 M 84 spastic  di IV - slp 
  6  13 F 60 spastic/dyskinetic  tetra V 1.00 spe, uro, slp, vis 
  7    9 F 22 spastic/dyskinetic  tetra V 1.36 spe, dro, con, uro, slp, epi, aud 
  8  16 M 51 spastic  tetra V - spe, dro, con, epi 
  9  16 F 35 spastic  tetra V - spe, dro, con, uro, slp, vis, epi, brp 
10    7 M 24 spastic  tetra V 1.35 spe, dro, uro, slp, epi 
11  14 M 17 spastic  tetra V 0.59 spe, dro, con, uro, slp, vis, epi, brp 
12  12 F 33 spastic  tetra V - spe, dro, uro, vis 
13  16 M 70 spastic  di III 0.86 - 
14  16 F 48 spastic  di IV - con, uro  
15  15 F 33 spastic/dyskinetic  tetra V - spe, dro, con, uro 
16  10 F 27 spastic  tetra V 1.11 spe, dro, con, vis 
17  12 M 21 spastic  tetra V 1.43 spe, dro, con, slp 
a GMFCS, Gross Motor Function Classification System; b spe = speech problem; dro = drooling; con = constipation; 
uro = urological problem; slp = sleeping disorder; vis = visual impairment; epi = epilepsy; brp = bronchopulmonary 
problem; aud = auditory problem  
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Effects 
All 17 children showed a positive clinical effect in response to an ITB bolus dose. 
Table 3.3 shows the number of test days, the study medication randomisation 
sequences, and the effective ITB dose per child. The effective ITB dose was 12.5 
μg in one child, 20 μg in another, 25 μg in ten and 50 μg in five children. For the 
child who already responded to ITB 12.5 μg, we deviated from the protocol by 
starting with this lower dose. This child was known to experience side effects 
easily in response to different oral medications. The child who responded to ITB 
20 μg had two separate test treatments. During the first day of the first test 
treatment he experienced apathy and, in upright position, nausea and vomiting. 
His vital signs were normal. We broke the test treatment off, because his 
condition impeded the observation of effects and side effects. During a second 
admission, we did an open-label test treatment administering ITB 20 μg by 
lumbar puncture. This resulted in a positive clinical response and slight lethargy 
as side effect. We excluded the test results of this boy from statistical analyses 
because the test treatment had not been carried out double-blind.  
The five children who required ITB 50 μg were significantly older (p = 0.037) and 
weighed more (p = 0.007) than the 12 children who responded to a lower dose 
of ITB. No significant difference was found for sex, GMFCS, CP type or the use of 
oral baclofen. The caregivers noted effects from about 1.5 to 9.5 hours after 
administration of the effective ITB dose, with a maximum effect after 4.5 hours. 
The Ashworth scores, assessed 2, 4, and 6 hours after administration of the 
effective ITB dose, significantly decreased in comparison with baseline for all 
muscle groups (0.001 ≤ p ≤ 0.040), except for the left hip flexors 2 hours after ITB 
administration (p = 0.080). The Ashworth score after placebo administration did 
not change significantly in any muscle group at any test moment 
(0.083 ≤ p ≤ 1.000). In the three children who had two placebo days, the results 
of the first placebo day were used for the Ashworth and VAS analyses. 
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Table 3.3 Study medication randomisation sequence, effective intrathecal baclofen (ITB) dose, side 
effects and complications  
Complications Case Study medication 
sequence 
(P = placebo) 
(B = baclofen) 
Effective 
ITB dose 
(μg) 
Side effects ITB Catheter 
in situ 
(days) 
Symptoms of 
lowered CSF 
pressure 
Other 
complications 
1 P-B 25 No 4           No Defective 
connection 
catheter cap 
2 P-B 25 No 3           No  
3 B 20a Lethargy 2 Yes  
4 P-B 12.5 No 3 Yes  
5 P-B-B 50 No 4 Yes  
6 B-P-P-B 50 Lethargy 5 Yes  
7 P-B 25 Lethargy 4 Yes Disconnection 
catheter cap 
8 P-B-B 50 Lethargy 4 Yes  
9 B-P 25 No 3 Yes  
10 B 25 Lethargy 
Excessive hypotonia 
3 Yes  
11 B-P 25 Lethargy 3 Yes Disconnection 
catheter cap 
12 P-B 25 Lethargy 3 Yes  
13 B-P-P-B 50 No 5 No Radiculopathy 
14 B-P 25 No 3 Yes Gastroenteritis 
15 P-B-P-B 50 No 5 Yes  
16 B-P 25 Perspiration of  
hands and feet 
3 Yes  
17 B-P 25 No 3 Yes  
CSF = cerebrospinal fluid; a positive clinical effect during a second, open-label test treatment by 
lumbar puncture 
 
 
The VAS scores were rated by the caregivers for 15 children; two children rated 
the VAS scores themselves (cases 13 and 14). Table 3.4 shows that both the VAS 
for pain and the VAS for ease of care significantly improved after administration 
of the effective ITB dose without placebo effect. Fourteen of the 17 children were 
bed-bound because they had symptoms of lowered CSF pressure. Consequently, 
certain individually formulated problems could not be evaluated during the test 
treatment. In individual cases, improvements were noted concerning transfers, 
voiding, startle responses, operating the electric wheelchair, and arm function. 
One boy (case 13) underwent the test treatment because of deteriorating gait in 
spite of multilevel treatment with botulinum toxin. He saw his goals fulfilled as 
with ITB 50 μg the pain in his hamstrings disappeared and walking took less 
energy. 
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Table 3.4 Mean visual analogue scale (VAS) scores for ease of care and for pain, at baseline, and 
after intrathecal administration of placebo and effective baclofen dose 
VAS-score Scale  Treatment n 
Baseline After bolus 
administration 
Difference 
 
p 
Ease of care Placebo 13 2.4 ± 1.4 3.3 ± 2.0 0.9 ± 1.7 0.093 
 Baclofen 14 2.3 ± 1.4 7.4 ± 2.2 5.1 ± 2.1 0.001 
Pain Placebo 10 3.2 ± 2.1 4.3 ± 2.6 1.1 ± 3.5 0.262 
 Baclofen 11 3.2 ± 2.0 6.5 ± 3.1 3.3 ± 2.9 0.010 
Scores are shown as mean ± SD 
Side effects and complications 
Table 3.3 shows the side effects and complications for each child. Nine side 
effects of ITB were registered in eight children. Seven children became slightly 
lethargic, including a child who also suffered from transient excessive hypotonia. 
The main complication, which occurred in 14 of the 17 children, consisted of 
one or more symptoms that could fit in with the diagnosis of lowered CSF 
pressure. These symptoms included lethargy, decreased appetite, dry mouth, 
dizziness, perspiration, pallor, nausea, vomiting and headache. The last four 
symptoms appeared or increased only in an upright position. In three children, 
CSF leaked from the catheter connection. In one of these, the catheter connection 
was defective, so a new catheter had to be inserted; in the other two, 
reconnection of the cap solved the problem. We did not observe symptoms of 
lowered CSF pressure in three children in whom the neurosurgeon had tunnelled 
the catheter subcutaneously for a few centimetres. Fourteen children preventively 
received one to four doses of cefazoline perioperatively. One child had radicular 
pain in his right leg postoperatively. The pain was completely resolved by 
retracting the catheter for 5 cm. Another child first had abdominal cramps due to 
constipation, developing gastroenteritis later on. At that time, more children on 
the ward had gastroenteritis.  
Overall, none of the children required respiratory support or admission to 
intensive care. None of the children developed meningitis. 
DISCUSSION 
The test treatment was successful in all 17 children, and all went on to the 
randomised, open-label pump implantation phase. Intrathecal bolus 
administration of baclofen reduced muscle tone, diminished pain and facilitated 
care. Placebo did not have these effects. In individual cases, gait, transfers, 
voiding, operating the electric wheelchair and arm control improved, while 
startle responses decreased. A satisfying clinical effect was achieved with ITB 
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bolus doses of between 12.5 μg and 50 μg. The older and heavier children more 
often required ITB 50 μg. Side effects included slight lethargy in seven of 17 
children, and transient excessive hypotonia in one child. We would expect fewer 
side effects during CITB treatment, being able to titrate the baclofen dose with the 
programmable infusion pump. The main complication concerned symptoms of 
lowered CSF pressure in 14 of 17 children, caused by CSF loss during the 
operation or CSF leaking alongside or from the catheter. Children with CP may 
be more susceptible to lowered CSF pressure symptoms, owing to decreased 
compliance of the CSF compartment.22,23 Albright et al. postulated that the 
increased incidence of CSF leaking during ITB therapy in children with CP might 
be caused by occult hydrocephalus.24 They performed lumbar punctures in 24 
children with CP and asymptomatic ventriculomegaly, resulting in abnormal high 
opening pressures in 23 children. However, lumbar punctures were performed 
under general anaesthesia, which can increase CSF pressure.24,25 They found no 
correlation between the opening pressures and the extent of ventriculomegaly.24 
We did not measure opening pressures, because the children did neither have 
clinical symptoms nor magnetic resonance imaging signs of increased 
intracranial pressure. In the three children with a tunnelled catheter we observed 
no symptoms of lowered CSF pressure. The counterpressure created probably 
caused any CSF leaking along the catheter to cease. In three other children, CSF 
leaking was related to the catheter connection. These problems probably belong 
to the past because the firm of B-Braun has replaced the former, vulnerable 
connector of the Perifix® 300 mini set with a solid click system. 
Since the review of the American Academy for Cerebral Palsy and 
Developmental Medicine, a few reports about ITB treatment including children 
with CP have been published.4,9,26-30 We cannot compare or contrast our results 
with these reports, because none was placebo-controlled. Moreover, all studies 
focused on the pump implantation and follow-up without much attention on the 
preceding test treatment. Apart from Vloeberghs et al.28, who used an ITB 30 μg 
bolus in the smallest children, test treatments started with an adult 50 μg ITB 
bolus.4,27,29 We would expect many side effects with this high starting dose, as we 
and others noted side effects in response to ITB bolus doses as low as 20 and 10 
μg, respectively.31 However, information on the children’s weight and the 
incidence of side effects and complications was either limited or absent.4,26-30 Not 
all studies had a 100% success rate of the test treatment.26,28 After 83 test 
treatments, Vloeberghs et al. reported five non-responders and six children with a 
response not fulfilling the expectations of the caregivers.28 It is unclear whether 
they tried only one ITB bolus per child or also higher doses in non-responders. 
We would encourage our colleagues to report more comprehensively on the 
design, results and complications of ITB test treatments in children. 
On the basis of our experience, we put forward some ideas to optimise the design 
of the test treatment and to decrease the incidence of catheter-related 
Thesis_hoving_v5.pdf   57 19-3-2008   12:31:41
58   Chapter 3 
complications. From now on, we shall no longer use placebo. However, because 
a placebo-effect has been reported, outcome measures are important for 
sustaining a clinically observed positive effect.2,11 We suggest using the original 
Ashworth scale and the soleus H-reflex for this goal. The Ashworth scale has its 
limitations14,32, but it quickly provides information on muscle tone and can be 
easily measured several times a day. The soleus H-reflex is an objective measure 
to quantify the decreasing motoneuron excitability in response to ITB bolus 
administration and is feasible in children with severe CP.32 We believe that the 
effective ITB dose can be fairly predicted considering the child’s age, weight, CP 
type and individual treatment goals. Because most children will require only one 
ITB test dose, bolus administration by lumbar puncture may be considered in 
children who understand the procedure and are able to cooperate. In case ITB 
administration by an external catheter is required, we would suggest tunnelling 
the catheter subcutaneously. General anaesthesia is often required in that case. 
Summarising, we believe that the design of each test treatment should be tailored 
to the characteristics and treatment goals of the individual child. More studies are 
needed to optimise ITB care for children. These studies should also address 
children with posture and movement disorders due to traumatic brain injury, 
near-drowning, hereditary spastic paraparesis, and spinal cord lesions.  
CONCLUSION 
ITB bolus administration is effective and safe for carefully selected children with 
intractable spastic type CP. Most children responded to ITB 25 μg, which is half 
the usual starting bolus dose for adults. The children who required ITB 50 μg 
were significantly older and weighed more. Symptoms of lowered cerebrospinal 
fluid pressure frequently complicated the test treatment. Given these experiences, 
we have put forward ideas to optimise future ITB test treatments. The results of 
the randomised, open-label pump implantation phase and follow-up of the Dutch 
national ITB study in children with spastic type CP are forthcoming (Chapters 4 
and 5 of this thesis). 
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ABSTRACT 
Background 
Intractable spasticity can be treated effectively with continuous infusion of intrathecal 
baclofen. Because evidence for its use in the treatment of children with spastic cerebral 
palsy is lacking, we conducted a randomised controlled trial. 
 
Aims 
To test whether continuous infusion of intrathecal baclofen is effective in comparison with 
standard treatment only. 
 
Methods 
Seventeen children, aged 13.2 ± 2.8 years, with intractable spastic cerebral palsy were 
randomised to receive a Synchromed pump for continuous infusion of intrathecal baclofen 
after either one month (CITB group) or six months (Control group). Primary outcomes were 
the 6-month-change scores on the 0-10 visual analogue scale for individually formulated 
problems and the Caregiver Assistance scale of the Pediatric Evaluation of Disability 
Inventory self-care domain. One of the secondary outcome measures was health related 
quality of life as measured with the Child Health Questionnaire-PF50. 
 
Results 
Nine children were randomly assigned to the CITB group and eight to the Control group. 
The visual analogue scale for individual problems improved with 4.0 ± 1.7 in the CITB 
group and changed with -0.2 ± 1.3 in the Control group (p = 0.001). Pediatric Evaluation 
of Disability Inventory scores did not change significantly. The Child Health 
Questionnaire-PF50 6-month-change score significantly differed in favour of the CITB 
group for the domains of bodily pain/discomfort (p = 0.014), mental health (p = 0.045), 
psychosocial status (p = 0.027) and parents’ personal time limitation (p = 0.043).  
 
Conclusion 
The results of this randomised controlled trial establish continuous infusion of intrathecal 
baclofen to be effective in carefully selected children with problems caused by intractable 
spastic cerebral palsy. 
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INTRODUCTION 
With a prevalence of about 2 per 1000 live births in Western countries, cerebral 
palsy (CP) is the most common cause of severe physical disability in childhood.1 
Spasticity accounts for 70 to 91% of the motor disorders associated with CP and 
is intractable in a substantial group of children.2 Intractable spasticity can cause 
pain, sleeping disorders, increased energy requirements, and interference with 
positioning, transfers, dressing, and body hygiene. Secondary phenomena such as 
contractures and pressure sores can add to the treatment problems. Continuous 
infusion of intrathecal baclofen (CITB) can be very effective in the treatment of 
intractable spasticity.3 
In 2000, the American Academy for Cerebral Palsy and Developmental Medicine 
published a systematic review on the degree of evidence about CITB for spasticity 
in individuals with CP.4 They concluded that except for two case reports, none of 
the studies solely concerned children. They underlined the need for prospective, 
randomised trials that use valid and reliable outcome measures, in well-described 
and homogeneous patient groups. Therefore, we started a prospective Dutch 
national study on the efficacy and safety of CITB for intractable spasticity in 
children with CP in 2002.5-8 The study included the selection, test treatment, 
pump implantation, and follow-up phase. Recently, we reported on the double-
blind, randomised, placebo-controlled, dose-finding test treatment.5 Bolus 
administration of intrathecal baclofen (ITB) significantly reduced muscle tone, 
diminished pain, and facilitated ease of care. Placebo did not have these effects.5 
Our present article addresses the pump implantation phase. The aim of this 
randomised controlled trial (RCT) was to study the efficacy of CITB in the 
treatment of children with problems caused by intractable spastic CP. 
METHODS 
Participants and study design 
Seventeen children, nine girls and eight boys, aged between 7 and 16 years 
(mean age 13.2 ± 2.8 years), participated in the Dutch ITB study. The eligibility 
criteria of this study are shown in Table 4.1.5 After a successful test treatment, the 
children were randomised to receive a programmable Synchromed infusion 
pump (Medtronic, Inc., Minneapolis, MN) after either 1 month (CITB group) or 6 
months (Control group; Figure 4.1). In both groups, standard treatment was 
continued, including any physiotherapy, speech therapy and occupational 
therapy. Before the start of the Dutch ITB study, an independent statistician 
generated the allocation schedule with an unpredictable sequence of 
assignments. The investigator who enrolled the children had no entry to this list 
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and was, at the time of each enrolment, not aware of the next assignment in the 
sequence. For assignment, the investigator called the independent statistician 
who consulted the allocation list. After randomisation, the treatment was open-
label and non-blinded. An experienced neurosurgeon inserted the pumps under 
general anaesthesia in the lateral abdomen. All children participated in the 
3-monthly follow-up visits. All pump implantations and follow-up visits took 
place at the University Hospital Maastricht in the Netherlands. The main 
investigator was present during all admissions and follow-up visits of the 
children. 
 
 
Table 4.1 Eligibility criteria for the Dutch ITB study 
Inclusion criteria 
   1) Age between 4 and 16 years 
   2) Spastic diplegia or tetraplegia as part of cerebral palsy 
   3) Insufficient response to oral spasticity-reducing medication 
   4) In a mixed cerebral palsy syndrome, spasticity is the most prominent sign 
   5) Spasticity results in a decrease in the quality of life of the child and/or its caregivers 
   6) Sufficient motivation for study participation including availability for follow-up 
   7) Magnetic resonance imaging of the brain rules out progressive diseases 
   8) Minimal weight of 20 kg (valid until January 1st 2004) 
   9) Wheelchair bound without ability to creep or sit unsupported (valid until January 1st 2004) 
 10) Child is able to understand and carry out instructions (valid until January 1st 2004) 
Exclusion criteria 
   1) Hypersensitivity to baclofen 
   2) Contraindications for general anaesthesia 
   3) Insufficient general health 
   4) Intractable epileptic seizures 
   5) Infection of the lumbar skin 
   6) Systemic infection 
 
Outcome measures 
We used the International Classification of Functioning, Disability and Health 
(ICF) for the selection of a broad choice of outcome measures (Figure 4.2).9 For 
all outcome measures, we compared the 6-month-change scores between the 
CITB group and the Control group. The two primary outcome measures included 
the Caregiver Assistance scale of the self-care domain of the Pediatric Evaluation 
of Disability Inventory (PEDI) and the visual analogue scale (VAS) for individually 
formulated problems. 
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Figure 4.1 CONSORT flow diagram for the first three phases of the Dutch ITB study 
 
 
The VAS is a valid and reliable measure for rating pain intensity in children over 
six, and has also been used to measure anxiety, sadness, anger, worry, happiness 
and fatigue.10-12 The VAS showed preliminary reliability and validity for both 
child self-report and parent-proxy report.10 When clinicians rated the VAS, the 
VAS validly identified the minimal clinically important difference on the PEDI.13 
Since the children in our study had different problems, we used a separate VAS 
for three individually formulated problems per child. We used the average of 
these three VAS scores for statistical analysis.10 Since ease of care and pain were 
the most frequently reported problems, we also analysed these VASs separately. 
The VAS is a straight 10-cm horizontal line with anchor points ‘very dissatisfied’ 
(score 0) and ‘very satisfied’ (score 10).5 Depending on both the ability to 
Dutch ITB study
Assessed for eligibility (n=38)
Excluded (n=21)
Not meeting eligibility criteria
Analysed after 6 months (n=9)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Allocated to CITB group:
CITB and standard treatment (n=9)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Allocated to Control group:
Standard treatment only (n=8)
Analysed after 6 months (n=8)
Pump implantation phase (RCT)
Randomisation (n=17)
Test treatment phase (n=17)
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understand the test and to draw a vertical line, the VAS was rated by the child or 
by a parent. Two children and 15 parents rated the VASs. 
The study included several secondary outcome measures. In the ICF domain of 
body functions and structures, we used the original Ashworth scale.5 Ashworth 
scores were bilaterally assessed by the same experienced paediatric physical 
therapist in four upper extremity muscle groups (elbow and wrist flexors and 
extensors) and seven lower extremity muscle groups (hip adductors, flexors and 
extensors; knee flexors and extensors; and ankle plantarflexors and dorsiflexors).14 
Since the Ashworth scale is an ordinal scale, we separately analysed the scores of 
the 22 muscle groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 International Classification of Functioning, Disability and Health (ICF) model of 
Disability 
 
 
In the ICF domains of activities and participation, we used the Dutch versions of 
the PEDI and the Gross Motor Function Measure (GMFM), both valid and reliable 
measures.15 Within the self-care domain, we used the Functional Skills scale, 
which measures capability, and the Caregiver Assistance scale, which measures 
performance.16 The GMFM is a criterion-referenced observational measure for 
addressing change in gross motor function for children with CP. The 88 items of 
the GMFM are scored on a 4-point ordinal scale and grouped into five 
dimensions: 1) lying and rolling, 2) sitting, 3) crawling and kneeling, 4) standing, 
and 5) walking, running and jumping. Five-year-old children without motor 
delays are usually able to accomplish all GMFM items. We used the GMFM-88 
in two ways. First, we addressed the scores per dimension, expressed as a 
percentage of the maximum score for that dimension. Second, we defined any 
goal dimensions per child. In case we selected more than one goal dimension, 
the percentage scores of the chosen dimensions were averaged. In addition to the 
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GMFM-88, we used the 66-item version of the GMFM, which is based on interval 
scaling and has good psychometric properties.17 
Since CP specific health related quality of life (HRQL) measures were lacking, we 
used the Dutch version of the Child Health Questionnaire-Parent Form 50 (CHQ-
PF50).18 The CHQ-PF50 is a generic child health instrument designed to measure 
the physical and psychosocial well-being of children aged 5 years and older.18 
The CHQ comprises several domains that are scaled from 0 to 100. Higher scores 
reflect a better HRQL. Physical and psychosocial summary scores were 
calculated using normative data from North American children.18 
Statistical analysis 
We used SPSS for Windows statistical package, Release 11.0.1. for statistical 
analyses. Because of the small sample size, we used the non-parametric Mann-
Whitney U Test to compare the change in outcome measures between baseline 
and follow-up at 6 months in the CITB and the Control group. Results with 
p ≤ 0.05 were considered statistically significant. The Mann-Whitney U Test only 
supplies p-values without information on effect sizes and their confidence 
intervals. To gain insight in the effect sizes, we calculated medians with ranges 
for ordinal measures and means with standard deviations for interval and ratio 
measures. 
Power calculation 
We based the power calculation on the results of a study about children with 
spastic CP, who were treated with selective dorsal rhizotomy.19 In this study, 
Caregiver Assistance scaled scores of the PEDI self-care domain at baseline and 
12-month follow-up were compared. After 12 months, PEDI scores had 
significantly improved with 4.42 ± 1.32 points. We assumed that in our study, 
the children would not have reached maximum improvement after 6 months yet. 
Therefore, we set the clinically significant difference worth to detect in our study, 
at three points with an estimated standard deviation of 1.82 points. With a 
significance level of 0.05 and a power of 90%, the number of patients needed 
per group = (2σ2 / δ2) * (α + β)2 = 7.7 = 8.  In total 16 children were needed. 
Allowing for a drop out of 10%, a maximum of 18 children would be included. 
Ethical aspects 
The study was approved by the medical ethical committee of the University 
Hospital Maastricht and the Maastricht University. In accordance with local 
legislation, we obtained written informed consent from the parents, and also from 
the children if they were aged 12 years or older and capable of understanding the 
nature and impact of the study. 
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RESULTS 
Participants and procedures 
Nine children were assigned to the CITB group and eight children to the Control 
group (Figure 4.1). Table 4.2 shows the baseline characteristics. Children were 
randomised from July 2002 until January 2005. The last follow-up visit for this 
phase of the Dutch ITB study was attended in October 2005. In the CITB group, 
the mean time between the test treatment and pump implantation was 46 ± 19 
days; the mean time between the pump implantation and the 6-month follow-up 
visit was 181 ± 27 days. In the Control group, the mean time between the test 
treatment and the 6-month follow-up visit was 183 ± 26 days. The neurosurgeon 
placed the catheter tip under fluoroscopic guidance between T5-T7 in all 
children. In the CITB group, the mean daily CITB dose was 67 ± 25 μg right after 
pump implantation and 176 ± 118 μg 6 months later. Three children in the CITB 
group and four in the Control group used oral baclofen. The children in the CITB 
group gradually discontinued this use, all during the first 10 postoperative days. 
 
Table 4.2 Baseline characteristics per group 
Group n Age 
(y) 
Sex Weight 
(kg) 
Oral 
baclofen 
GMFCS 
level (n) 
Spasticity 
type (n) 
CP type  
(n) 
  
Mean ± SD 
Median 
(range) 
M/F Mean ± SD (n) III IV V 
Diplegia/ 
Tetraplegia 
Spastic 
Spastic- 
dyskinetic 
CITB 9 13.9 ± 2.3 15.0 (10-16) 5/4 36.4 ± 20.3 3 0 1 8 1/8 7 2 
Control 8 12.4 ± 3.2 12.5   (7-16) 3/5 40.9 ± 17.3 4 1 1 6 2/6 5 3 
GMFCS = Gross Motor Function Classification System 
 
Effects 
Table 4.3 shows the effects for all outcome measures, except for the original 
Ashworth scale (too many data). Table 4.4 shows the distribution of the 51 
individually formulated problems among both trial groups. The VAS for 
individual problems improved with 4.0 ± 1.7 in the CITB group and changed 
with -0.2 ± 1.3 in the Control group (p = 0.001; Figure 4.3). The 6-month-change 
score of the PEDI Caregiver Assistance scale of the self-care domain did not 
significantly differ between both trial groups (p = 0.720). 
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Table 4.4 Distribution of the individually formulated problems per group  
Group n Ease of 
care 
(n) 
Pain 
 
(n) 
Transfers 
 
(n) 
Sitting 
position 
(n) 
Use of 
wheelchair 
(n) 
Startle 
response 
(n) 
Urinating 
 
(n) 
Miscellaneous 
 
(all n = 1) 
CITB 9 9 6 3 3 1 0 1 
Pushing head backwards 
Absent hand function 
Sleep 
Tense body feeling 
Control 8 7 6 2 0 2 2 1 
Right arm function 
Extreme excitement during eating 
Walking distance 
Energy use during walking 
 
 
In the ICF domain of body functions and structures, the 6-month-change 
Ashworth score between both trial groups significantly differed in favour of the 
CITB group for the right wrist flexors (p = 0.038), the left hip adductors 
(p = 0.025) and both hip flexors (right p = 0.022, left p = 0.043). The VAS for 
ease of care improved with 3.9 ± 2.2 in the CITB group and with 0.1 ± 1.6 in the 
Control group (p = 0.008; Figure 4.4). The VAS for pain improved with 4.2 ± 2.9 
in the CITB group and worsened with -1.3 ± 2.4 in the Control group (p = 0.016; 
Figure 4.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Change in the 0-10 VAS for individual problems per group. A higher VAS score 
represents less problems 
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Figure 4.4 Change in the 0-10 VAS for ease of care per group. A higher VAS score represents 
improved ease of care 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Change in the 0-10 VAS for pain per group. A higher VAS score represents less pain 
 
 
In the ICF domains of activities and participation, the GMFM-66 improved with 
1.2 ± 2.3 points in the CITB group and worsened with -1.6 ± 3.0 points in the 
Control group (p = 0.028). The GMFM-88 sitting dimension improved with 3.3 
points (range 0.0 to 10.0) in the CITB group and remained unchanged in the 
Control group (median 0.0 points, range -7.0 to 7.0; p = 0.085). Table 4.5 shows 
the distribution of the nine GMFM goal dimensions among both trial groups. The 
CITB (n=9) Control (n=7)
0
2
4
6
8
10
V
A
S
fo
r 
ea
se
of
 c
ar
e
baseline
6 months
V
A
S
fo
r 
ea
se
of
 c
ar
e
V
A
S
fo
r 
ea
se
of
 c
ar
e
V
A
S
fo
r 
ea
se
of
 c
ar
e
CITB (n=6) Control (n=6)
0
2
4
6
8
10
V
A
S
fo
rp
ai
n
baseline
6 months
V
A
S
fo
rp
ai
n
V
A
S
fo
rp
ai
n
V
A
S
fo
rp
ai
n
Thesis_hoving_v5.pdf   73 19-3-2008   12:31:42
74   Chapter 4 
GMFM goal dimension score improved with 3.0 points (range 2.0 to 10.0) in the 
CITB group and with 1.3 points (range -6.0 to 6.0) in the Control group 
(p = 0.140). The 6-month-change score of the PEDI Functional Skills scale of the 
self-care domain did not significantly differ between both groups (p = 0.663). 
 
 
Table 4.5 Distribution of Gross Motor Function Measure (GMFM) goal dimensions per group 
Group n Age  
(y) 
Sex Spasticity type 
(n) 
CP type 
 (n) 
 GMFCS 
level (n) 
 GMFM goal dimensions  
(n) 
  
Mean ± SD M/F 
Diplegia/ 
Tetraplegia 
Spastic 
Spastic-
dyskinetic 
 III IV V  
Lying/ 
rolling 
Sitting 
Standing/ 
walking 
CITB 5 13.4 ± 2.7 3/2 1/4 3 2  0 1 4  1 4 0 
Control 4 14.5 ± 1.9 2/2 2/2 3 1  1 1 2  0 2 2 
 
 
The CHQ-PF50 domain score of bodily pain/discomfort improved with 
24.4 ± 20.7 points in the CITB group and worsened with -10.6 ± 26.8 points in 
the Control group (p = 0.014). This also counted for the domains of mental health 
(CITB group 9.1 ± 9.1 points versus Control group -3.5 ± 15.1 points; p = 0.045), 
parental impact-time (CITB group 5.2 ± 18.1 points versus Control group -
19.8 ± 29.0 points; p = 0.043) and the psychosocial summary score (CITB group 
3.4 ± 7.9 points versus Control group -5.7 ± 8.8 points; p = 0.027). 
DISCUSSION 
This is the first RCT addressing the efficacy of CITB in children with intractable 
spastic CP. Because of the varying nature of the children and the numerous 
outcomes of primary interest, others have considered a RCT practically 
impossible or inappropriate for evaluating treatment in children with CP.20 In our 
present RCT, CITB reduced individually formulated problems, it relieved pain, 
and it improved both ease of care and gross motor functioning, significantly. 
Moreover, the HRQL significantly improved for the domains of bodily 
pain/discomfort, mental health (the extent of anxiety, depression and positive 
affect), psychosocial status, and parents’ personal time limitation. 
Since the review of the American Academy for Cerebral Palsy and 
Developmental Medicine, a few reports about ITB treatment including children 
with CP, have been published.21-27 Though we cannot directly compare or 
contrast our results with these non-randomised studies, our findings are in 
keeping with previous reports. In our study, the main indications for CITB were 
pain and problems with ease of care. CITB attenuates spasticity associated pain, 
but also exerts direct antinociceptive effects.28,29 Contrary to the significant 
improvement on the VAS for ease of care, the two PEDI self-care domain scores 
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did not improve. This means that the facilitation in ease of care did not comprise 
that the children could take better care of themselves, nor that they needed less 
assistance. According to the caregivers, the decrease in muscle tone and pain 
both facilitated ease of care and made care less time consuming. Nine children in 
our study had one or more functional goals. In comparison with standard 
treatment only, the GMFM-66 score improved significantly, while the GMFM 
goal dimension score improved non-significantly. We believe CITB accounted for 
the improved gross motor functioning, since mean GMFM scores of children with 
serious CP (Gross Motor Function Classification System (GMFCS) levels III-V) 
without specific treatment (ITB, botulinum toxin, selective dorsal rhizotomy) 
reach a plateau by 7 years of age.30 The efficacy of CITB was also manifested in 
an improved HRQL. Although HRQL measurement has a high priority in current 
CP research, previous reports on CITB in children with spastic CP did not include 
HRQL measures. 
Our present study has a few limitations. The first concerns the inability to blind 
the participants and investigators for group assignment. Secondly, the 
generalisability of the results is confined to relatively older children with 
intractable spastic CP who rely on wheeled mobility (GMFCS levels IV and V). 
However, in clinical practice CITB is mostly indicated for children with GMFCS 
levels IV and V.27 
We conclude that CITB is effective in the treatment of carefully selected children 
with problems caused by intractable spastic CP. The safety and 1-year efficacy of 
CITB will be addressed in our article on the follow-up phase of the Dutch ITB 
study (Chapter 5 of this thesis). 
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ABSTRACT 
Background 
Prospective studies that address both efficacy and safety of continuous infusion of 
intrathecal baclofen in children with spastic cerebral palsy, and that use outcome 
measures beyond muscle tone, are lacking. 
 
Aims 
To study the efficacy at 12 months and safety up to 24 months after start of continuous 
infusion of intrathecal baclofen in children with intractable spastic cerebral palsy.  
 
Methods 
Nine girls and eight boys, aged 13.7 ± 2.9 years, received a Synchromed pump for 
continuous infusion of intrathecal baclofen. We prospectively recorded effects and 
adverse events at regular follow-up visits up to 24 months. Outcome measures included 
the 0-10 visual analogue scale for individual problems, Gross Motor Function Measure 
and health related quality of life as measured with the Child Health Questionnaire-PF50. 
 
Results 
Continuous infusion of intrathecal baclofen for 12 months significantly improved the 
visual analogue scale for individual problems with 4.7 ± 2.0 (p = 0.000), visual analogue 
scale for ease of care with 5.2 ± 2.1 (p = 0.000), visual analogue scale for pain with 
5.4 ± 2.7 (p = 0.002); Gross Motor Function Measure sitting dimension with 3.3 points 
(range -4.0 to 22.0; p = 0.022), Gross Motor Function Measure goal dimension with 4.0 
points (range 0.0 to 26.0; p = 0.007); and Child Health Questionnaire-PF50 domains of 
bodily pain/discomfort with 25.6 ± 35.9 points (p = 0.016) and mental health with 
9.8 ± 11.3 points (p = 0.007). During a mean follow-up of 18.4 months (range 12 to 24), 
we recorded 80 adverse events. Eight adverse events were serious, but not life-threatening. 
 
Conclusions 
Continuous infusion of intrathecal baclofen was effective at 12 months and safe up to 24 
months for carefully selected children with intractable spastic cerebral palsy. Continuous 
infusion of intrathecal baclofen relieved pain, facilitated ease of care and improved mental 
health. The majority of children could extend their activities and participation. 
 
Thesis_hoving_v5.pdf   80 19-3-2008   12:31:43
 Safety and one-year efficacy   81 
INTRODUCTION 
Continuous intrathecal baclofen infusion (CITB) can be very effective in the 
treatment of intractable spasticity.1 However, in 2000 the American Academy for 
Cerebral Palsy and Developmental Medicine stated that evidence for the use of 
CITB in children with cerebral palsy (CP) is lacking.2 Since then, a few studies 
about CITB that included children with spastic CP have been published.3-7 In a 
consecutive case series, Murphy et al. retrospectively studied the efficacy and 
complications of CITB in 23 children with CP.3 Side effects were not addressed. 
Another limitation of this study was the use of the Ashworth scale as single 
outcome measure.3 Campbell et al. reviewed the long-term safety and efficacy of 
CITB in the treatment of 21 children and adolescents.4 It mainly was a 
retrospective study, that included patients with spastic CP, mixed type CP, and 
patients with other causes of cerebral spasticity.4 Awaad et al. prospectively 
studied the efficacy of CITB in 29 patients with spastic CP, focussing on 
impairments, functional limitations and disability.5 They did not only include 
children, but also adults, whereas safety of CITB was not structurally addressed.5 
Albright et al. prospectively evaluated the complications associated with CITB via 
a Synchromed EL 10-ml pump in 100 children of whom 90 were diagnosed with 
CP.6 Their study did not address efficacy and possible side effects of CITB.6 Motta 
et al. retrospectively studied the incidence of three common complications of 
CITB in 200 children (175 with CP) without addressing other safety aspects.7 We 
conclude that there still is a lack of prospective studies that address efficacy and 
safety of CITB in a homogeneous group of children with spastic CP, using 
outcome measures beyond the Ashworth scale.  
In 2002, we started a Dutch national study on the efficacy and safety of CITB in 
children with intractable spastic CP.8-11 This study included a randomised 
controlled trial, which showed that CITB was effective in comparison with 
standard treatment only (Chapter 4 of this thesis). CITB for 6 months significantly 
relieved pain, and significantly improved individually formulated problems, ease 
of care, gross motor functioning and health related quality of life (HRQL) for the 
domains of bodily pain/discomfort, mental health, psychosocial status and 
parents’ personal time limitation. Our present article describes the prospective 
continuation of the RCT. It addresses the one-year efficacy of CITB and its safety 
from pump implantation up to 24 months of follow-up. We discuss the efficacy of 
CITB both in terms of HRQL and in terms of body functions, activities and 
participation as defined in the International Classification of Functioning, 
Disability and Health (ICF).12 
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METHODS 
Seventeen children, nine girls and eight boys, participated in the Dutch ITB 
study. We refer to our prior article for the eligibility criteria of this study.8 The 
children were aged 13.7 ± 2.9 years (range 7 to 17) at time of pump 
implantation. An experienced neurosurgeon inserted a programmable 
Synchromed infusion pump (Medtronic, Inc., Minneapolis, Minnesota) under 
general anaesthesia subcutaneously or, in children with little subcutaneous fat, 
subfascially in the lateral abdomen. All children received prophylactic antibiotics 
peroperative and during the first postoperative day. We programmed the pumps 
to infuse intrathecal baclofen in a simple continuous mode directly following 
implantation. We usually started with a daily CITB dose of twice the effective 
intrathecal baclofen test treatment bolus dose.8 We then optimised the CITB dose 
during hospitalisation and after discharge. After pump implantation, the children 
participated in the 3-monthly follow-up visits at the University Hospital 
Maastricht in the Netherlands for at least one year. The main investigator was 
present during all admissions and follow-up visits of the children. 
Outcome measures 
Figure 5.1 shows which outcome measures we used to evaluate efficacy during 
the first follow-up year. For details of the applied outcome measures, we refer to 
prior articles and our RCT (Chapter 4 of this thesis).8,11 In addition, we always 
asked for changes in common CP associated problems, including speech, 
swallowing, bowel movements, urological problems, sleep, drooling, epileptic 
seizures and changes in transfers and in operating the wheelchair. Regarding 
their overall satisfaction with CITB we asked during the last follow-up visit, 
whether the children and their caregivers would participate in the test treatment 
and implantation procedures again. 
Adverse events 
We structurally recorded adverse events on standardised forms. We defined an 
adverse event as any undesirable experience occurring to a participant during the 
study, whether or not considered related to CITB. Adverse events included 
aggravation of symptoms or signs, which were present before CITB started. A 
serious adverse event was defined as any untoward medical occurrence or effect 
that: 1) resulted in death, 2) was life-threatening, 3) required hospitalisation or 
prolongation of existing hospitalisation, or 4) resulted in persistent or significant 
disability or incapacity. We subdivided the recorded adverse events in procedure 
and device related events and non-procedure and device related events. We also 
noted whether the event was temporary or enduring at time of the child’s last 
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follow-up visit. We related the total number of events to the number of follow-up 
patient-months. 
Statistical analysis 
We used SPSS for Windows statistical package, Release 11.0.1., for statistical 
analyses. We used the non-parametric Wilcoxon Signed Rank Test to compare 
the results of the outcome measures at the 6-month and 12-month follow-up visit 
with those at baseline. Baseline measurements were carried out before pump 
implantation (Figure 5.1). Results with p ≤ 0.05 were considered statistically 
significant. The Wilcoxon Signed Rank Test only supplies p-values without 
information on effect sizes and their confidence intervals. To gain insight in the 
effect sizes, we calculated medians with ranges for ordinal measures, and means 
with standard deviations for interval and ratio measures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Outcome measures for measuring efficacy 
FU = follow-up; H-reflex = soleus H-reflex; Ashworth = original Ashworth scale; VAS = 
visual analogue scale; GMFM = Gross Motor Function Measure; PEDI = Pediatric 
Evaluation of Disability Inventory; CHQ-PF50 = Child Health Questionnaire-Parent Form 
50  
Ethical approval and consent 
The study was approved by the medical ethical committee of the University 
Hospital Maastricht and the Maastricht University. In accordance with local 
legislation, we obtained written informed consent from the parents, and also from 
the children if they were aged 12 years or older and capable of understanding the 
nature and impact of the study.   
Baseline Pump implantation FU 3 mo FU 6 mo FU 9 mo FU 12 mo 
H-reflex
Ashworth
VAS
GMFM
PEDI
CHQ-P50
H-reflex
Ashworth
VAS
GMFM
PEDI
CHQ-P50
H-reflex
Ashworth
VAS
GMFM
PEDI
CHQ-P50
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RESULTS 
Participants 
Table 5.1 shows the clinical characteristics of the 17 participating children at 
time of pump implantation. One neurosurgeon implanted all pumps between 
September 2002 and April 2005. Table 5.2 summarises the pump implantation 
details per child. The neurosurgeon placed the catheter tip under fluoroscopic 
guidance between T5-T7 in all children. The mean CITB daily dose was 61 ± 27 
μg directly after pump implantation, 189 ± 132 μg after 6 months and  233 ± 170 
μg after 12 months. Seven children took oral baclofen at time of the pump 
implantation. It was gradually discontinued during the first 10 postoperative days 
in six children. In one child the dose was largely reduced (case 10). The last 
follow-up visit was attended in May 2006.  
 
 
Table 5.1 Children’s clinical characteristics at time of pump implantation  
Case  Age 
 and 
 sex 
Weight
(kg) 
Cerebral palsy  
type 
Diplegia/ 
tetraplegia
GMFCSa
level 
Oral 
baclofen 
dose (mg/kg) 
CP associated problemsb 
1  15 F 36 spastic/dyskinetic tetra V - con, uro 
2  11 M 25 spastic tetra V - spe, dro, con, uro, swa, brp  
3  14 M 31 spastic tetra V - spe, dro, con, uro, epi, brp 
4  13 F 40 spastic/dyskinetic tetra V - spe, dro, con, swa, vis 
5  16 M 84 spastic di IV - con, slp 
6  14 F 63 spastic/dyskinetic tetra V 0.95 spe, uro, slp, vis 
7    9 F 26 spastic/dyskinetic tetra V 1.15 spe, dro, con, uro, swa, slp, epi, aud 
8  17 M 53 spastic tetra V - spe, dro, con, uro, epi 
9  16 F 35 spastic tetra V - spe, dro, con, uro, swa, slp, vis, epi, brp 
10    7 M 27 spastic tetra V 1.20 spe, dro, uro, swa, slp, epi 
11  14 M 18 spastic tetra V 0.56 spe, dro, con, uro, swa, slp, vis, epi, brp 
12  13 F 33 spastic tetra V - spe, dro, uro, vis 
13  17 M 70 spastic di III 0.86 con 
14  17 F 48 spastic di IV - con, uro  
15  16 F 33 spastic/dyskinetic tetra V - spe, dro, con, uro 
16  11 F 27 spastic tetra V 1.11 spe, dro, con, uro, swa, vis 
17  12 M 24 spastic tetra V 1.25 spe, dro, con, swa, slp 
a GMFCS, Gross Motor Function Classification System; b spe = speech problem; dro = drooling; con = constipation; 
uro = urological problem; swa = difficulty swallowing; slp = sleeping disorder; vis = visual impairment; epi = 
epilepsy; brp = bronchopulmonary problem; aud =  auditory problem  
Effects 
Table 5.3 shows the effects of CITB for all outcome measures, except for the 
original Ashworth scale (too many data). In the following sections we report the 
one-year efficacy of CITB.  
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Table 5.2 Device, implantation and CITB dose (μg/day) details per child 
Case SynchroMed  
pump modela 
Position pump in 
abdominal wallb 
Catheter 
modela 
CITB starting 
dose 
CITB dose at 
6 months 
CITB dose at 
12 months 
1 EL 8627-18 Left SC 8709   50 105 360 
2 EL 8626L-10 Left SC 8709   50 200 215 
3 EL 8626L-10 Left SF 8709   40   76 110 
4 EL 8627-10 Right SF 8709   25 319 263 
5 EL 8627-18 Right SC 8709 100 300 350 
6 EL 8627L-18 Left SC 8731 100 530 740 
7 II 8637-20 Right SF 8731   50 110 169 
8 II 8637-20 Left SC 8731 100 415 456 
9 II 8637-20 Right SF 8731   50   68   75 
10 II 8637-20 Left SC 8731   25 120 132 
11 II 8637-20 Right SF/SC 8731   50   88 106 
12 II 8637-20 Left SF 8731   50 104 104 
13 II 8637-20 Left SC 8731 100 143 142 
14 II 8637-20 Right SC 8731   50 230 288 
15 II 8637-20 Right SF 8731 100 210 210 
16 II 8637-20 Left SC 8731   50   97 136 
17 II 8637-20 Left SF 8731   50 101 101 
a Medtronic, Inc., Minneapolis, Minnesota; b SC = subcutaneous; SF = subfascial 
 
 
Table 5.4 lists the individually formulated problems of the children. The 0-10 
visual analogue scale (VAS) for individually formulated problems significantly 
improved with 4.7 ± 2.0 (p = 0.000; Figure 5.2). Because ease of care and pain 
were the most frequently reported problems, we also analysed these VASs 
separately. The VAS for ease of care significantly improved with 5.2 ± 2.1 
(p = 0.000; Figure 5.3). The VAS for pain significantly improved with 5.4 ± 2.7 
(p = 0.002; Figure 5.4). 
In the ICF domain of body functions and structures, the H/M ratio at both legs 
decreased significantly (p ≤ 0.001). The Ashworth score decreased significantly in 
five out of eight upper extremity muscle groups (0.008 ≤ p ≤ 0.046) and nine out 
of 14 lower extremity muscle groups (0.002 ≤ p ≤ 0.046). As spasticity and pain 
decreased, children could extend their activities and participation in several 
ways. For instance, one boy (case 11) resumed swimming and 12 children could 
sit longer and/or more comfortably in their wheelchairs (cases 1-6 and cases 10-
15). The parents of one girl (case 4) could put the riding gloves on in two instead 
of the prior 20 minutes. Improved arm extension in another boy (case 8) meant 
he could grasp, move and push objects, which used to be out of reach. With 
CITB he became independent in operating the computer and entering and 
leaving the house. Four children resumed or improved supported standing, 
cycling and/or walking (cases 4, 13, 14, and 16). Moreover, seven families could 
more easily set off for visits and day trips (cases 3, 4, 6, 9-11, and 15).  
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Table 5.4 Individually formulated problems (three per child) 
Individual problem   n 
Ease of care 16 
Pain 12 
Transfers   5 
Sitting position   3 
Use of wheelchair   3 
Startle response   2 
Urinating   2 
Pushing head backwards   1 
Absent hand function   1 
Sleep   1 
Tense body feeling   1 
Right arm function   1 
Extreme excitement during eating   1 
Walking distance   1 
Energy use during walking   1 
Total 51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 VAS (0-10) for individual problems at baseline and 6 and 12 months with CITB. A higher 
VAS score represents less problems 
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Figure 5.3 VAS (0-10) for ease of care at baseline and 6 and 12 months with CITB. A higher VAS 
score represents improved ease of care 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 VAS (0-10) for pain at baseline and 6 and 12 months with CITB. A higher VAS score 
represents less pain 
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GMFM goal dimension score significantly improved with 4.0 points (range 0.0 to 
26.0; p = 0.007). One boy who was classified at GMFCS level III (case 13), 
intended to improve his gait with CITB. Figure 5.5 shows his GMFM dimension 
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the GMFM sitting dimension after which he extended his standing and walking 
abilities. Within the self-care domain, PEDI Functional Skills and Caregiver 
Assistance scales did not improve with CITB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 GMFM dimension scores of a boy (GMFCS level III) 6 months before pump implantation 
(-6 mo), at baseline (BL) and after 6 and 12 months with CITB 
 
 
HRQL, as measured on the 100-point child health questionnaire-parent form-50 
scale, improved with 25.6 ± 35.9 points for bodily pain/discomfort (p = 0.016), 
with 9.8 ± 11.3 points for mental health (p = 0.007), and with 5.4 ± 9.0 points for 
the psychosocial status (p = 0.088). Table 5.5 summarises the effects on common 
CP associated problems at one year with CITB. Speech improved in three out of 
13 children and swallowing in two out of eight children. In one child (case 3), 
both speaking and swallowing worsened along with the increasing CITB dose. 
Four out of five children could better operate their electric wheelchairs. One girl 
(case 4) used to suffer from extension spasms while riding. Moreover, in response 
to all kind of stimuli, her hand would lose contact with the joystick. With CITB 
she could safely and independently ride her electric wheelchair along a busy 
road, which resulted in an important increase in participation. Constipation 
improved in five out of 14 children. The bowel movements worsened in two out 
of 14 children due to problems pushing the faeces out of the rectum. In all 
children with constipation, the bowel movements could be well regulated with 
laxatives. CITB had a positive influence on sleep in five out of seven children due 
to a reduction in pain, spasms and, in one child (case 10), epileptic seizures. 
Transfers, all by carrying the child, improved in all four children. 
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Table 5.5 Effects of CITB on common CP associated problems at 12 months 
Change with CITB Problem Problem present 
before CITB Better No change Worse 
 (n) (n) (n) (n) 
Constipation 14 5   7 2 
Urological problem 13 0 12 1 
Speech 13 3   9 1 
Drooling 12 3   7 2 
Swallowing   8 2   5 1 
Sleep   7 5   2 0 
Epilepsy   6 2   4 0 
Operating electric wheelchair   5 4   1 0 
Transfers   4 4   0 0 
 
Before the start of CITB, six children had epilepsy of whom five used antiepileptic 
medications (Table 5.1). The child without medication (case 3) was known with 
10-100 paroxysms of staring per week. With CITB this incidence clearly 
decreased. Another child (case 10) was diagnosed with symptomatic localisation 
bound epilepsy with on average three tonic seizures per month. With CITB, he 
became seizure free. One child kept being seizure free (case 7). Seizure activity 
did not change with CITB in two children (cases 9 and 11). One boy had been 
without seizures for years, when he experienced one tonic-clonic seizure 6 
months after pump implantation (case 8). After the dose of his anticonvulsant was 
adjusted to his increased weight, he did not experience seizures anymore. One 
child (case 12) had three new-onset seizures in the first year with CITB. Two 
electroencephalograms, of which one after sleep deprivation, did not show 
epileptic discharges. We did not start antiepileptic medications, since the girl 
refused to take any. 
Adverse events 
We recorded adverse events for a mean duration of 18.4 months (range 12 to 24 
months). Fourteen of the 17 children experienced a total of 51 non-procedure or 
device related adverse events during a follow-up of 312 patient-months 
(incidence 0.16 per patient-month [95% CI: 0.12-0.20]). Twenty-four different 
events were reported (Table 5.6). The most frequently observed event was 
lethargy, which occurred in eight children. In all children, the lethargy either 
disappeared spontaneously or after slightly reducing the CITB dose. Temporary 
pressure sores were noted in four children respectively at the toe, foot, hip and 
ear. Nausea, vomiting, excessive hypotonia and/or decreased appetite mainly 
occurred during the first postoperative days and seemed related to the taking of 
oral baclofen simultaneously with CITB. After we increased the CITB dose from 
50 μg to 58 μg, one boy (case 3) experienced relative hypotension and 
bradycardia, a headache, nausea and decreased appetite. These events 
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disappeared by decreasing the dose and did not return during later dose 
increases. Five of the 51 non-procedure or device related adverse events were 
considered as serious, because they resulted in significant disability. None of the 
adverse events was life-threatening and no hospitalisation was necessary. The 
children with an excessive hypotonia all had a high tone of the extremities in 
combination with trunk hypotonia and a mediocre head balance.  
 
Table 5.6 Non-procedure and device related adverse events (mean follow-up 18.4 months) 
Adverse events (n) Number labelled 
as serious 
 Adverse event Total 
(n) 
Enduring Temporary   
Cases 
Constipation 2    2   8,9 
Sweating 3   1   2   1,2,4 
Dry mouth 2    2   1,3 
Lethargy 8    8   1,2,3,4,6,7,13,16 
Drooling 4   2   2   1,4,16,17 
Hair loss 1    1   1 
Bradycardia 1    1   3 
Hypotension 1    1   3 
Nausea 3    3   3,6,7 
Vomiting 2    2   6,7 
Decreased appetite 2    2   3,7 
Difficulty swallowing 1   1  1  3 
Dyspnoea 1    1   3 
Dysarthria 1   1  1  3 
Headache 3    3   3,6,13 
Urinary incontinence 1    1   5 
Urinary hesitancy 1   1    8 
Faecal incontinence 1    1   5 
Pressure sore 4    4   5,9,15,16 
Excessive hypotonia 4   3   1 2  4,7,16,17 
Paroxysmal dizziness 1    1   8 
Paroxysmal paleness 1    1   8 
Urticaria 1    1   17 
Epileptic seizure 2   1   1 1  8,12 
Total      51 10 41 5   
 
 
Fourteen of the 17 children experienced a total of 29 procedure or device related 
adverse events during a follow-up of 312 patient-months (incidence 0.09 per 
patient-month [95% CI: 0.06-0.12]; Table 5.7). One third of these events 
concerned a swelling at the pump or catheter insertion site. Except for one 
swelling10, these always resolved either spontaneously or with a temporary 
pressure dressing. We considered three of the 29 events as serious, because these 
children required a second operation resulting in a prolonged hospital stay. None 
of the children had a wound infection or meningitis and none of the pumps had 
to be removed. 
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Overall satisfaction 
Fifteen of the 17 children and/or their parents stated they would participate in all 
procedures again. Two parents were not sure, in spite of the achieved individual 
treatment goals for their children. The doubts in case 12 were based on both the 
new-onset seizures and the girl’s stress during pump refills. The doubts in case 16 
were based on a worsened trunk tone and head balance.   
DISCUSSION 
CITB was both effective at 12 months and safe up to 24 months for children with 
problems caused by intractable spastic CP. Early and great effects were a relief of 
pain and the facilitation of ease of care. CITB decreased both upper and lower 
extremity tone. With the control of pain and spasticity, most children were able 
to extend their activities and participation. HRQL improved for the domains of 
bodily pain/discomfort and mental health. Adverse events frequently occurred, 
but were for the greater part short-lasting and nonserious. Overall patient 
satisfaction was high.   
The GMFM sitting and goal dimension scores kept improving beyond 6 months 
after pump implantation. One explanation for this ongoing improvement is that 
most children had not reached their optimal CITB dose after 6 months yet. 
Secondly, children need time to adapt to the altered tone, before they can show 
progress in gross motor abilities. We believe CITB accounted for the improved 
gross motor functioning, since mean GMFM scores of children with serious CP 
(GMFCS levels III-V) without specific treatment (intrathecal baclofen, botulinum 
toxin, selective dorsal rhizotomy) reach a plateau by 7 years of age.13 The GMFM 
results of the ambulant boy suggest children will first improve functional skills 
they already control before improving and gaining more difficult skills. 
Most children experienced one or more non-procedure or device related adverse 
events. Lethargy occurred in almost half of the children and resolved either 
spontaneously or after slightly decreasing the CITB dose. Among the serious 
adverse events were new-onset seizures in one girl. However, in five of the six 
children who had epilepsy before pump implantation, seizure frequency 
remained stable or decreased. Epilepsy occurs in 15% to 60% of people with CP 
and its course tends to be severe.14 Buonaguro et al. retrospectively studied the 
relationship between epilepsy and CITB in 150 children with CP.15 Sixty of these 
children had epilepsy before CITB started. Seizure frequency decreased in eight 
children, worsened in two and one child had new-onset seizures. In conclusion, 
CITB does not seem to trigger or worsen seizure activity. Therefore, we do not 
consider intractable epilepsy as an absolute contraindication for CITB. 
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During a follow-up of 312 patient-months, the incidence of procedure and 
device related adverse events (often called complications) was 0.09 per patient-
month (95% CI: 0.06-0.12). Three complications were serious, because they 
required surgical management and resulted in a prolonged hospital stay. Albright 
et al. reported 69 procedure and device related complications during a follow-up 
of 1178 patient-months (incidence 0.06 per patient-month [95% CI: 0.05-0.07]) 
in 100 spastic children with a SynchroMed EL 10-ml pump.6 Forty-seven of 69 
complications were serious. They also found that the incidence of serious 
procedure related adverse events was significantly higher in children younger 
than 8 years.6 Murphy et al. reported 27 complications during a follow-up of 468 
patient-months (incidence 0.06 per patient-month [95% CI: 0.04-0.08]) in 23 
children with CP, aged between 4.5 and 17.4 years (mean 8.8), weighing 23.7 kg 
on average.3 Eleven of the 25 implanted systems (44%) had to be explanted. Eight 
of 11 pumps were removed due to wound infection or dehiscence. Lower age, 
height and weight were associated with higher explantation rates.3 Motta et al. 
studied the incidence of three common complications of CITB in 200 children 
(175 with CP), aged 13.7 ± 6.6 years.7 They recorded 75 complications during a 
follow-up of 10,142 patient-months (incidence 0.0075 per patient-month [95% 
CI: 0.0058-0.0092]). Twenty children (10%) had an infection, 34 (17%) leakage 
of cerebrospinal fluid (one pump removal) and 21 (10.5%) catheter associated 
complications (15 pump removals). The incidence of infections decreased from 
10% to 4.8% after adoption of the subfascial implantation technique and 
modification of the preoperative prophylaxis procedures.7  
In our study, none of the children developed wound infections and none of the 
pumps had to be explanted. A possible explanation may be that the children in 
our study were relatively old (mean age 13.7) and heavy (mean weight 39.6 kg). 
Secondly, regarding the importance of postoperative wound healing, we did not 
allow discharge before the wounds had healed well. Thirdly, we used the new 
SynchroMed II pump for the last 11 implantations. This pump is only 19.5 mm 
thick as opposed to the older SynchroMed EL 10-ml and 18-ml pumps which are 
21.6 mm and 27.5 mm thick, respectively. The smaller SynchroMed II pump 
gives less skin and wound tension, which may result in less skin erosion, wound 
dehiscence and infections. 
The complication incidences of the reported studies should be interpreted with 
caution. Studies with a relatively short follow-up may show a higher 
complication incidence, because the majority of complications occurs during the 
first postoperative months. Another bias concerns differences in the definition 
and inclusion of complications, e.g. Motta et al. only included three types of 
complications.7 Although children are more prone to device or procedure related 
complications than adults, the complication incidence in children is decreasing 
due to the standard use of prophylactic antibiotic agents, improved surgical 
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techniques and technological advances in the design of pumps and 
catheters.1,3,7,16   
Now that we have established CITB to be effective and safe in the treatment of 
problems caused by intractable spasticity in children with CP, we should aim to 
optimise its appliance. A future challenge regarding treatment with CITB is to 
select the right children at the right age. Currently, available pumps are 
sufficiently small so that there is no longer a need for any size or weight 
restrictions.17 However, younger, malnourished, and the most seriously affected 
spastic children seem to be more vulnerable to adverse events.3,6,7 On the other 
hand, early treatment with CITB can prevent contractures, dislocations and the 
subsequent need for orthopaedic procedures.18,19 Another challenge is to predict 
which catheter tip level is best for the individual child. We emphasise the role of 
multidisciplinary teams in specialised centres to make well considered, child 
centred treatment plans. Individual treatment goals should be clear, relevant and 
realistic. Outcome measures should include highly individualised, subjective 
measures such as the VAS or goal attainment scaling and more standardised 
measures, such as relevant GMFM dimensions, PEDI scales or HRQL 
domains.20-24 
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ABSTRACT 
Background 
The aim of this study was to introduce a useful diagnostic method to evaluate baclofen 
pump system-related complications without disturbing the continuous delivery of 
intrathecal baclofen.  
 
Methods 
We present a case report on the use of an indium111 diethylenetriaminepentaacetic acid 
(DTPA) flow study in the evaluation of a lumbar swelling in a 16-year-old girl with spastic 
cerebral palsy, treated with continuous intrathecal baclofen.  
 
Results 
Disconnection or damage of the catheter leading to leakage of baclofen into the lumbar 
swelling could be ruled out by the use of an indium111 DTPA flow study. This is the first 
report to illustrate the implementation of an indium111 DTPA flow study without interrupting 
the infusion of continuous intrathecal baclofen.  
 
Conclusion 
An indium111 DTPA flow study is a non-invasive, safe and patient friendly diagnostic 
method, which can be of great help in the evaluation of pump- or catheter-related 
complications and does not need to interfere with the delivery of continuous intrathecal 
baclofen. 
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INTRODUCTION 
Continuous intrathecal baclofen (CITB) infusion is a treatment option used to 
manage intractable spasticity. The intrathecal drug delivery system is composed 
of a programmable infusion pump implanted in an abdominal subcutaneous or 
subfascial pocket and a connecting catheter which is inserted in the intrathecal 
space in the spine, usually in the thoracic or lower cervical region. Children with 
severe spasticity of cerebral origin can benefit substantially from treatment with 
CITB in terms of pain and spasm relief, better sleep and improved ease of care.1 
However, more than fifty percent of the patients experience side effects or 
complications of CITB therapy.2 The most commonly reported baclofen pump 
system-related problems are seromas, cerebrospinal fluid (CFS) leaks, and 
problems with the catheter, such as kinks, perforations or disconnections. CSF 
leaking along the intrathecal catheter may accumulate subcutaneously at the 
back or flow along the catheter to accumulate around the pump. A fluid 
collection at the back more often consists of CSF than serous fluid. Serous fluid 
will usually be absorbed in time, whereas CSF accumulation commonly requires 
therapy.2 
 
Two diagnostic methods used in the evaluation of a pump- or catheter-related 
complication of CITB are a plain X-ray study to assess catheter continuity and a 
contrast study to evaluate catheter integrity.2 Contrast studies are only possible in 
pump models with a side port through which you need to inject the contrast 
medium directly into the catheter. This is a difficult procedure, which requires 
experience. Another disadvantage of this procedure is the disruption of CITB 
delivery, which can result in serious aggravation of spasticity. 
 
We report on the implementation of an indium111 diethylenetriaminepentaacetic 
acid (DTPA) flow study as a useful and patient friendly diagnostic method in the 
evaluation of a lumbar swelling in a 16-year-old girl with spastic cerebral palsy, 
treated with CITB. Indium111 DTPA was used instead of technetium99 DTPA, 
because the European regulation states that only the former radiopharmacon may 
be used for intrathecal studies in Europe. 
CASE REPORT 
In a 16-year-old girl with a medical history of spastic quadriplegic cerebral palsy, 
epilepsy and profound cognitive impairments (Gross Motor Function 
Classification System level V), spasticity had increasingly led to pain and 
interference with care, restricting participation in social activities. After a 
successful intrathecal baclofen (ITB) bolus trial, treatment with CITB was started, 
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delivered via a subfascially implanted SynchroMed II pump (Medtronic, Inc., 
Minneapolis, Minnesota, USA) and a two-piece connecting catheter (model 
8731) entering the lumbar dural sac with the tip of the catheter located at the 
level of the fifth thoracic vertebra. Three weeks after pump implantation, the 
parents observed a lumbar swelling. In the mornings this lump was hardly visible, 
but during the day it would swell to a height of about 2 cm. Although spasticity 
clearly decreased since CITB delivery, the child’s general condition was 
mediocre. She was withdrawn into herself, lacked energy, fainted several times 
and she was pale. We could not rule out any headache or nausea, as the girl was 
not able to communicate verbally or non-verbally. During physical examination 
of the lumbar region, the connection of the two catheters was palpable within a 
fluctuating swelling of about three centimetres in average (Figure 6.1A). No 
swelling or abnormalities were found along the catheter or in the pump region at 
the abdomen. The differential diagnoses of this swelling were leakage of CSF 
along the catheter, leakage of baclofen from a tear or perforation in the catheter, 
a catheter disconnection or a seroma. We had no clear explanation for the poor 
condition of the girl and we could not rule out a catheter-related cause on 
clinical grounds. Moreover, the experience in this field was limited, so our 
multidisciplinary team decided to further elaborate on this problem. A plain X-ray 
showed an unchanged position of the pump and the catheter system in 
comparison with early postoperative films and did not reveal any kinks or a clear 
disconnection of the catheters (Figure 6.1C). A lumbar ultrasound showed an 
encapsulated cyst filled with clear fluid, sized 2.0 x 3.6 x 0.8 cm, enclosing the 
catheter connector (Figure 6.1B). As we would rather not interrupt the continuous 
delivery of ITB, we decided to carry out an indium111 DTPA flow study on an out 
patient basis. We first emptied the drug reservoir of the pump. We then refilled it 
with exactly 5 ml of baclofen in an unchanged ITB concentration of 500 μg/ml 
and 20.7 MBq indium111 DTPA in 0.5 ml of 0.9% saline solution. Adding the 
0.9% saline solution, the ITB concentration was changed to 455 μg/ml. We did 
not enter this change in concentration into the pump computer, nor did we 
program a compensatory change in ITB dose. As a result, the ITB dose was 
indirectly lowered with 9%. In our patient, this did not result in an unacceptable 
increase in spasticity. We calculated that it would take the radiopharmaceutical 
2.9 days to reach the tip of the catheter (ITB dose of 71.3 μg per day divided by 
the ITB concentration 500 of μg/ml is 0.14 ml per day. Total volume of the 
catheters plus the dead space of the pump is 0.417 ml divided by 0.14 ml/day is 
2.9 days). Static anterior and lateral images of the abdomen were obtained with a 
two-headed gamma camera (Multispect II, Siemens, Chicago, Illinois, USA) 5, 60 
and 300 minutes and 1, 2, 3, 4, 7, 10 and 15 days post injection (p.i.) of the 
indium111 DTPA into the pump reservoir. Consistent with our calculation, the 
images revealed radioactivity outside the pump in the proximal catheter system 
from the second day p.i. On days 4, 7 and 10 p.i., the complete catheter system 
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was visible with a more intense focal accumulation of radioactivity in the area of 
the swelling. The exact edges of the lumbar swelling were marked on the skin 
using a cobalt57 marker. This revealed the size of the swelling to be clearly larger 
than the area of the focal accumulation of radioactivity (Figure 6.1D). The more 
intense focal accumulation was interpreted to be corresponding with the local 
loop of the catheter, visible on the X-ray (Figure 6.1C). At day 10 p.i., we emptied 
the pump again and refilled it with ITB 500 μg/ml. At day 15 p.i. the images did 
not show radioactivity in the catheter anymore. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 6.1 A The lumbar swelling in our patient 
 B Ultrasound of the swelling showing an encapsulated cyst 
 C Plain X-ray showing the pump and a part of the catheter system 
 D Image made on day 7 after injection of indium111 DTPA into the pump showing 
radioactivity in the catheter with a more focal accumulation in the area of the 
swelling. Marks at the edges of the swelling, using a cobalt57 marker on the skin, 
revealed the size of the swelling to be clearly larger than the area with the more 
intense focal accumulation of radioactivity which was interpreted as corresponding 
with the catheter loop, as shown on the plain X-ray film (C) 
Left
Left Left
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DISCUSSION 
In our patient, the lumbar swelling appeared while sitting at daytime and 
disappeared after having lain in bed at night. This pattern suggested leakage of 
CSF along the catheter into the swelling. However, in the case of a significant 
leakage of CSF, we would have expected a larger swelling as well as signs of an 
intracranial hypotension syndrome. A complete disconnection of the catheter 
was not very probable, as the girl kept responding successfully to CITB delivery. 
However, either an incomplete disconnection or damage of the catheter could 
have led to leakage from the catheter into the swelling. These complications 
could not be ruled out with an X-ray. The ultrasound showed an encapsulated 
cyst, but this could not provide us with information on possible leakage of fluid 
into the cyst. 
 
Indium cisternography can be used to localise a tear in the dura mater leading to 
leakage of CSF.3,4 In our patient, the images of the indium111 DTPA flow study 
showed no radioactivity outside the pump and catheter system. On the basis of 
this finding we ruled out a disconnection and any perforations in the extradural 
catheter part. In our patient, 0.14 ml of the indium111 DTPA solution per day 
entered the intrathecal space via the tip of the catheter. The indium111 DTPA 
solution was then diluted with roughly a factor 1000, as people have about 150 
ml of CSF in total and the daily CSF production is about 150 to 500 ml. The 
question is whether the images would reveal such a small amount of radioactivity 
in the area of the swelling in case of leakage along the catheter. Considering the 
modest size of the swelling, we decided not to undertake any further action with 
respect to the cyst. One year after pump implantation, the cyst was still present 
and had not changed. In the meantime the general condition of the girl had 
improved along with an improving nutritional state and better adjustment of the 
CITB dose.  
 
An indium111 DTPA flow study is a safe and reliable procedure in the evaluation 
of pump function and patency of an intrathecal, slow-flow infusion system.5-8 The 
refill procedure before and after the DTPA flow study is not different from other 
refills, so there is no reason to believe that there is an increased risk of adverse 
reactions. This is the first report to illustrate the implementation of an indium111 
DTPA flow study without interrupting the delivery of CITB. The latter is possible 
as indium111 DTPA has a long half life of 2.8 days which allows delayed 
imaging.9 This is a great advantage for patients, as any interruption of the 
continuous delivery of ITB can result in severe rebound spasticity. We would like 
to highlight an indium111 DTPA flow study as a patient friendly, safe, and reliable 
diagnostic method in identifying or excluding pump- or catheter-related 
complications of CITB treatment. 
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ABSTRACT 
Background   
In a substantial group of children with spastic cerebral palsy, spasticity does not respond 
to regular therapies. New treatment options such as intrathecal baclofen therapy can be 
very effective, but cost a lot. Since escalating health care expenditures are a worldwide 
concern, economic evaluations become increasingly important in order to justify the 
introduction of expensive therapies. A cost of illness study defines the magnitude of an 
illness in monetary terms and can serve as a basis for any economic evaluation. 
 
Methods   
The aims of this Dutch cost of illness study were to estimate and categorise the 
expenditures for children with intractable spastic cerebral palsy by conducting a bottom-
up, disease specific, prevalence based cost of illness study from the societal perspective. 
Data were collected by a patient survey and by consulting files of health care institutions 
and local governments for a one-year period. 
 
Results   
We included eight girls and seven boys, aged between 7 and 16 years (mean 13.2 ± 2.9 
years). From the societal perspective, mean annual costs were €40,265, which is more 
than eleven fold the mean expenditures on care per Dutch capita. Home care and 
guidance accounted for the highest expenditures (€23,000; 57%), followed by special 
equipment and aids (€6927; 17%), therapy and rehabilitation (€3262; 8%), and 
transportation (€3101; 8%). The expenditures for medical care were relatively small 
(€1573; 4%). 
 
Conclusions   
The economic impact of intractable spastic cerebral palsy in children is relatively high and 
largely related to the motor impairments. Cost-effectiveness studies are needed to evaluate 
whether early and better treatment of spasticity might not only improve the children’s 
quality of life, but also reduce the high associated costs.  
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INTRODUCTION 
Cerebral palsy (CP) is a term for a heterogeneous group of clinical syndromes that 
are characterised by abnormal motor actions and postural mechanisms, and that 
are due to non-progressive abnormalities of the developing brain.1 CP is the most 
common cause of severe physical disability in childhood.2 The overall reported 
CP prevalence is 2.4 per 1000 children in developed countries.2,3 There is no 
cure, so treatment focuses on improving the quality of life of the child and its 
caregivers. Spasticity accounts for 70 to 91% of the motor disorders associated 
with CP.4,5 Spasticity is a motor disorder characterised by a velocity-dependent 
increase in tonic stretch reflexes with exaggerated tendon jerks, resulting from 
hyperexcitability of the stretch reflex.6 Spasticity can cause pain, sleeping 
disorders, increased energy requirements, and interference with positioning, 
transfers, dressing, and body hygiene. Secondary phenomena such as 
contractures and pressure sores can add to the treatment problems.7 A substantial 
group of children with serious spastic CP does not respond to regular treatments, 
such as physical therapy, orthopaedic surgery or oral medication. An effective 
treatment option for intractable spasticity is continuous infusion of intrathecal 
baclofen.8-10 However, evidence for continuous infusion of intrathecal baclofen 
in the treatment of children with spastic CP is lacking.11 As a result, this 
promising therapy is not reimbursed for children in the Netherlands. Therefore, 
we started a Dutch national study on the efficacy and safety of continuous 
infusion of intrathecal baclofen for intractable spasticity in children with CP in 
2002. 
Throughout the world, spending on health care is outpacing economic growth.12 
Policy makers and governmental officials agree that these rapidly escalating 
health expenditures must be controlled. This implies that in order to justify the 
introduction of any expensive medical treatment, it should go together with a 
cost analysis. For that reason, we embedded a cost of illness (COI) study and a 
cost-effectiveness analysis in the Dutch ITB study for children. A COI study 
defines the magnitude of a disease or injury in monetary terms.13 It can provide 
an economic framework for programme evaluation, assist in the allocation of 
research money, and it can serve as a basis for any economic evaluation, such as 
a cost-effectiveness, cost-benefit or cost-utility analysis.13-15 The aims of the 
present COI study were to estimate and categorise the expenditures for children 
with intractable CP from the societal perspective as well as the perspectives of 
the government, health insurers and families of the children.  
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METHODS 
This COI study was embedded in the Dutch ITB study on the efficacy and safety 
of continuous infusion of intrathecal baclofen in the treatment of intractable 
spasticity in children with CP.16 We refer to our prior article for the eligibility 
criteria of this study.16 Medical specialists referred children from all parts of the 
Netherlands to the University Hospital Maastricht, where all phases of the study 
took place. 
Study design 
We conducted a bottom-up, disease specific, prevalence based COI study from 
the perspectives of society, the health insurers, the government and the families 
of the children. This means that we interviewed the parents about the costs of 
health care consumption and the use of other resources (bottom-up) for their 
child with spastic CP (disease-specific). In a prevalence based COI study, the 
costs within a given period of time are calculated for all the patients affected.15 
We considered a one-year period. The perspective of a COI study indicates from 
which point of view the study is being considered. The chosen perspective 
determines which costs are included and thus which conclusions can be drawn 
from that particular COI study. The preferable, broadest perspective is the 
societal perspective, which provides an estimate of the economic impact of a 
disease to society.13 We left any production losses due to the illness out of 
consideration, as the study population consisted of children.14  
Data sources 
Data were collected by means of a questionnaire and a cost diary. Table 7.1 
shows the various categories of resource use included in the questionnaire and 
diary. Parents completed the questionnaire, which covered the one-year period 
preceding the test treatment. The questionnaire also included questions on 
personal budgets and on resources with lifetimes longer than one year. A 
personal budget is a sum of money, allocated by the Dutch government, allowing 
parents to arrange and purchase any care, help and support the child needs. We 
validated and completed retrospectively collected data by retrieving information 
from records of the involved health care and governmental institutions. In 
addition to the retrospective questionnaire, the parents prospectively kept a cost 
diary during one month. The diary enclosed questions about weekly to monthly 
recurring consumption of different health care resources (Table 7.1). We 
extrapolated the data obtained from the diary over a one-year period. Both the 
questionnaire and the diary were completed before any intervention as part of the 
Dutch ITB study had taken place.  
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Table 7.1 Categories of resource use included in questionnaire and diary 
Questionnaire, part 1 (one-year time period) 
General practitioner care 
Outpatient specialist medical care  
Alternative therapies 
Emergency department attendances 
Ambulance transfers 
Hospitalisation 
Tests 
Prescribed medication 
Over-the-counter medication 
Subscriptions to patients’ associations 
Questionnaire, part 2 (variable time period, see text) 
Personal budget 
Wheelchair van and adaptations 
Wheelchair and adaptations 
Home modifications 
Special equipment and aids 
Diary (one-month time period) 
Occupational, physical and speech therapy 
Outpatient rehabilitation 
Nursing 
Personal care 
Household care 
Activating guidance 
Supportive guidance 
Incontinence products 
Costs 
We valued the majority of costs using the Dutch guidelines for 
pharmacoeconomic research and real unit prices excluding taxes, as assigned by 
the University Hospital Maastricht (Table 7.2).17 Costs were estimated for the year 
2003 in Euros. We discounted costs that were not available for the year 2003 
with 4% per year according to the Dutch guidelines.17 Unit prices of medication 
were collected from the Pharmacotherapeutical Compass, a publication of the 
Dutch Health Care Insurance Board. We estimated unit costs of outpatient 
consultations of medical specialists by multiplying a baseline price with a 
weighing factor per speciality according to the Dutch guidelines for 
pharmacoeconomic research for university hospitals.17 For all resources with a 
lifetime longer than one year, a base lifetime was estimated for the calculation of 
the annual costs. Travelling expenses only concerned travelling to and from the 
hospital or to the therapist. We estimated the total costs for wheelchair vans 
differently per child, depending whether the van was only used for the child or 
also for other purposes. If a family had one or more cars plus the wheelchair van, 
we included the purchasing costs for the van, costs for maintenance, insurance 
and road tax in this category. Fixed annual rates for insurance, maintenance and 
road tax of respectively €936, €360 and €336 were used (source: Dutch 
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Consumer’s Organisation Guide, August 2004). In case families also used the 
wheelchair van for general family purposes, the purchasing costs were lowered 
with those of a car in the medium-price range (€5460 per year; source: Dutch 
Consumer’s Organisation Guide, August 2004). In the latter case, we did not take 
any costs for insurance, maintenance and road tax into account. Ultimately, we 
categorised the costs into eight main groups: 1) medical care, 2) therapy and 
rehabilitation, 3) special equipment and aids, 4) incontinence products, 5) 
transportation, 6) home care and guidance, 7) home modifications, and 8) out-of-
pocket costs.  
 
Table 7.2 Annual costs per resource unit in Euro  
 Unit 
cost 
Source 
unit costa 
Quantity 
per year per 
child (mean) 
Quantity 
per year per 
child (range) 
Annual 
costs 
(mean) 
Annual  
costs 
(range) 
Hospitalisation        
   - university hospital per day  476.00 1  0.07  0  -     1  33  0 -   476 
Outpatient visits, universal rate       
   - specialist in a university hospital  100.00 1  3.67  1  -   11  367  100 - 1100 
   - specialist in a general hospital  56.00 1  3.00  0  -   10  168  0 -   560 
   - botulinum toxin treatment  375.21 2  0.13  0  -     1  49  0 -   375 
Outpatient visits at a university  
hospital, differentiated rates 
    
   Neurologist  144.16 1  2.07  1  -     4  298  144  -   577 
   Paediatrician  84.83 1  0.60  0  -     3  51  0  -   254 
   Rehabilitation specialist  76.70 1  2.67  0  -     8  205  0  -   614 
   Ophthalmologist  20.92 1  0.33  0  -     2  7  0  -     42 
   Orthopaedist  168.50 1  0.93  0  -     2  157  0  -   337 
   Ear, nose and throat specialist  29.05 1  0.07  0  -     1  2  0  -     29 
General practitioner       
   - home visit  40.40 1  0.20  0  -     1  8  0  -     40 
   - telephone contact  10.10 1  1.53  0  -   15  15  0  -   152 
   - consultation at the office  20.20 1  1.67  0  -     5  34  0  -   101 
Alternative medicine       
   Homeopath  22.75 3  0.87  0  -   12  20  0  -   273 
Tests       
   X-ray hip joints  25.02 1  0.60  0  -     1  15  0  -     25 
   X-ray spinal column  25.02 1  0.13  0  -     1  3  0  -     25 
   MRI-spinal column  120.02 1  0.07  0  -     1  8  0  -   120 
   MRI-knee  70.00 1  0.07  0  -     1  5  0  -     70 
   Electroencephalogram  99.40 1  0.13  0  -     1  13  0  -     99 
   Barium swallowing test  94.03 1  0.07  0  -     1  7  0  -     94 
   Salivary measurement  191.82 1  0.07  0  -     1  13  0  -   192 
Therapy and rehabilitation       
   Speech therapist  25.40 1  32.76  0  -   96  832  0  - 2438 
   Physiotherapist  22.75 1  68.04  0  - 144  1548  0  - 3276 
   Physiotherapist, single evaluation  32.60 1  1.00                  1  33                33 
   Occupational therapist  12.90 1  27.24  0  -   96  351  0  - 1238 
   Outpatient rehabilitation, hourly rate  83.00 1  6.00  0  -   90  498  0  - 7470 
Transport       
   Price per kilometre (by car)  0.16 1  396.33  75  - 797  63  12  -   128 
a Sources: 1 Dutch guideline for pharmacoeconomic research, 2 Data University Hospital Maastricht, 3 Patient 
questionnaire. 
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Sensitivity analysis 
Sensitivity analyses can be carried out to investigate the impact of certain 
assumptions on the study results.18 In this study we have applied different 
sensitivity analyses. First, we explored the sensitivity of results concerning 
variations in lifetimes of resources such as wheelchairs and wheelchair vans. 
Secondly, we recalculated the costs for consultations of medical specialists using 
a fixed rate for consulting specialists at university hospitals and a fixed rate for 
consulting specialists at general hospitals. Finally, we compared the amounts of 
allocated personal budgets of two consecutive years. We registered the personal 
budgets of two successive years, as the year of allocation of one personal budget 
often did not exactly parallel the year for which the questionnaire was 
completed. 
Ethical approval and consent 
The study was approved by the medical ethical committee of the University 
Hospital Maastricht. In accordance with local legislation, we obtained written 
informed consent from the parents, and also from the children if they were aged 
12 years or older and capable of understanding the nature of the study. The 
informed consent also included permission for the retrieval of personal data.  
RESULTS 
We included eight girls and seven boys, aged between 7 and 16 years (mean 
13.2 ± 2.9 years), in this COI study. One child was classified on the Gross Motor 
Function Classification System (GMFCS) at level III, two at level IV and 12 at 
level V.19 Children classified at GMFCS levels III and IV had a spastic diplegia 
and children classified at GMFCS level V had a spastic tetraplegia. Two children 
were living in a home for children with a handicap during the week; all other 
children lived with their respective families. Both the one-year period covered by 
the first part of the questionnaire and the one-month period covered by the diary 
fell in all cases between January 2002 and February 2005. The response rate for 
the questionnaires as well as the diaries was 100%. 
Costs from the societal perspective   
Table 7.2 shows the various resources, including their unit costs, quantities of use 
and the total annual costs per resource. Table 7.3 shows the annual societal costs 
as distributed among the eight main resource categories. From the societal 
perspective, the mean annual costs were €40,265. The highest costs fell under 
the categories of home care and guidance (€23,000; 57%), special equipment 
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and aids (€6927; 17%), therapy and rehabilitation (€3262; 8%), and 
transportation (€3101; 8%). The costs within the category of medical care were 
relatively low accounting for only 4% of total costs. Within the category of home 
care and guidance, four children did not have any consumption. One child got 
348 hours of home care per year (hourly rate €40.40; in total €14,059), which 
was not paid from a personal budget. Ten children had a personal budget of 
€33,094 on average (range €15,507 to €56,400). Within the category of special 
equipment and aids, the purchase, adaptations and maintenance of wheelchairs 
accounted for 74% of the costs. All children had a non-electric wheelchair. 
Besides this, 13 of them also had an electric wheelchair. Within the category of 
therapy and rehabilitation, 13 children had physical therapy, nine had 
occupational therapy and seven had speech therapy on a regular basis. One child 
visited a rehabilitation centre once a week. Within the category of transportation 
costs, expenditures for wheelchair vans accounted for 97% of the costs. 
Costs from the perspectives of the health insurers, government and 
families 
The societal costs can be subdivided into costs of the health insurers, the 
government and the families (Table 7.4). From the perspective of the health 
insurers, mean annual costs per child were estimated at €28,663. The highest 
costs fell into the categories of home care and guidance (€23,000; 80%). The 
expenditures for medical care accounted for only 5% of costs. From the 
perspective of the government, mean annual costs were estimated at €9614 of 
which €6607 (69%) for special equipment and aids. From the family perspective, 
mean annual costs were estimated at €1988 of which €1471 (74%) for 
wheelchair vans.  
Sensitivity analyses 
Table 7.3 shows the results of the sensitivity analyses, conducted from the 
societal perspective. The most noticeable result was the increase in mean 
personal budget as allocated in two successive years. For three children the 
height of the personal budget did not change. For the other seven children, the 
allocated personal budgets increased from an average of €33,094 to €46,436 per 
child (mean increase 39%; range 1% -146%). The maximum allocated personal 
budget was €109,500 a year. This rise is explained by a fundamental change in 
the regulation of personal budgets in the Netherlands since April 2003. The 
change from product to care function based budgeting has especially resulted in 
higher budgets for people with a mental handicap. The sensitivity analysis of the 
lifetimes of special equipment and aids showed a considerable range (€5660 to 
€9885) in mean costs. The sensitivity analyses of wheelchair vans and home 
modifications showed somewhat smaller ranges in mean costs. Taking all 
Thesis_hoving_v5.pdf   114 19-3-2008   12:31:46
 Cost of illness study   115 
sensitivity analyses into account, the estimated societal costs of €40,265 could in 
fact vary between €37,659 and €53,141 (Table 7.3). This range is mainly caused 
by the large increases in allocated personal budgets. 
 
Table 7.3 Mean annual costs per resource category from the societal perspective (in Euro), including the results 
of the sensitivity analyses 
Base  Sensitivity analyses Resource category 
Mean  
costs 
% of 
 total 
 
 
Mean 
costs 
% of 
total 
Mean costs 
including all 
lowest costs 
Mean costs 
including all 
highest costs 
Medical care 
   Hospitalisation  
   Emergency department care  
   Specialist medical care 
    - differentiated rates (base)    
    - universal rates 
   General practitioner care 
    Tests 
    Medication 
    Alternative medicine 
Therapy and rehabilitation 
Special equipment and aids 
   Wheelchairs 
   Other equipments and aids 
   - Depreciation 5 years (base) 
   - Depreciation 3 years 
   - Depreciation 7 years 
Incontinence products 
Transportation 
   - Van depreciation 7 years (base) 
   - Van depreciation 5 years 
   - Van depreciation 9 years 
   Travelling expenses 
Home care and guidance 
    - Personal budget year 1 (base) 
    - Personal budget year 2 
   Home care (no personal budget) 
Home modification 
   - Depreciation 10 years (base) 
   - Depreciation 15 years 
Out-of-pocket  
 1573 
 70 
 0 
 
 760 
 
 57 
 64 
 602 
 20 
 3262 
 6927 
 5102 
 1825 
 6927 
 
 
 547 
 3101 
 2997 
 
 
 104 
  23,000 
  22,063 
 
 937 
 1812 
 1812 
 
 43 
       3.91 
 0.17 
 0.00 
 
 1.89 
 
 0.14 
 0.16 
 1.50 
 0.05 
 8.10 
 17.20 
 12.67 
 4.53 
 17.20 
 
 
 1.36 
 7.70 
 7.44 
 
 
 0.26 
 57.12 
 54.80 
 
 2.32 
 4.50 
 4.50 
 
 0.11 
  
 
 
 
 
  585 
 
 
 
 
 
 
 
 
 
9885 
5660 
 
 
 
4021 
2427 
 
 
 
  30,957 
 
 
 
1219 
 
 
 
 
 
 
  1.46 
 
 
 
 
 
 
 
 
 
22.87 
14.51 
 
 
 
  9.74 
  6.11 
 
 
 
62.97 
 
 
 
  3.07 
 
 1397 
 
 
 
 
 
 
 
 
 
 3262 
 5660 
 
 
 
 
 
 547 
 2531 
 
 
 
 
       23,000 
 
 
 
 1219 
 
 
 43 
 1573 
 
 
 
 
 
 
 
 
 
 3262 
 9885 
 
 
 
 
 
 547 
 4125 
 
 
 
 
      31,894 
 
 
 
 1812 
 
 
 43 
Total of mean annual costs   40,265    100.00           37,659  53,141 
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Table 7.4 Mean annual costs per resource category from the perspectives of the health insurers, the government 
and the families (in Euro) 
Health insurer 
perspective 
Governmental 
perspective 
Family  
perspective 
Resource category 
Mean costs % of total Mean costs % of total Mean costs % of total 
Medical care 
   Hospitalisation 
   Emergency department care  
   Specialist medical care   
   General practitioner care 
   Tests 
   Medication 
   Alternative medicine 
Therapy and rehabilitation 
Special equipment and aids 
   Wheelchairs 
   Other equipments and aids 
Incontinence products 
Transportation 
   Van  
   Travelling expenses 
Home care and guidance 
   Personal budget 
   Home care (no personal budget) 
Home modification 
Out-of-pocket  
 1487 
 70 
 0 
 760 
 57 
 64 
 516 
 20 
 3262 
 304 
 18 
 286 
 547 
 63 
 0 
 63 
   23,000 
   22,063 
 937 
 0 
 0 
 5.19 
 0.24 
 0.00 
 2.65 
 0.20 
 0.22 
 1.80 
 0.07 
 11.38 
 1.06 
 0.06 
 1.00 
 1.91 
 0.22 
 0.00 
 0.22 
 80.24 
 76.97 
 3.27 
 0.00 
 0.00 
 0 
 0 
 0 
 0 
 0 
 0 
 0 
 0 
 0 
 6607 
 5084 
 1523 
 0 
 1526 
 1526 
 0 
 0 
 0 
 0 
 1481 
 0 
 0 
 0 
 0 
 0 
 0 
 0 
 0 
 0 
 0 
68.72 
52.88 
15.84 
 0 
15.87 
15.87 
 0 
 0 
 0 
 0 
15.40 
 0 
 86 
 0 
 0 
 0 
 0 
 0 
 86 
 0 
 0 
 16 
 0 
 16 
 0 
 1512 
 1471 
 40 
 0 
 0 
 0 
 331 
 43 
 4.32 
 0 
 0 
 0 
 0 
 0 
 4.32 
 0 
 0 
 0.80 
 0 
 0.80 
 0 
 76.05 
 74.01 
 2.03 
 0 
 0 
 0 
 16.67 
 2.17 
Total of mean annual costs    28,663  100.00  9614    100.00  1988  100.00 
DISCUSSION 
In this COI study we defined the magnitude of intractable spastic CP in children 
in monetary terms and we categorised the costs. We estimated the mean annual 
costs per child from the societal perspective at €40,265. This is more than eleven 
fold the mean expenditures on care per capita (€3512) in the Netherlands in 
2003.20 The societal costs were for 71% borne by the health insurers, for 24% by 
the government, and for 5% by the families. 
Considering the division of expenditures, we found that 95% of costs fell outside 
the medical care sector. These costs mainly resulted from the motor impairments, 
which by definition characterise the CP syndromes.21 In spite of the high 
incidence of concomitant problems such as mental retardation, epilepsy, bladder 
and bowel dysfunction, the expenditures for medical care were relatively small 
(4%). This may be explained by the aetiology of CP, as it comprises a non-
progressive lesion of the brain. From the perspectives of society as well as the 
health insurers, by far the highest costs fell under the category of home care and 
guidance. These high expenditures are in agreement with the significantly greater 
care needs of children with severe disabilities in comparison with non-disabled 
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children.22,23 In 2004, the Dutch government allocated an average personal 
budget of €15,234 per year to 69,500 people. The average annual personal 
budget allocated to the children included in our study increased to €46,436. 
Ireys et al. studied the expenditures for care of children with one of eight selected 
chronic health conditions enrolled in the Washington State Medicaid Program. 
Medicaid claims data were analysed for 310,977 children of whom 950 children 
were diagnosed with CP.24 Mean expenditures for children with CP accompanied 
by tetraplegia were about two times higher than children with CP as a whole. 
This illustrates the general pattern in which relatively few children account for a 
disproportionate share of the expenditures. In comparison with the other seven 
chronic illnesses among which asthma, cystic fibrosis, spina bifida and diabetes, 
expenditures for CP were relatively lowest for inpatient care, highest for durable 
medical equipment and second highest for home health care services. These 
findings are in line with our results, illustrating that in CP the motor handicap 
accounts for the majority of costs.  
Our study has underestimated the already high economic impact of intractable 
CP in children, as we left expenditures for special education and day-care out of 
consideration. The particular institutions could not provide us with these cost 
estimates. We think that expenditures for special education and day-care would 
not be influenced by therapeutic interventions for CP. Therefore, leaving these 
costs out will probably not have important consequences for future economic 
evaluations. Though we have obtained most data retrospectively, we believe we 
have been able to retrieve the great majority of data within the previously 
selected cost categories. The parents were all motivated to participate in this 
study, resulting in a 100% response rate for both the questionnaires and the cost 
diaries. Moreover, in case the parents doubted the completeness of their provided 
data, it was generally easy to obtain any additional information from Dutch 
health care institutions and local governments.  
The results of this COI study can serve as a basis for any cost evaluation 
including children with intractable spastic CP. Our study showed that in these 
children the main economic burden was related to the motor impairments. The 
question arises whether early treatment of spasticity would not only improve the 
children’s quality of life, but also would reduce the high associated costs. For 
example, early treatment of spasticity with continuous infusion of intrathecal 
baclofen can prevent contractures, dislocations and the subsequent need for 
orthopaedic procedures.25 Economic evaluations such as cost-effectiveness or 
cost-utility analyses are required to address this question.26 
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ABSTRACT 
In a Dutch national study, we recently established the effectiveness and safety of 
continuous intrathecal baclofen infusion in children with intractable spastic cerebral palsy. 
Because prospective studies on the cost-effectiveness of continuous intrathecal baclofen 
infusion in children with spastic cerebral palsy are lacking, we conducted a cost-
effectiveness analysis alongside our prospective, national study. We compared the costs 
and health effects of continuous intrathecal baclofen infusion to those of standard 
treatment only, from the health care perspective for a one-year period. Health effects were 
expressed in terms of a visual analogue scale for individual problems and quality-adjusted 
life-years (QALYs). QALYs were derived from the EuroQol-5D. We included eight females 
and seven males, aged between 7 and 17 years (mean age 13y8m ± 3y0m). Eleven 
children had spastic cerebral palsy and four children had spastic-dyskinetic cerebral palsy. 
One child was classified on the Gross Motor Function Classification System at level III, 
two children at level IV and 12 at level V. Continuous intrathecal baclofen infusion was 
more effective and more costly than standard treatment only. Gaining one QALY cost on 
average €32,737. We conclude that based on the threshold-willingness to pay for one 
QALY in the Netherlands (€80,000), our results sustain the cost-effectiveness of 
continuous intrathecal baclofen infusion for carefully selected children with intractable 
spastic cerebral palsy. 
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INTRODUCTION 
With a prevalence of about 2 per 1000 live births in Western countries, cerebral 
palsy (CP) is the most common cause of severe physical disability in childhood.1 
Spasticity accounts for 70% to 91% of the motor disorders associated with CP 
and is intractable in a substantial group of children.2 Intractable spasticity can 
cause pain, sleeping disturbances, increased energy requirements, pressure sores, 
and interference with positioning, transfers, dressing, and body hygiene. Besides 
the negative impact on quality of life, serious spasticity involves high costs. In a 
cost of illness study (Chapter 7 of this thesis), we estimated the mean societal 
costs in Dutch children with intractable spastic CP at €40,265.3 This is more than 
eleven fold the mean expenditures for care per Dutch capita.3  
In a prospective Dutch national study,4-6 we recently established the effectiveness 
and safety of continuous intrathecal baclofen infusion (CITB) in children with 
intractable spastic CP (Chapters 4 and 5 of this thesis). Our randomised 
controlled trial showed that CITB significantly improved individually formulated 
problems, ease of care, pain and gross motor functioning. Moreover, health-
related quality of life (HRQL) significantly improved for the domains of bodily 
pain/discomfort, mental health, psychosocial status and parents’ personal time 
limitation. Our results are in keeping with those of non-randomised trials.7 
Health care expenditures are rising and resources - people, time, facilities, 
equipment and knowledge - are scarce. Decision makers, including policy 
makers, health care insurers, health care providers, and even patients consider 
information on both costs and effects when choosing between different 
interventions. One way to control health care costs is to apply a transparent and 
rational decision-making process for the reimbursement of new therapies. For 
these reasons, it is important to be informed on the cost-effectiveness of a new 
intervention. 
In a cost-effectiveness analysis (CEA), the additional costs of an intervention are 
compared with the additional health effects of that intervention. The additional 
health effects are expressed in clinical units related to the intervention, such as a 
decrease in pain as measured with a visual analogue scale (VAS). A cost-utility 
analysis (CUA) differs from a CEA in that the additional health effects are 
measured in quality-adjusted life-years (QALYs).8 A CUA reports the costs per 
QALY, which reflects how much money has to be spent in order to gain one life 
year in full health. The lower this amount, the more cost-effective the health 
intervention is.   
Because prospective studies on the cost-effectiveness of CITB in children with 
intractable spastic CP are lacking, we conducted a cost-effectiveness analysis 
alongside our prospective Dutch national study. The aim of this combined 
CEA/CUA was to evaluate the cost-effectiveness of CITB in the treatment of 
children with intractable spastic CP. 
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METHODS 
This combined CEA/CUA was embedded in the Dutch national study on the 
efficacy and safety of CITB for intractable spasticity in children with CP.4 Medical 
specialists referred children from all parts of the Netherlands to the University 
Hospital Maastricht. In Maastricht, where all phases of the study took place, a 
multidisciplinary team decided whether the child met the eligibility criteria.4 We 
planned a placebo-controlled intrathecal baclofen test treatment for the eligible 
children, which was successful in all.4 Subsequently, all children had a 
programmable infusion pump (Medtronic, Inc., Minneapolis, Minnesota, USA) 
implanted by always the same neurosurgeon. We programmed the pump to 
continuously infuse baclofen intrathecally, starting right after the implantation. 
Study design, time horizon and perspective 
We compared the costs and health effects of CITB and standard treatment with 
those of standard treatment only, for a one-year period. Children received only 
standard treatment in the year preceding the test treatment versus CITB in 
addition to standard treatment from the pump implantation onwards. Standard 
treatment included physical therapy, occupational therapy and/or rehabilitation. 
For the assessment of the additional costs of CITB, we compared the costs in the 
year before the test treatment to the costs in the first year after the pump 
implantation (before-after comparison). For the assessment of the additional 
health effects of CITB, we used the VAS for individual problems in the CEA and 
the EuroQol-5D (EQ-5D) in the CUA. We compared the values at the one-year 
follow-up visit with those obtained before pump implantation (baseline). The 
perspective of both the CEA and the CUA was that of the health care. This means 
that we took into account all relevant resources consumed within the care sector.  
Data collection, data sources and costs 
We included intervention costs and other health care costs. For the latter, data 
were collected by means of a questionnaire and a cost diary. The questionnaire 
included the following health care resources: general practitioner care, outpatient 
specialist medical care, alternative therapies, emergency department attendances, 
ambulance transfers, hospitalisations, tests and prescribed medication. Parents 
completed this questionnaire retrospectively for the year preceding the test 
treatment and prospectively for the first year with CITB. Retrospectively collected 
data were validated and completed by retrieving information from records of the 
involved health care institutions. The parents prospectively kept a cost diary 
twice; for one month in the year preceding the start of CITB and for one month in 
the year afterwards. This diary covered regular resource consumption, which we 
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assumed to be stable during the two-year study period. The diary included the 
following resources: incontinence products, occupational therapy, physical 
therapy, speech therapy and outpatient rehabilitation. The data obtained from the 
diaries were extrapolated over a one-year period. 
Intervention costs included expenditures for the test treatment phase, the pump 
implantation phase, and the pump refills. The intervention costs also included 
expenditures related to any adverse events that occurred during these phases. The 
test treatment and pump implantation unit data were obtained from registries of 
the University Hospital Maastricht. Considering the test treatment, we did not 
include costs related to the days on which we administered placebo. These costs 
were protocol-driven, because placebo is not used in regular clinical practice. 
We assumed that most children would be treated with CITB for at least 10 years, 
so we divided the costs of the test treatment by 10 to calculate the annual costs. 
Mortality across this 10-year period can be considered very low.1 Because the 
pump has to be replaced every 5 to 7 years depending on the lifetime of the 
battery, we divided the costs of the pump implantation phase by five to calculate 
the annual costs.9 Because of the roughness of these estimates, we did not take 
into account the interest over the depreciation periods. Pump refill costs included 
costs for specialist medical care, refill kits and baclofen during the first year after 
pump implantation.  
The majority of costs were valued using the Dutch guidelines for 
pharmacoeconomic research10 and real unit prices excluding taxes, as assigned 
by the University Hospital Maastricht. Costs were estimated for the year 2003 in 
Euros. We discounted costs that were not available for the year 2003 with 4% per 
year according to the Dutch guidelines.10 The Euro/Dollar exchange rate in 2003 
was: 1 Euro = 1.12 American Dollars.11 
Outcome measures 
The VAS is a valid and reliable measure for rating pain intensity in adults and 
children over six.12,13 In paediatric patients, aged 5-17 years, the VAS has also 
been applied to measure anxiety, sadness, anger, worry, happiness and 
fatigue.14,15 The VAS showed preliminary reliability and validity for both child 
self-report and parent-proxy report.14 Because the children in our study had 
different problems, we used a VAS for each individually formulated problem.4 
We formulated three problems per child and used the average of these three VAS 
scores for statistical analysis (Table 8.1).14 The VAS is a straight 10-cm horizontal 
line with anchor points ‘very dissatisfied’ (score 0) and ‘very satisfied’ (score 10).4 
The VAS scores were rated by the caregivers for 13 children, while two children 
rated the VAS scores themselves. 
The EQ-5D has been developed to generate a single index for health status for 
use in economic evaluations.16 The caregiver describes the child’s health state of 
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that day on five dimensions: mobility, self-care, usual activities, pain/discomfort 
and anxiety/depression. Each dimension has three response categories 
corresponding to no problem, some problem and extreme problem. The 
descriptive system defines a total of 243 possible health states to which two 
further states (dead and unconscious) were added. Any classified health state can 
then be converted into a single index value (EQ-5D index) by applying scores 
from one of the European valuation sets.16-18 The EQ-5D health indexes lie on a 
scale on which full health has the value 1 and dead has the value 0. We used the 
Dutch valuation set (Dutch EQ-5D index) for the core analysis.17 The United 
Kingdom (UK) valuation set (UK EQ-5D index) was used in a sensitivity 
analysis.18 
 
Table 8.1 Individually formulated problems (three per child) 
Individual problem n 
Ease of care  14 
Pain  12 
Transfers  4 
Sitting position  2 
Use of wheelchair  3 
Startle response  2 
Urinating  2 
Sleep  1 
Tense body feeling  1 
Right arm function  1 
Extreme excitement during eating  1 
Walking distance  1 
Energy use during walking  1 
Total  45 
 
Cost-effectiveness 
Participants with both cost and effectiveness data were included in the CEA and 
CUA. For the intervention period, we calculated QALYs from the area under the 
curve of the mean EQ-5D health index as it changed from baseline.8 We assumed 
that utility values changed in a linear way in between the assessments at baseline 
and the follow-up visits at 6 and 12 months.  
Because we included a relatively small group of children, we used the bootstrap 
method to verify the reliability of the results.19 During bootstrapping, the costs 
and effects were recalculated on the participants’ sample several times. We ran 
1000 replication bootstraps, which generated 1000 estimates of the cost-
effectiveness and cost-utility ratios.19 We plotted these estimates on a cost-
effectiveness and cost-utility plane. Cost-effectiveness and cost-utility planes have 
a horizontal axis representing the difference in effect and a vertical axis 
representing the difference in costs. CITB can be considered as more cost-
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effective than standard treatment only, in one of the following situations: 1) it is 
more effective and less costly, 2) it is more effective and more costly, but the 
additional costs per QALY are worth paying by decision makers, and 3) it is less 
effective and less costly, but the additional costs per extra QALY of standard 
treatment only are not worth paying by decision makers.8 The point estimates on 
the cost-utility plane identify whether one of these situations applies. 
Statistical analysis 
We used SPSS for Windows statistical package, Release 11.0.1. for statistical 
analysis. We used the non-parametric Wilcoxon Signed Rank Test to compare the 
results of the VAS for individual problems and the EQ-5D at the one-year follow-
up visit with those obtained before pump implantation (baseline).20 We 
considered results with p ≤ 0.05 statistically significant. For bootstrapping, we 
used a specially designed macro on Microsoft Excel software. 
Ethics 
The study was approved by the medical ethical committee of the University 
Hospital Maastricht and the Maastricht University. In accordance with local 
legislation, we obtained written informed consent from the parents, and also from 
the children if they were aged 12 years or older and capable of understanding the 
nature and impact of the study. The informed consent also included permission 
for the retrieval of economic data. 
RESULTS 
We included 15 children, eight girls and seven boys, aged between 7 and 17 
years at time of the pump implantation (mean age 13y8m ± 3y0m). Eleven 
children had spastic CP and four children spastic-dyskinetic CP. One child was 
classified on the Gross Motor Function Classification System (GMFCS) at level III, 
two children at level IV, and 12 children at level V. All data were collected 
between January 2002 and May 2006. All questionnaires and diaries were 
completed by the parents. There were no missing VAS or EQ-5D data. 
Costs 
The mean health care costs were €5296 for the year during which the children 
received standard treatment only and €9028 for the year during which the 
children also received CITB. The mean additional annual health care costs of 
CITB were €3732 (Table 8.2). 
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We estimated the mean intervention related health care costs at €4226 per year 
(Table 8.2). The mean annual costs for the test treatment phase, the pump 
implantation phase and the pump refills accounted for, respectively, €335, €3412 
and €479 (Tables 8.2 and 8.3). During the test treatment phase, hospitalisation 
accounted for the highest annual costs (€189; Table 8.3). The children were on 
average hospitalised for 5 days (range 3 to 8). Fourteen of the 15 children had 
symptoms that could fit in with the diagnosis of lowered cerebrospinal fluid 
pressure.4 As a result of this complication, some children had a prolonged stay in 
hospital. During the pump implantation phase, the pumps accounted for the 
highest annual costs (€2300; Table 8.3), followed by the hospitalisation costs 
(€738). The children were on average hospitalised for 10 days (range 9 to 14). 
Two children required a second operation to solve a catheter related adverse 
event. Within the expenditures for the pump refills, specialist medical care 
accounted for the highest costs (€377; Table 8.2). 
The other health care costs remained fairly stable, except for the medication 
costs, which decreased from €516 to €289 with CITB (Table 8.2). 
 
Table 8.2 Annual health care costs (2003 Euro) 
Mean annual costs Resource category 
Standard treatment 
only 
CITB and standard 
treatment 
Intervention related health care costs 
   Test treatment phase 
   Pump implantation phase 
   Refills 
   - Refill kits 
   - Baclofen 
   - Specialist medical care 
Other health care costs 
   Hospitalisation 
   Emergency department care  
   Specialist medical care 
   General practitioner care 
   Tests 
   Medication 
   Alternative medicine 
   Incontinence products 
   Therapy and rehabilitation 
 0 
 0 
 0 
 0 
 0 
 0 
 0 
 5296 
 70 
 0 
 760 
 57 
 64 
 516 
 20 
 547 
 3262 
 4226 
 335 
 3412 
 479 
 57 
 45 
 377 
 4802 
 0 
 8 
 788 
 50 
 54 
 289 
 0 
 547 
 3066 
Total  5296  9028 
Additional mean annual costs of CITB   3732 
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Table 8.3 Costs (2003 Euro) related to the test treatment and the pump implantation phase 
Resource Unit cost Quantity 
test 
treatment 
phase 
Mean 
costs test 
treatment 
phase 
Quantity 
pump 
implantation 
phase 
Mean costs 
pump 
implantation 
phase 
Admission costs  28.00 1.07 30  1.07  30 
Hospitalisation per day  364.00 5.20 1893  10.13  3689 
Paediatrician  86.40 1.07 92  1.07  92 
Neurologist; consultation  6.10 5.20 32  10.13  62 
Neurologist; administration test bolus  41.00 1.40 57   
Neurosurgeon; insertion lumbar catheter  107.00 1.00 107   
Anaesthetist; pre-op consultation  48.20 1.00 48   
Anaesthetist; insertion catheter  109.00 1.00 109   
External lumbar catheter a  299.88 1.00 300   
Laboratory tests variable - 14   
Operation room   452.00 1.00 452  1.13  512 
X-ray; catheter position peroperative  114.70 0.07 7  1.13  129 
Soleus H-reflex measurement  86.20 2.41 207  1.00  86 
Anaesthetist; pump implantation  144.00    1.13  163 
Neurosurgeon; pump implantation  378.50    1.13  429 
Synchromed EL pumpb  9363.00    0.27  2497 
Synchromed II pumpb  12,280.12    0.73  9005 
Intrathecal catheter model 8731b  359.75    0.80  288 
Intrathecal catheter model 8709b  329.29    0.20  66 
Baclofen 20 cc  11.00    1.00  11 
Absolute mean costs   3349   17,059 
Annual mean costsc   335   3412 
a Perifix® 300 Mini Set; B.Braun, Melsungen, Germany; b Medtronic, Inc., Minneapolis, Minnesota, 
USA; c Absolute mean costs of the test treatment phase divided by 10 and mean costs of the pump 
implantation phase divided by 5 (see text for explanation). 
 
Cost-effectiveness 
On the cost-effectiveness plane all point estimates are found in the same 
quadrant (Figure 8.1). This means that CITB was more effective and more costly 
than standard treatment only. The VAS for individual problems improved from 
2.3 ± 1.1 at baseline to 7.2 ± 1.7 after one year of CITB (p = 0.001). 
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Figure 8.1 Cost-effectiveness plane. CITB is more effective and more costly than standard treatment 
only. 
Cost-utility 
On the cost-utility plane derived from the Dutch EQ-5D index, all point estimates 
are found in the same quadrant (Figure 8.2). This means that CITB was more 
effective and more costly than standard treatment only. The cost-utility plane 
derived from the UK EQ-5D index showed no appreciable difference. One QALY 
cost on average €32,737, using the Dutch EQ-5D index and €28,273, using the 
UK EQ-5D index. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2 Cost-utility plane. CITB is more effective and more costly than standard treatment only. 
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DISCUSSION 
This is the first cost-effectiveness analysis on CITB in children with intractable 
spastic CP that was conducted alongside a prospective clinical study. CITB was 
both more effective and costly than standard treatment only. In the CEA, the VAS 
for individual problems significantly improved with 4.9 on average. In the 
literature, the minimal clinically important change on a 0-10 VAS for pain ranged 
from 0.9 to 1.8.21 The mean additional annual health care costs of CITB were 
€3732. 
In the CUA, CITB cost €32,737 per QALY, using the Dutch EQ-5D index. The 
costs per QALY using the UK EQ-5D index were €28,273, which is in the same 
order of magnitude. There is no consensus on the cost per QALY that represents 
acceptable value for money. The Council for Public Health and Health Care 
proposed €80,000 per QALY as a reasonable benchmark in the Netherlands.22 
Therefore, CITB can be considered cost-effective. However, cost-effectiveness is 
one of many factors in any assessment of a new intervention. Other important 
factors are the disease burden, the expected number of treatment recipients, the 
total health budget, society’s moral and ethical values and whether or not 
effective treatment alternatives exist.8 Most children eligible for CITB suffer from 
intractable spasticity without any effective treatment alternative available. The 
health status of children with moderate to severe CP (GMFCS levels III-V) is 
significantly lower than that of children without CP.23 The disease burden of 
intractable spasticity is usually high for both the children and their caregivers. 
Moreover, treatment with CITB is confined to a carefully selected group of 
children, resulting in a very limited impact on the total health budget. We expect 
to start CITB in at most 20 children per year in the Netherlands, resulting in a 
burden on the Dutch total health budget of about €75,000 per year. In 
conclusion, our results sustain the cost-effectiveness of CITB for carefully selected 
children with intractable spastic CP and, from an economic point of view, justify 
the reimbursement of CITB for this group of children in the Netherlands.   
Our results are in keeping with those of two retrospective studies.9,24 Sampson et 
al. reviewed the cost-effectiveness of CITB in a heterogeneous, mainly adult 
patient group with spasticity.9 They considered the cost-benefit ratio acceptable 
in comparison with other interventions that are funded by the health service in 
the UK. The results of a cost-effectiveness analysis in American children with 
severe spasticity of cerebral origin also indicated that CITB offers good value for 
money.24 By means of mathematical modelling and computer simulation, the 
investigators estimated the additional costs of CITB per QALY at $42,000. This 
amount is less than the widely accepted range of $50,000 to $100,000 in the 
United States.24  
Our cost-effectiveness analysis has a few limitations. First, the generalisability of 
the results is confined to relatively older children with intractable spastic CP, who 
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rely on wheeled mobility (GMFCS levels IV and V). However, in clinical practice 
CITB is mostly indicated for children with GMFCS levels IV and V. The 
generalisability of the results beyond the Netherlands may be limited by 
differences in the behaviour of patients and health care providers and differences 
in unit cost prices, financing and supply of health care. The second limitation 
concerns the use of the EQ-5D in the CUA. The EQ-5D is a broad, generic HRQL 
measure that may be insensitive to some of the HRQL-changes experienced by 
children with intractable spastic CP.25 Therefore, the cost-effectiveness of CITB 
may be more favourable than we have estimated. Thirdly, because of the limited 
time-horizon of our study, any long-term effects and complications of CITB could 
not be addressed. Factors that increased the external validity of our results are the 
following: 1) the exclusion of protocol-driven resource use, 2) the inclusion of 
children from all parts of the Netherlands, 3) the used eligibility criteria for 
treatment with CITB also apply to regular clinical practice, and 4) there was no 
artificially enhanced compliance. 
In conclusion, the results of this combined CEA/CUA sustain the cost-
effectiveness of CITB for carefully selected children with intractable spastic CP. 
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GENERAL DISCUSSION 
A substantial group of children with cerebral palsy (CP) suffer from serious 
spasticity, which does not respond to regular treatments. This so-called 
intractable spasticity can be well treated with continuous infusion of intrathecal 
baclofen (CITB).1 However, evidence for the use of CITB in the treatment of 
children with spasticity is lacking.2 This thesis addresses the results of a Dutch 
national study, in which we studied the efficacy and safety of intrathecal baclofen 
therapy in children with intractable spastic CP. The Dutch ITB study comprised 
four phases: 1) the selection phase, 2) the test treatment phase, 3) the pump 
implantation phase, and 4) the follow-up phase. Furthermore, the Dutch ITB 
study embedded a clinical neurophysiological study and a cost analysis.3-5 
Selection phase 
During the selection phase, medical specialists referred children from all parts of 
the Netherlands to the University Hospital Maastricht for possible participation in 
the study. In Maastricht, our multidisciplinary team decided whether the children 
met the eligibility criteria. We expected that hundreds of children would be 
eligible for intrathecal baclofen therapy in the Netherlands. Therefore, we were 
surprised to see that only 21 children were referred to our team between January 
2002 and December 2003. During these two years, we included only seven 
children. The other 14 children did not meet the eligibility criteria for one or 
more of the following reasons: age over 16 years (n = 1); weight less than 20 kg 
(n = 4); insufficient cognitive abilities (n = 6); intractable epileptic seizures 
(n = 3); insufficient motivation for study participation (n = 2); and/or spasticity 
which did not seem to result in a decreased quality of life (n = 4). It was 
interesting to see that 10 of the 21 referred children beforehand did not meet one 
or more of the eligibility criteria. We had several explanations for the 
disappointingly low inclusion. First, the most frequent mentioned spasticity 
associated problems were ‘pain’ and ‘problems with ease of care’ and not so 
much ‘problems with functioning’. Therefore, we decided to widen the eligibility 
criteria from January 2004 on. Children did not need to understand and carry out 
instructions anymore and we also dropped the weight criterion. We subsequently 
gave a few presentations in the Netherlands to explain the new eligibility criteria. 
During these presentations we found out that some of our colleagues were 
sceptical about ITB therapy and therefore were hesitant to refer their patients to 
our study team. Nevertheless, 17 children were referred in 2004 of whom eight 
were included in our study. We excluded nine children for the following reasons: 
age over 16 years (n = 1); insufficient motivation for study participation (n = 1); 
spasticity which did not seem to result in a decreased quality of life (n = 3); 
spasticity was not the most prominent sign in a mixed CP syndrome (n = 2); and 
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serious axial hypotonia (n = 2). Owing to the widened eligibility criteria, we 
could still include two children who under the first criteria were excluded. 
Test treatment phase 
We included 17 children during the selection phase.6 They all participated in the 
double-blind, randomised, placebo-controlled, dose-finding test treatment phase. 
The aims of the test treatment were to: 1) further select children eligible for CITB, 
2) assess the effective ITB bolus dose, and 3) evaluate the effects, side effects, 
complications, and procedures. The test treatment was successful in all 17 
children. Intrathecal bolus administration of baclofen and not placebo reduced 
both muscle tone and the individually formulated problems, significantly. A 
satisfying clinical effect was achieved with ITB bolus doses ranging between 12.5 
μg and 50 μg. The older and heavier children more often required ITB 50 μg. 
Although ITB bolus administration via an external lumbar catheter turned out to 
be safe, 14 of the 17 children suffered from symptoms of lowered cerebrospinal 
fluid pressure. The three children with a tunnelled catheter did not have these 
symptoms. 
What do our results add to the existing literature? First, it was the first placebo-
controlled study in children with spastic CP. We provided evidence that the 
established effects resulted from the intrathecal administration of baclofen and 
not placebo. Second, other investigators usually started the test treatment in 
children with the administration of an ITB 50 μg, 75 μg, or 100 μg bolus.7-11 The 
results of our study showed that the majority of children positively responded to 
an ITB bolus dose half that of the usual adult ITB 50 μg starting dose. Even with 
relatively low ITB bolus doses, one has to take into account that children might 
temporarily become slightly lethargic. Third, the test treatment was highly 
appreciated by most children and their parents in spite of symptoms of lowered 
cerebrospinal fluid pressure. 
Pump implantation and follow-up phase 
After a successful test treatment, all 17 children were admitted to the randomised, 
controlled, open-label, pump implantation phase. Because of the varying nature 
of the children and the numerous outcomes of primary interest, others have 
considered a randomised controlled trial (RCT) practically impossible or 
inappropriate for evaluating treatment in children with CP.12 We endorsed these 
problems, but succeeded to conduct an ethically sound RCT in which we studied 
the 6-month efficacy of CITB in comparison with standard treatment only. CITB 
reduced individually formulated problems, it relieved pain, and it improved both 
ease of care and gross motor functioning, significantly. Moreover, health related 
quality of life significantly improved for the domains of bodily pain/discomfort, 
mental health, psychosocial status and parents’ personal time limitation. After the 
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RCT, the children in the control group also received a pump for CITB. 
Subsequently, all 17 children participated in the follow-up phase. In this phase, 
we prospectively studied the one-year efficacy of CITB and its safety from pump 
implantation up to 24 months of follow-up. The results were in keeping with 
those of the RCT. Adverse events frequently occurred, but were for the greater 
part short-lasting and non-serious. Overall patient satisfaction was high. 
What makes our research special? Most of all, this was the first RCT establishing 
the efficacy of CITB in the treatment of children who suffer from problems caused 
by intractable spastic CP. Our follow-up study furthermore showed that effects 
lasted or became even stronger after 12 months and that CITB was safe. Our 
study also distinguishes itself from previous reports for the inclusion of a broad 
choice of outcome measures. For example, we illustrated how children were able 
to extend their activities and participation after spasticity and pain had been 
controlled. It was interesting to see that these clear individual improvements were 
not always manifested by objective outcome measures such as the Gross Motor 
Function Measure or the Pediatric Evaluation of Disability Inventory. This 
phenomenon also applied to ease of care, which was the most reported spasticity 
related problem. Contrary to the unchanged Pediatric Evaluation of Disability 
Inventory self-care domain scores, the visual analogue scale for ease of care 
showed an enormous improvement. This means that the facilitation in ease of 
care did not comprise that the children could take better care of themselves, nor 
that they needed less assistance. However, the caregivers experienced that pain 
relief and the decrease in muscle tone facilitated ease of care and made care less 
time consuming. Another novelty of the Dutch ITB study was that it showed 
important effects of CITB on health related quality of life. 
Clinical neurophysiological study 
When treating a child with CITB, we are most of all interested in the clinical 
benefits, for example whether the child reaches his or her individual treatment 
goals. However, there are clinical situations in which there is doubt about the 
effectiveness of ITB therapy. Therefore, we needed an objective and sensitive test, 
which: 1) can quantify the spinal cord neuronal response to ITB administration; 
2) can be easily applied in clinical practice; and 3) is feasible in spastic children. 
From a pathophysiological point of view, both the soleus H-reflex and the flexor 
reflex could be suitable. Our study was the first randomised, double-blind, 
placebo-controlled, dose-escalation study in children. It showed that the H-reflex 
is a feasible, useful, and objective test to quantify the decreasing motoneuron 
excitability in response to ITB bolus administration. There are several useful 
applications for the H-reflex during different phases of ITB therapy. If a patient for 
example does not respond to increasing ITB doses, the H-reflex values can 
confirm or negate successful ITB delivery.13 Recording an individual H-reflex 
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profile can also be useful, because sudden or gradual increases in the H-reflex 
values can early identify pump and catheter system malfunction.14 It is very 
important to detect complications at an early stage, as abrupt interruption of ITB 
delivery can result in the potentially life threatening ITB withdrawal 
syndrome.15,16   
Cost analysis 
The Dutch national ITB study included a cost of illness study and a cost-
effectiveness analysis. We started with a cost of illness study to define the 
magnitude of intractable spastic CP in children in monetary terms and to 
categorise the costs. In this bottom-up, prevalence based study, data were 
collected by a patient survey and by consulting files of health care institutions 
and local governments for a one-year period. From the societal perspective, 
mean annual costs were €40,265 per child, which is more than eleven fold the 
mean expenditures on care per capita in the Netherlands.17 The societal costs 
were for 71% borne by the health insurers, for 24% by the Dutch government, 
and for 5% by the families. For an individual family, this amounts to a large 
burden of about €2000 a year, including approximately €1500 for a wheelchair 
van. We conclude that the government could for instance assist in the family 
costs by (further) subsidising the expenditures for a wheelchair van. 
We subsequently categorised the costs and found out that 95% of the costs fell 
outside the medical care sector. These costs were largely related to the motor 
impairments, including expenditures for home care and guidance, special 
equipment and aids, therapy and rehabilitation, and transportation. We were 
impressed that the parents had to address so many different health care 
organisations and governmental institutions to try to get the necessary 
arrangements and finance to be able to care for their children. This situation 
leaves much to be desired. Some of the parents did not even find their way in the 
jungle of red tape and regulations. Moreover, lengthy application procedures and 
disproportional delivery periods for wheelchairs add to the frustration of the 
children and their parents. Recently, these problems were addressed in the Dutch 
national media. Hopefully, things will improve soon. We believe that some 
improvements in this field would add to the quality of life of people with 
disabilities.     
Prospective studies on the cost-effectiveness of CITB in children with spastic CP 
are lacking. Therefore, we conducted a prospective cost-effectiveness analysis 
alongside our Dutch ITB study. The analysis showed that CITB cost about 
€30,000 per quality-adjusted life-year (QALY). The Council for Public Health and 
Health Care proposed €80,000 per QALY as a reasonable bench-mark in the 
Netherlands.18 Therefore, we established CITB to be cost-effective. Besides its 
cost-effectiveness, more factors are in favour of reimbursement of CITB for 
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children with intractable spastic CP. These factors comprise the high disease 
burden and the lack of effective treatment alternatives in most children.19,20 
Moreover, we expect to start CITB in at most 20 children a year in the 
Netherlands, resulting in a small burden on the Dutch total health care budget of 
about €75,000 per year. We conclude that the results of our study comprise the 
cost-effectiveness of CITB for carefully selected children with intractable spastic 
CP and, from an economic point of view, justify the reimbursement of CITB for 
this group of children in the Netherlands. 
Future 
The results of our Dutch ITB study establish CITB to be (cost)-effective and safe in 
the treatment of carefully selected children with problems caused by intractable 
spastic CP.  Therefore, CITB merits a place in regular health care. Our proposal 
for the Netherlands would be to start confining ITB therapy for children to two or 
three health care centres. 
A future challenge regarding CITB treatment is to select the right children at the 
right age. Strictly speaking, the generalisability of the results of the Dutch ITB 
study is confined to relatively older children with intractable spastic CP who rely 
on wheeled mobility. In clinical practice, CITB is most frequently applied in this 
group of children.21,22 We reported a successful test treatment and subsequent 
pump implantation in all 17 included children. This means that our 
multidisciplinary team succeeded in selecting the right children. However, it may 
also mean that we unjustly withheld a test treatment from part of the excluded 
children. For example, we excluded two older children in whom spasticity 
seemed to be mostly replaced by stiffness. Based on our current experiences, we 
would probably have offered these children a test treatment at that time. During 
the inclusion period of the Dutch ITB study, we widened the eligibility criteria for 
treatment with CITB. Currently, available pumps are sufficiently small so that 
there is no longer a need for any size or weight restrictions.23 However, younger, 
malnourished and the most seriously affected spastic children seem to be more 
vulnerable to adverse events.21,24,25 On the other hand, early treatment with CITB 
can prevent contractures, dislocations and the subsequent need for orthopaedic 
procedures.11,26 Moreover, we do not consider intractable epilepsy as an absolute 
contraindication for ITB therapy anymore. 
We believe the indication for CITB goes beyond children with intractable spastic 
CP who rely on wheeled mobility. CITB should certainly be considered in 
children with a spastic diplegia in whom spasticity interferes with standing, 
walking and/or cycling. We reported on an ambulant boy who suffered from 
worsened gait in spite of multilevel treatment with botulinum toxin. He saw his 
goals fulfilled as with CITB the pain in his hamstrings disappeared and walking 
took him less energy. Bleyenheuft et al. reported on seven children and young 
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adults with diplegic and tetraplegic CP in whom spasticity resulted in a 
progressive decrease in walking abilities.27 With CITB, walking improved in all 
patients.27 Another treatment option for children with spastic diplegia is selective 
dorsal rhizotomy.28 CITB is the treatment of choice for children with both 
dystonia and spasticity, because selective dorsal rhizotomy does not improve 
dystonia. CITB is also recommended in children with spastic quadriplegic CP, 
because CITB can decrease both upper and lower limb spasticity. The best 
candidates for selective dorsal rhizotomy are children, aged between 3 and 8 
years, with spastic diplegia and reasonably well-preserved leg strength.28 In case 
both CITB and selective dorsal rhizotomy are considered, their pros and contras 
have to be weighed for the individual child. CITB has the unique advantage of 
being reversible and titratable to meet individual needs. Disadvantages of CITB 
are the required pump refills, re-operation for battery failure and possible 
additional operations to solve complications. In comparison with CITB, selective 
dorsal rhizotomy is a more invasive procedure. However, it does not require re-
operation or repeated visits to a medical centre for refills. 
Recently, experts in the field brought the status of an ITB test treatment in 
children up for discussion.1 Albright and Ferson stated that they no longer 
indicate an ITB test treatment preceding pump implantation in children with 
spasticity only.1 Their experience is that almost all spastic children respond to an 
ITB bolus dose. We also reported a successful test treatment in all, but carefully 
selected children who all had one or more realistic treatment goals. Nevertheless, 
we advocate maintaining the test treatment for the following reasons. First, CITB 
therapy comprehends more than the implantation of a pump and catheter system. 
It most of all implies a long-standing contract with medical care, including 
regular pump refills, which cannot be missed out once. Second, in our centre 
most children and/or their parents attached great value to the test treatment. 
Before having a pump implanted, they wanted proof of the anticipated ITB effect. 
Third, the nature of the response to the ITB test bolus helps to assess the initial 
CITB daily dose, which usually is twice the effective ITB bolus dose. Lastly, 
thanks to the test treatment more children can be eligible for CITB therapy. For 
example, in children with a less straightforward treatment goal, the test treatment 
can show whether or not ITB gives the desired effect. 
Having expounded the rationale of an ITB test treatment, we put forward some 
ideas to optimise its design and to decrease the incidence of cerebrospinal fluid 
leakage. From now on, we shall no longer use placebo. Because a placebo-effect 
has been reported, outcome measures are important for sustaining a clinically 
observed positive effect.10,29 We suggest using the original Ashworth scale, the 
soleus H-reflex, and the visual analogue scale for this goal. The Ashworth scale is 
useful, because it quickly provides information on muscle tone and can be easily 
measured several times a day by one assessor. The soleus H-reflex should be 
measured once before the test treatment, and at each test day, about four hours 
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after ITB bolus administration. The visual analogue scale is a feasible measure to 
assess any change in the individually formulated problems, including pain and 
ease of care.6  
The high incidence of symptoms of cerebrospinal fluid leakage is a major 
problem, which needs to be addressed. One solution might be to avoid the use of 
an external catheter and administer the ITB test bolus by lumbar puncture 
instead. We believe the effective ITB dose can be fairly predicted considering the 
child’s age, weight, CP type, and individual treatment goals.1 Because most 
children will require only one ITB test dose, bolus administration by lumbar 
puncture may be considered in children who understand the procedure and are 
able to cooperate. In case ITB administration by an external catheter is required, 
we would suggest tunnelling the catheter subcutaneously. General anaesthesia is 
often required in that case. We conclude that the design of each test treatment 
should be tailored to the characteristics and treatment goals of the individual 
child. 
Considering the implantation of the pump and catheter system for CITB, a 
challenge is to predict which catheter tip level is best for the individual child. 
Experts in the field advise to position the catheter tip between levels T10-T12 for 
spastic diplegia and between levels C5-T2 for spastic tetraplegia.30 In our study, 
the tip was positioned between levels T5-T7 in all children. In two children with 
tetraplegia and axial hypotonia, and one child with tetraplegia and bulbar side 
effects, we might better have positioned the tip between levels T10-T12. On the 
other hand we reported on a girl with a diplegic distribution, who said to have 
normal upper extremity function before pump implantation. Nevertheless, with 
CITB she could clearly move her fingers quicker, which facilitated her computer 
work and thus participation. Therefore, we do not advocate standard tip levels.  
We emphasise the role of multidisciplinary teams in specialised centres to make 
well considered, child centred treatment plans. Individual treatment goals should 
be clear, relevant and realistic. Outcome measures should include: 1) a highly 
individualised, subjective measure to evaluate any change in the individual 
treatment goals such as a visual analogue scale, 2) one or more standardised 
measures such as relevant GMFM dimensions or PEDI scales, and 3) a measure of 
health related quality of life, because clinical measurements fail to reflect the 
well-being of the child and his or her family.31-35 Recently, the European 
KIDSCREEN and DISABKIDS projects have developed a new instrument to assess 
the health related quality of life of children and adults who suffer from chronic 
medical conditions.36,37 This instrument includes seven condition-specific 
modules, including a module addressing CP.37  
Children treated with CITB will need long-term follow-up in order to answer 
questions regarding long-term efficacy, safety, and functional outcome. Other 
questions still to be addressed are whether tolerance would play a role or, 
conversely, the need for CITB would decrease by age. The efficacy and safety of 
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CITB in children with spasticity due to traumatic brain injury, near drowning, 
spinal cord lesions, and neurodegenerative diseases furthermore should be 
studied more extensively. A prospective, multicentre approach may be best to 
study these select paediatric populations. 
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SUMMARY 
This thesis addresses the results of a Dutch national study, in which we 
prospectively studied the efficacy and safety of intrathecal baclofen (ITB) therapy 
in children with intractable spastic cerebral palsy (CP). Intractable spasticity can 
be well treated with continuous infusion of intrathecal baclofen (CITB). However, 
evidence for the use of CITB in the treatment of children with spasticity is 
lacking. The Dutch ITB study comprised the selection phase, the test treatment 
phase, the pump implantation phase, and the follow-up phase. Furthermore, the 
Dutch ITB study embedded a clinical neurophysiological substudy and a cost 
analysis. 
 
In daily clinical practice, there has been no objective outcome measure yet to 
evaluate the effect of ITB therapy in spastic children. In spite of its clear 
limitations, the standard clinical scale for measuring spasticity is the Ashworth 
scale. Chapter 2 addresses the clinical neurophysiological study on the utility 
and feasibility of the soleus H-reflex and flexor reflex in identifying spinal cord 
neuronal response to ITB bolus administration in children with intractable spastic 
CP. During a randomised, double-blind, placebo-controlled, dose-escalation test 
treatment, maximum H-amplitude/maximum M-amplitude (H/M ratio) and flexor 
reflex parameters were bilaterally recorded at baseline and 2 to 3 hours after 
intrathecal bolus administration of placebo and increasing doses of baclofen until 
both an improvement in the individual treatment goal(s) and a one-point 
reduction on the Ashworth scale were observed. We studied the 
electrophysiological data of 14 children. The H-reflex was feasible in 13 
children, the flexor reflex threshold area in nine and the flexor reflex, elicited 
with supramaximal stimulation, in only one child. After administration of ITB the 
H/M ratio significantly decreased (left: 0.67 ± 0.47 to 0.15 ± 0.18, p = 0.005; 
right: 0.55 ± 0.32 to 0.14 ± 0.19, p = 0.002) without placebo effect. The flexor 
reflex threshold area only decreased significantly after ITB administration in 
children not taking oral baclofen (left: 146 ± 53 mVms to 41 ± 54 mVms, 
p = 0.000; right: 156 ± 80 mVms to 66 ± 48 mVms, p = 0.002). We concluded 
that this first randomised, double-blind, placebo-controlled, dose-escalation 
study in spastic children demonstrated the soleus H-reflex to be a feasible and 
objective measure to quantify the decreasing motoneuron excitability in response 
to ITB bolus administration. Only in children not taking oral baclofen, the flexor 
reflex threshold area could also be used as an objective outcome measure, yet 
feasibility is limited. We suggested introducing the H-reflex as the 
electrophysiological gold standard for the evaluation of the effect of ITB in spastic 
children. 
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Chapter 3 describes the double-blind, randomised, placebo-controlled, dose-
finding ITB test treatment. The aims were to select children eligible for CITB, to 
assess the effective ITB bolus dose and evaluate the effects, side effects and 
complications. Outcome measures included the original Ashworth scale and the 
visual analogue scale (VAS) for individually formulated problems. We included 
nine girls and eight boys, aged between 7 and 16 years (mean 13y2m ± 2y9m). 
Twelve children had spastic CP and five children spastic-dyskinetic CP. One 
child was classified on the Gross Motor Function Classification System (GMFCS) 
at level III, two at level IV and 14 at level V. The test treatment was successful in 
all 17 children with an effective ITB bolus dose of 12.5 μg in one child, 20 μg in 
another, 25 μg in ten and 50 μg in five children. ITB significantly reduced muscle 
tone, diminished pain and facilitated ease of care. Placebo did not have these 
effects. We registered nine side effects of ITB, including slight lethargy in seven 
children. Fourteen children had symptoms of lowered cerebrospinal fluid 
pressure. This complication did not occur in three children in whom the 
neurosurgeon had tunnelled the catheter subcutaneously. We concluded that ITB 
bolus administration is effective and safe for carefully selected children with 
intractable spastic CP. 
 
Chapter 4 is about the prospective, randomised controlled, open-label, 
implantation phase. In a randomised controlled trial (RCT), we studied the 
6-month efficacy of CITB in comparison with standard treatment only. After the 
test treatment, the 17 children were randomised to receive a Synchromed pump 
for CITB after either one month (CITB group) or six months (Control group). 
Primary outcomes were the 6-month-change scores on the 0-10 VAS for 
individually formulated problems and the Caregiver Assistance scale of the 
Pediatric Evaluation of Disability Inventory (PEDI) self-care domain. One of the 
secondary outcome measures was health related quality of life as measured with 
the Child Health Questionnaire (CHQ)-PF50. Nine children were randomly 
assigned to the CITB group and eight to the Control group. The VAS for 
individual problems improved with 4.0 ± 1.7 in the CITB group and changed 
with -0.2 ± 1.3 in the Control group (p = 0.001). The VAS for pain improved with 
4.2 ± 2.9 in the CITB group and worsened with -1.3 ± 2.4 in the Control group 
(p = 0.016). The VAS for ease of care improved with 3.9 ± 2.2 in the CITB group 
and with 0.1 ± 1.6 in the Control group (p = 0.008). PEDI scores did not change 
significantly. The CHQ-PF50 domain score of bodily pain/discomfort improved 
with 24.4 ± 20.7 points in the CITB group and worsened with -10.6 ± 26.8 points 
in the Control group (p = 0.014). This also counted for the domains of mental 
health (CITB group 9.1 ± 9.1 points versus Control group -3.5 ± 15.1 points; 
p = 0.045), parental impact-time (CITB group 5.2 ± 18.1 points versus Control 
group -19.8 ± 29.0 points; p = 0.043) and the psychosocial summary score (CITB 
group 3.4 ± 7.9 points versus Control group -5.7 ± 8.8 points; p = 0.027).  
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Summarising, CITB reduced individually formulated problems, it relieved pain, 
and it improved ease of care, significantly. Moreover, health related quality of life 
significantly improved for the domains of bodily pain/discomfort, mental health, 
psychosocial status, and parents’ personal time limitation. We concluded that the 
results of this RCT establish CITB to be effective in carefully selected children 
with problems caused by intractable spastic CP. 
 
Chapter 5 comprises the follow-up phase, in which we prospectively studied the 
one-year efficacy of CITB, and its safety from pump implantation up to 24 months 
of follow-up. The test treatment had been successful in all 17 children and they 
all had a Synchromed pump implanted for CITB. The outcome measures 
included the 0-10 VAS for individual problems, Gross Motor Function Measure 
(GMFM) and health related quality of life as measured with the CHQ-PF50. CITB 
for 12 months significantly improved the VAS for individual problems with 
4.7 ± 2.0 (p = 0.000), VAS for ease of care with 5.2 ± 2.1 (p = 0.000), VAS for 
pain with 5.4 ± 2.7 (p = 0.002); GMFM sitting dimension with 3.3 points (range 
-4.0 to 22.0 (p = 0.022), GMFM goal dimension with 4.0 points (range 0.0 to 
26.0; p = 0.007); and CHQ-PF50 domains of bodily pain/discomfort with 
25.6 ± 35.9 points (p = 0.016) and mental health with 9.8 ± 11.3 points 
(p = 0.007). During a mean follow-up of 18.4 months, we recorded 51 non-
procedure or device related adverse events (incidence 0.16 per patient-month; 
95% CI 0.12-0.20) and 29 procedure or device related adverse events (incidence 
0.09 per patient-month; 95% CI: 0.06-0.12). Eight adverse events were serious, 
but not life threatening. None of the children had a wound infection or 
meningitis and none of the pumps had to be removed. We concluded that CITB 
was effective at 12 months and safe up to 24 months for carefully selected 
children with intractable spastic CP. CITB relieved pain, facilitated ease of care 
and improved mental health. The majority of children could extend their 
activities and participation. 
 
Chapter 6 comprises a case report on the use of an indium111 
diethylenetriaminepentaacetic acid (DTPA) flow study in the evaluation of a 
lumbar swelling in a 16-year-old girl with spastic CP, who was treated with CITB. 
We used the indium111 DTPA flow study to rule out damage or a disconnection of 
the catheter, which could have led to leakage of baclofen into the lumbar 
swelling. The indium111 DTPA flow study did not interrupt the continuous 
infusion of ITB. We concluded that an indium111 DTPA flow study is a non-
invasive, safe and patient friendly diagnostic method, which can be of great help 
in the evaluation of pump- or catheter-related complications and does not need 
to interfere with CITB. 
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Because health care expenditures are rising and resources are scarce, economic 
evaluations become increasingly important in order to justify the introduction of 
expensive therapies. In chapter 7 we describe our cost of illness (COI) study, 
which was a substudy of the Dutch ITB study. A COI study defines the magnitude 
of an illness in monetary terms and can serve as a basis for any economic 
evaluation. The aims of our COI study were to estimate and categorise the 
expenditures for children with intractable spastic CP by conducting a bottom-up, 
disease specific, and prevalence based COI study from the societal perspective. 
Data were collected by a patient survey and by consulting files of health care 
institutions and local governments for a one-year period. We included eight girls 
and seven boys, aged between 7 and 16 years (mean 13y2m ± 2y11m). Eleven 
children had spastic CP and four children had spastic-dyskinetic CP. One child 
was classified on the GMFCS at level III, two children at level IV and 12 at level 
V. From the societal perspective, mean annual costs were €40,265, which is 
more than eleven fold the mean expenditures on care per Dutch capita. Home 
care and guidance accounted for the highest expenditures (€23,000; 57%), 
followed by special equipment and aids (€6927; 17%), therapy and rehabilitation 
(€3262; 8%), and transportation (€3101; 8%). The expenditures for medical care 
were relatively small (€1573; 4%). We concluded that the economic impact of 
intractable spastic CP in children is relatively high and largely related to the 
motor impairments. 
 
Prospective studies on the cost-effectiveness of CITB in children with spastic CP 
are lacking. Therefore, we conducted a cost-effectiveness analysis (chapter 8) 
alongside our prospective Dutch ITB study. We compared the costs and health 
effects of CITB to those of standard treatment only, from the health care 
perspective for a one-year period. Health effects were expressed in terms of a 
VAS for individual problems and quality-adjusted life-years (QALYs). QALYs 
were derived from the EuroQol-5D. We verified the robustness of the results with 
bootstrap and sensitivity analyses. This cost-effectiveness analysis included the 
same 15 children as the COI study (chapter 7). CITB was more effective and more 
costly than standard treatment only. Gaining one QALY cost on average €32,737. 
We concluded that based on the threshold-willingness to pay for one QALY in 
the Netherlands (€80,000), our results sustain the cost-effectiveness of CITB for 
carefully selected children with intractable spastic CP. 
 
The results of our Dutch ITB study established CITB to be (cost)-effective and safe 
in the treatment of carefully selected children with problems caused by 
intractable spastic CP.   Therefore, CITB merits a place in regular health care. In 
the general discussion (chapter 9) we put forward some ideas to optimise ITB 
therapy in children with spastic CP. We also discussed future challenges on this 
subject.  
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SAMENVATTING 
Dit proefschrift beschrijft de resultaten van een Nederlandse nationale studie 
waarin we prospectief hebben onderzocht of toediening van intrathecale 
baclofen (ITB) een effectieve en veilige behandeling is voor kinderen met 
onbehandelbare spastische cerebrale parese (CP). Het is bekend dat 
onbehandelbare spasticiteit goed kan worden behandeld met continue 
intrathecale toediening van baclofen (CITB). Er is echter onvoldoende 
bewijskracht voor toepassing van CITB als behandeling voor kinderen met 
spasticiteit. De Nederlandse ITB studie bestond achtereenvolgens uit de 
selectiefase, proefbehandelingsfase, pompimplantatiefase en follow-up fase. 
Daarnaast verrichtten we binnen de Nederlandse ITB studie een klinisch 
neurofysiologische substudie en een kostenanalyse. 
 
In de kliniek ontbrak tot op heden een objectieve test om de effecten van ITB als 
behandeling voor kinderen met spasticiteit te meten. Een vaak gebruikte klinische 
schaal voor het meten van spasticiteit was en is de Ashworth schaal, waarmee in 
wezen spiertonus op subjectieve wijze wordt gemeten. Hoofdstuk 2 betreft een 
klinisch neurofysiologische studie met als vraagstelling of de soleus H-reflex en 
de flexor reflex het effect van ITB op het niveau van het ruggenmerg kunnen 
meten. Daarnaast onderzochten we de toepasbaarheid van deze testen in 
kinderen met onbehandelbare spastische CP. Het onderzoek vond plaats tijdens 
de gerandomiseerde, dubbelblinde, placebogecontroleerde, dose-finding proef-
behandelingsfase. Voor aanvang van de proefbehandeling bepaalden we de 
uitgangswaarden van de maximum H-amplitude/maximum M-amplitude (H/M 
ratio) en de flexor reflex parameters voor beide benen. Vervolgens werd op 
iedere testdag, 2 tot 3 uren na intrathecale bolus toediening van placebo en 
toenemende doseringen baclofen, gemeten tot en met de dag dat er zowel een 
verbetering in de individueel gestelde behandelingsdoelen als een verbetering 
van minimaal één punt op de Ashworth schaal werd geobserveerd. We 
bestudeerden de elektrofysiologische data van 14 kinderen. De H-reflex was 
toepasbaar in 13 kinderen, de flexor reflex drempel area in negen en de flexor 
reflex, opgewekt met supramaximale stimulatie, in één kind. Na toediening van 
ITB daalde de H/M ratio significant (links van 0.67 ± 0.47 naar 0.15 ± 0.18, 
p = 0.005; rechts van 0.55 ± 0.32 naar 0.14 ± 0.19, p = 0.002) zonder placebo 
effect. De flexor reflex drempel area daalde alleen significant in de groep 
kinderen die oraal geen baclofen gebruikten (links van 146 ± 53 mVms naar 
41 ± 54 mVms, p = 0.000; rechts van 156 ± 80 mVms naar 66 ± 48 mVms, 
p = 0.002). De resultaten van deze eerste gerandomiseerde, dubbelblinde, 
placebogecontroleerde, dose-finding studie in spastische kinderen hebben 
aangetoond dat de soleus H-reflex een objectieve en toepasbare test is om de 
afnemende excitabiliteit van het motoneuron in respons op ITB bolus toediening 
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te kwantificeren. Alleen in kinderen die oraal geen baclofen gebruiken, kan ook 
de flexor reflex drempel area worden gebruikt als objectieve uitkomstmaat; de 
toepasbaarheid is echter beperkt. Ons voorstel is de H-reflex te introduceren als 
elektrofysiologische gouden standaard in de evaluatie van het effect van ITB in 
spastische kinderen. 
 
Hoofdstuk 3 beschrijft de gerandomiseerde, dubbelblinde, placebo-
gecontroleerde, dose-finding proefbehandeling. De doelen waren het selecteren 
van kinderen voor CITB, het vaststellen van de effectieve ITB bolus dosering en 
het registreren van effecten, bijwerkingen en complicaties. Als uitkomstmaten 
gebruikten we de originele Ashworth schaal en een visueel analoge schaal (VAS) 
voor individuele doelen. We includeerden negen meisjes en acht jongens tussen 
de 7 en 16 jaar oud (gemiddeld 13j2m ± 2j9m). Twaalf kinderen hadden 
spastische CP en vijf kinderen spastisch-diskinetische CP. Volgens het Grof 
Motorisch Functionerings Classificatie Systeem (GMFCS) classificeerden we één 
kind in niveau III, twee kinderen in niveau IV en 14 in niveau V. De 
proefbehandeling slaagde in alle 17 kinderen. De effectieve ITB bolus dosering 
bedroeg 12.5 μg in één kind, 20 μg in een ander, 25 μg in tien kinderen en 50 μg 
in vijf kinderen. ITB had een significant gunstig effect op spiertonus, pijn en 
verzorging. Placebo had deze effecten niet. We registreerden negen bijwerkingen 
waaronder geringe lethargie in zeven kinderen. Veertien kinderen hadden 
symptomen passend bij een verlaagde liquordruk. Deze complicatie trad niet op 
in drie kinderen waarbij de neurochirurg de katheter subcutaan had getunneld. 
We concludeerden dat ITB bolus toediening effectief en veilig is in zorgvuldig 
geselecteerde kinderen met problemen als gevolg van onbehandelbare spastische 
CP.   
 
Hoofdstuk 4 betreft de prospectieve, gerandomiseerde, gecontroleerde, open-
label implantatiefase. In een gerandomiseerd gecontroleerd onderzoek (RCT) 
vergeleken we de effectiviteit van 6 maanden CITB met die van standaard 
behandeling alleen. Na de proefbehandeling vond randomisatie plaats. Eén groep 
kinderen kreeg de Synchromed pomp na 1 maand (CITB groep) en de andere 
groep na zes maanden (Controle groep). Primaire uitkomsten waren de 6-
maanden-verschilscores binnen de 0-10 VAS voor individuele problemen en de 
Verzorgersassistentie schaal in het domein Zelfverzorging van de Pediatric 
Evaluation of Disability Inventory (PEDI). Een van de secundaire uitkomstmaten 
was kwaliteit van leven gemeten met de Child Health Questionnaire (CHQ)-
PF50. Negen kinderen kwamen na randomisatie in de CITB groep en acht in de 
Controle groep. De VAS voor individuele problemen verbeterde met 4.0 ± 1.7 in 
de CITB groep en verslechterde met -0.2 ± 1.3 in de Controle groep (p = 0.001). 
De VAS voor pijn verbeterde met 4.2 ± 2.9 in de CITB groep en verslechterde 
met -1.3 ± 2.4 in de Controle groep (p = 0.016). De VAS voor verzorging 
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verbeterde met 3.9 ± 2.2 in de CITB groep en met 0.1 ± 1.6 in de Controle groep 
(p = 0.008). PEDI scores lieten geen significante verandering zien. De CHQ-PF50 
score voor lichamelijke pijn en klachten verbeterde met 24.4 ± 20.7 punten in de 
CITB groep en verslechterde met -10.6 ± 26.8 punten in de Controle groep 
(p = 0.014). Dit patroon gold ook voor de CHQ-PF50 score voor mentale 
gezondheid (CITB groep 9.1 ± 9.1 punten versus Controle groep -3.5 ± 15.1 
punten; p = 0.045), impact op tijd ouders (CITB groep 5.2 ± 18.1 punten versus 
Controle groep -19.8 ± 29.0 punten; p = 0.043) en de psychosociale 
samenvattingscore (CITB groep 3.4 ± 7.9 punten versus Controle groep -5.7 ± 8.8 
punten; p = 0.027). Samenvattend had CITB een significant gunstig effect op pijn, 
verzorging en de individuele problemen. Daarnaast verbeterde CITB de kwaliteit 
van leven significant op de gebieden van lichamelijke pijn en klachten, mentale 
gezondheid, psychosociale toestand en de tijdsbeperking die de ouders ervaren 
door de handicap van hun kind. De resultaten van deze RCT laten zien dat CITB 
een effectieve behandeling is voor zorgvuldig geselecteerde kinderen met 
problemen veroorzaakt door onbehandelbare spastische CP.  
 
In hoofdstuk 5 beschrijven we de resultaten van de follow-up fase. We 
onderzochten prospectief zowel de 1-jaars effectiviteit van CITB als de veiligheid 
vanaf pompimplantatie tot een follow-up van maximaal 24 maanden. Alle 17 
kinderen hadden een geslaagde proefbehandeling en kregen een Synchromed 
pomp voor CITB. Als uitkomstmaten gebruikten we de 0-10 VAS voor individuele 
problemen, de Gross Motor Function Measure (GMFM) en kwaliteit van leven 
gemeten met de CHQ-PF50. CITB gedurende 12 maanden verbeterde de VAS 
voor individuele problemen met 4.7 ± 2.0 (p = 0.000), de VAS voor verzorging 
met 5.2 ± 2.1 (p = 0.000), de VAS voor pijn met 5.4 ± 2.7 (p = 0.002); de GMFM 
dimensie zitten met 3.3 punten (range -4.0 tot 22.0 (p = 0.022) en de GMFM 
doeldimensie met 4.0 punten (range 0.0 tot 26.0; p = 0.007). Daarnaast 
verbeterden de CHQ-PF50 scores voor lichamelijke pijn en klachten met 
25.6 ± 35.9 punten (p = 0.016) en voor mentale gezondheid met 9.8 ± 11.3 
punten (p = 0.007). Gedurende een gemiddelde follow-up van 18.4 maanden 
registreerden we 51 niet-procedure of pompsysteem gerelateerde adverse events 
(incidentie 0.16 per patiëntmaand; 95% CI 0.12-0.20) en 29 procedure of 
pompsysteem gerelateerde adverse events (incidentie 0.09 per patiëntmaand; 
95% CI: 0.06-0.12). Acht adverse events waren ernstig, maar niet 
levensbedreigend. Geen van de kinderen kreeg een wondinfectie of meningitis 
en geen van de pompen hoefde te worden verwijderd. Concluderend bleek CITB 
na 1 jaar effectief en daarnaast veilig gedurende de follow-up die in dit 
onderzoek maximaal 24 maanden duurde. CITB resulteerde in een vermindering 
van pijn, vergemakkelijking van de verzorging en een verbetering van de mentale 
gezondheid van de kinderen. De meerderheid van de kinderen kon zijn of haar 
activiteiten uitbreiden waarbij participatie in het dagelijks leven toenam.  
Thesis_hoving_v5.pdf   163 19-3-2008   12:31:52
164    
 
Hoofdstuk 6 betreft een case report over toepassing van een indium111 
diethylenetriaminepentaacetic acid (DTPA) flow onderzoek ter evaluatie van een 
lumbale zwelling in een 16 jaar oud meisje met spastische CP die werd 
behandeld met CITB. We gebruikten het indium111 DTPA flow onderzoek om 
onaannemelijk te maken dat door een katheterprobleem liquor en baclofen de 
zwelling inlekten. Tijdens het indium111 DTPA onderzoek werd de continue 
intrathecale toediening van baclofen niet onderbroken. We concludeerden dat 
een indium111 DTPA flow onderzoek een non-invasieve, veilige en 
patiëntvriendelijke test is welke van nut kan zijn in de evaluatie van pomp- of 
katheter gerelateerde complicaties zonder te interfereren met CITB. 
 
Aangezien de kosten van de gezondheidszorg toenemen en middelen beperkt 
zijn, worden economische evaluaties steeds belangrijker om het invoeren van 
dure behandelmethoden te rechtvaardigen. In hoofdstuk 7 beschrijven we een 
cost of illness (COI) studie als onderdeel van de Nederlandse ITB studie. Een COI 
studie drukt de omvang van een ziekte uit in financiële termen en kan dienen als 
basis voor elke economische evaluatie. Onze doelen waren het schatten en 
indelen van de uitgaven voor kinderen met onbehandelbare spastische CP 
middels het uitvoeren van een bottum-up, ziektespecifieke en prevalentie 
gebaseerde COI studie, verricht vanuit maatschappelijk perspectief. De gegevens 
werden voor een periode van een jaar verzameld middels een 
patiëntenvragenlijst en het consulteren van gezondheidsinstellingen en lokale 
overheden. We includeerden acht meisjes en zeven jongens tussen de 7 en 16 
jaar oud (gemiddeld 13j2m ± 2j11m). Elf kinderen hadden spastische CP en vier 
hadden spastisch-diskinetische CP. Volgens het GMFCS classificeerden we één 
kind in niveau III, twee kinderen in niveau IV en 12 in niveau V. Vanuit 
maatschappelijk perspectief waren de gemiddelde jaarlijkse kosten  €40,265 wat 
neerkomt op meer dan 11 maal de gemiddelde uitgaven per hoofd van de 
Nederlandse bevolking. De hoogste uitgaven waren voor thuiszorg en 
begeleiding (€23,000; 57%), gevolgd door speciale apparatuur en hulpmiddelen 
(€6927; 17%), therapie en revalidatie (€3262; 8%) en transport (€3101; 8%). De 
kosten van de medische zorg waren relatief bescheiden (€1573; 4%). Onze 
conclusie luidde dat de economische gevolgen van onbehandelbare spastische 
CP bij kinderen relatief groot zijn en hoofdzakelijk gerelateerd aan de motorische 
beperkingen. 
 
Parallel aan de Nederlandse ITB studie verrichtten we een 
kosteneffectiviteitanalyse, omdat prospectieve studies naar de kosteneffectiviteit 
van CITB in kinderen met spastische CP ontbreken (hoofdstuk 8). Gedurende een 
jaar vergeleken we de kosten en de gezondheidseffecten van CITB met die van 
standaard behandeling alleen vanuit het perspectief van de gezondheidszorg. We 
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drukten gezondheidseffecten uit in termen van de VAS voor individuele 
problemen en quality-adjusted life-years (QALYs). QALYs werden afgeleid van de 
EuroQol-5D. We verifieerden de resultaten met bootstrap en gevoeligheids-
analyses. Aan de kosteneffectiviteitanalyse deden dezelfde 15 kinderen mee als 
aan de COI studie (hoofdstuk 7). CITB was effectiever en duurder dan standaard 
behandeling alleen. Eén QALY verbetering kostte gemiddeld €32,737. In het licht 
van de Nederlandse ‘threshold-willingness to pay’ voor één QALY (€80,000) 
concludeerden we dat CITB een kosteneffectieve behandeling is voor zorgvuldig 
geselecteerde kinderen met problemen veroorzaakt door onbehandelbare 
spastische CP. 
 
De Nederlandse ITB studie heeft aangetoond dat CITB een (kosten)effectieve en 
veilige behandeling is voor zorgvuldig geselecteerde kinderen met problemen 
veroorzaakt door onbehandelbare spastische CP. CITB verdient daarom een 
plaats binnen de reguliere gezondheidszorg. In de algemene discussie (hoofdstuk 
9) hebben we ideeën naar voren gebracht over het optimaliseren van ITB 
therapie in kinderen met spastische CP. Daarnaast komen toekomstige 
uitdagingen rond dit onderwerp aan de orde.  
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DANKWOORD 
Een promotieonderzoek is als de terugreis van Odysseus naar Ithaka: 
 
Als je doel Ithaka is en je vertrekt daarheen,  
dan hoop ik dat je tocht lang zal zijn  
en vol nieuwe kennis, vol avontuur.  
Verwacht niet dat Ithaka je meer rijkdom geeft.  
Ithaka gaf je een prachtige reis, 
zonder Ithaka zou je nooit vertrokken zijn.  
 
Mijn reis is tot een rijke ervaring geworden dankzij de volgende mensen die me 
op weg stuurden, mijn koers bijstelden, stukken meevoeren of onderweg voor 
vertier zorgden. Bedankt! 
 
 
Allereerst de deelnemende kinderen en hun families. Voor jullie was deelname 
aan het onderzoek in Maastricht zowel letterlijk als figuurlijk een spannende reis. 
Jullie hebben me geraakt door jullie moed, doorzettingsvermogen en vrolijkheid. 
Dankzij jullie kunnen nu ook andere kinderen met ernstige spasticiteit behandeld 
worden met intrathecale baclofen.       
 
De Raad van Bestuur van het azM en in het bijzonder oud-voorzitter dr. Carpay. 
Dankzij uw vertrouwen in onze plannen en de financiële steun van het 
Profileringsfonds hebben we de Nederlandse nationale ITB studie in het azM 
kunnen uitvoeren. 
 
Prof. dr. Vles, beste Hans. Als voorzitter van de Landelijke Werkgroep voor 
Spasticiteit bij Kinderen vertrouwde je mij dit fantastische onderzoek toe. Het 
was het begin van een hechte samenwerking en een mooie tijd. Het is een 
voorrecht dat ik zoveel van je heb mogen leren over zowel neurologie als het 
leven. Je begeleiding was perfect. Je gaf me de ruimte mezelf te ontplooien, 
daarbij te vallen en weer op te staan. Maar wat er ook gebeurde, je was altijd 
bereikbaar. 
 
Dr. van Raak, beste Lisette. Samen met Hans maakte je deel uit van het dagelijks 
onderzoeksbestuur. Hoe druk je het ook had, jouw deur stond altijd voor me 
open. Je bijdrage aan het onderzoek is tijdsintensief en onmisbaar geweest. Ik 
bewonder je geduld, precisie en scherpe blik. Het was buitengewoon plezierig 
met je samen te werken.  
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Dr. Spincemaille en prof. dr. Beuls. Goede neurochirurgische faciliteiten, 
flexibiliteit en laagdrempelig overleg hebben bijgedragen aan het positieve 
verloop van de studie. Daarbij was het een geruststellende gedachte dat de 
kinderen door u werden geopereerd. 
 
De Landelijke Werkgroep voor Spasticiteit bij Kinderen en het Spasticiteitsteam 
voor Kinderen in het azM. Bedankt voor de fijne samenwerking en hetgeen ik 
van jullie heb geleerd. 
 
Liesbeth Palmans. De kinderen waren dol op je en sommige zelfs een beetje 
verliefd. We waren een goed team en ik heb genoten van je altijd goede humeur.  
 
De mensen van de afdeling KNF en speciaal dr. Vivianne van Kranen. Bedankt 
voor jullie expertise, flexibiliteit, gezelligheid en persoonlijke aandacht voor de 
kinderen.     
 
Dr. Evers en dr. Ament, beste Silvia en André. Het kostenonderzoek bleek een 
pittige uitdaging, maar is succesvol afgerond. Bedankt voor jullie hulp en 
aanmoedigingen.    
 
De vakgroep kindergeneeskunde en de verpleging van afdelingen MC-B2 en MC-
C5. Bedankt voor jullie enthousiasme en de prettige samenwerking op de 
afdeling. De meeste kinderen waren ver van huis, maar jullie zorg en aandacht 
maakten veel goed.  
 
De dames van de secretariaten neurologie, neurochirurgie, KNF, fysiotherapie en 
in het bijzonder Desiree Serpenti. Bedankt voor de secretariële en logistieke 
ondersteuning. 
 
Drs. van den Bergh, beste Fons. Tijdens mijn opleiding geneeskunde heb je me 
als wetenschapper ontgroend. Je begeleiding was inspirerend en het was altijd 
gezellig. Bijzonder leuk dat we dit jaar allebei promoveren. 
 
Prof. dr. Troost en prof. dr. Limburg. Mijn opleiding neurologie en het 
promotieonderzoek liepen parallel. Gelukkig had ik uw steun en is de kwaliteit 
van mijn opleiding bewaakt gebleven. 
 
Arjen van Prooijen. Dankzij jou is het proefschrift kunst geworden. 
 
Tiny Wouters. Jouw hulp is vele malen verder gegaan dan het maken van de lay-
out. Na elk consult Tiny wist ik weer dat alles goed zou komen. Je bent een 
engel. 
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De assistenten neurologie van het azM. We hebben samen veel lol gehad tijdens 
werk, borrels, etentjes, azM assistentenfeesten en promotieparty’s. Wordt 
vervolgd! Anita, Elske, Manuela en Tatjana, bedankt voor jullie speciale 
vriendschap.  
 
Annemarie Vlaar, paranimf. Vele fietstochten door de heuvels, Parijs, zwemmen, 
toneel, Costa Brava, hapje eten, film, skiën, klassiek concert, wandelen in 
Bemelen, borrelen … dat we nog tijd hadden voor promotieonderzoek?! 
 
Anne Starreveld. Friends for life. Ik vind het geweldig dat je voor mijn promotie 
overkomt uit Canada.  
 
Tennisvrienden van TC Ready. Geen betere ontspanning dan lekker meppen op 
de tennisbaan. 
 
Pieter en Maarten, bovenburen. Op de Gerechtigheidslaan 4 altijd leven in de 
brouwerij. 
 
De maatschap neurologie van het Diaconessenhuis Leiden; beste Elske, Job en 
Richard. Bedankt dat ik twee maanden later kon beginnen en daardoor tijd kreeg 
voor het afronden van mijn proefschrift. 
 
Petra, Coen en Quinten. Pé, jij hebt de kwaliteit van het Engels bewaakt en je 
bent mijn paranimf. Fijn dat je als zus er altijd voor me bent en gezellig dat we 
nu zo dicht bij elkaar wonen. 
 
Kees, Priska, Tim, Casper en Kiki. De zonnige, culinair hoogstaande 
verwenweekenden in Villa Sant Elm waren de perfecte energie booster tussen de 
onderzoeksactiviteiten door. Ik verheug me jullie straks veel meer te zien. 
 
De liefste oma van de wereld. Hoezo 91 jaar? Zelfstandig, modern, alle 
familienieuwtjes paraat; radio Slochteren is altijd een feest om naar te luisteren. 
Bedankt voor uw liefde, warmte en de energie die u me geeft tijdens onze 
wekelijkse telefonades.  
 
Lieve pa en ma, jullie liefde en onvoorwaardelijke steun betekenen heel veel 
voor me. Jullie geven me alle vrijheid, maar in Hotel Hoving is altijd een kamer 
vrij. 
 
Liefste Stefan. Aan het einde van mijn promotiereis kwam jij aan boord. Bij jou 
zijn en samen alles kunnen delen is de ultieme rijkdom. Ik verheug me op alle 
nieuwe avonturen die we samen gaan beleven! 
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CURRICULUM VITAE 
Marjanke Hoving werd op 7 juli 1976 geboren in Oosterhesselen. Na afronding 
van het Gymnasium aan het Christelijk Lyceum te Emmen studeerde zij 
Geneeskunde aan de Rijksuniversiteit Groningen. De propedeuse en 
doctoraalbul werden cum laude behaald. Naast de studie verrichtte zij onder 
leiding van radiotherapeut drs. A.C.M. van den Bergh wetenschappelijk 
onderzoek naar visusstoornissen bij patiënten met acromegalie. Na het doctoraal 
volgden de co-schappen in de Deventer Ziekenhuizen. Het keuze co-schap 
neurologie werd gevolgd aan The University Hospital of Alberta, Edmonton, 
Canada. Haar begeleiders waren E. Starreveld, MD FRCP(C), Associate Professor 
en M.G. Elleker, MD FRCP(C), Associate Professor. In 2000 behaalde Marjanke 
cum laude de artsenbul aan de Rijksuniversiteit Groningen. De opleiding tot 
neuroloog volgde zij in het Academisch Ziekenhuis Maastricht met als opleiders 
prof. dr. J. Troost en prof. dr. M. Limburg. Tijdens de opleiding verrichtte zij 
onder leiding van kinderneuroloog prof. dr. J.S.H. Vles wetenschappelijk 
onderzoek met dit proefschrift als resultaat. Een deel van het promotieonderzoek 
werd bekroond met de Assistentenprijs 2006 van de Nederlandse Vereniging 
voor Klinische Neurofysiologie en de Pelerinprijs 2006 van het Academisch 
Ziekenhuis Maastricht. Per 1 maart 2008 is Marjanke haar carrière als neuroloog 
begonnen in het Diaconessenhuis Leiden. 
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